Trading Analysis Report: ARM¶

Analysis date: 2026-10-08
Rating: Underweight
Generated: 2026-10-09 01:57:37
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-opus-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 275.29 USD Price As Of: 2026-10-08

ARM (Arm Holdings plc): Technical Analysis Report¶

1. Summary¶

ARM fell −6.48% on 2026-10-08, from 294.37 to 275.29. It opened at its high of the day (286.73), sold off to 270.26 and closed about 31% of the way up the day's range. Volume was 6.16M, roughly 1.9x the average of the prior three sessions (2.91M, 3.39M, 3.42M) and the heaviest since 09-28.

The drop completes a round trip of the September 21 gap rally: - Price closed at 275.29, below the 09-18 close (275.61) and 09-18 high (275.78). The 275.78–293.08 gap from 09-21 is now fully filled. - From the 09-22 closing peak of 333.20, price is down 17.38%.

Overall read: short-term bearish to neutral inside a long-term uptrend. - Bearish signals: the weekly and daily SuperTrend both point DOWN, MACD crossed below its signal line, RSI is back under 50, and price is below the 10-day EMA and the Bollinger middle band. - Still bullish: the monthly SuperTrend is UP, price is 25.5% above the 200-day SMA, and the 50-day SMA (269.37) is rising and sits just under today's low. - ADX is 12.45, which signals no trend. Price is moving within a range, so signals that follow trends are less reliable right now. - Price is not stretched. Z-scores are between −0.46 and −0.49 on the daily and weekly charts, and RSI is 46.7. This is not an oversold buy signal yet.

2. Indicator Selection and Rationale¶

The verified snapshot already supplies the 10 EMA, 50/200 SMA, RSI, MACD, Bollinger Bands and ATR. I added indicators to fill the gaps:

Role	Indicator	Why it fits now
Trend across timeframes	`supertrend`	The monthly, weekly and daily charts disagree. SuperTrend shows which direction each one points and gives a stop level for each.
Trend strength	`adx`	After a sharp spike and fade, it tells us whether price is trending or ranging. That decides which tactics to use.
Medium-term trend and support	`close_50_sma`	Price is testing it right now, and its slope matters.
Change in momentum	`macdh` (+ `macd`)	Pinpoints when momentum flipped after the September spike.
Level of momentum	`rsi` (history)	Tracks how momentum faded from 71 down to 46. I skipped `stochrsi` because it would repeat the same information.
Volatility and risk	`atr`	ARM moves about 6.5% of its price per day, so stop distances and position sizes depend on it.
Volume	`obv`	Tests whether the September rally and the pullback since have volume behind them.
Exhaustion	`td_9`	Shows whether a setup on the weekly, monthly or daily chart is close to running out.
How stretched price is	`z_score`	Checks whether today's drop has pushed price to an extreme yet.

Consistency check: every indicator pulled separately matches the verified snapshot: RSI 46.66, 50 SMA 269.37, MACD 7.55 with signal 9.67 and histogram −2.12, and ATR 17.76. The daily z-score of −0.49 also agrees with what the Bollinger Bands imply: (275.29 − 288.85) ÷ 27.96 ≈ −0.49. I found no discrepancies.

Data caveat: 2026-10-08 is today's date. If this bar was captured before the session ended, the close and volume may still change.

3. Price Over the Past Six Months (verified closes)¶

April–June, a huge advance: from 143.86 (04-07) to a closing high of 439.46 on 06-18, with an intraday high of 452.70. Volume that day was 34.2M, the largest in the window.
June–July, a sharp decline: down to a 224.89 close on 07-29. The lowest intraday low was 219.39 on 08-03.
August to mid-September, a base: closes mostly between 234 and 287. Intraday lows kept rising: 219.39 (08-03), 225.46 (09-03), 238.03 (09-14).
September spike: price gapped up on 09-21 (open 294.36 against a prior close of 275.61) on 13.0M shares, the biggest volume since 06-18. Price peaked at a 333.20 close on 09-22 and an intraday high of 336.98 on 09-23.
Fade since: the closing peaks went 333.20, then 310.32 (09-25), then 307.49 (10-02). That is a series of lower highs, ending with today's 275.29.

Pattern: highs are falling (439.46 in June, 333.20 in September) while lows are rising (219.39, 225.46, 238.03). Price is squeezing into a narrowing range, which fits the very low ADX. Price is 37.4% below the June closing high but has held well above the summer lows.

Retracement levels (my own arithmetic on verified closes, not tool output). The September swing ran from a 243.98 close (09-16) to 333.20 (09-22): - 50% retracement ≈ 288.59, almost the same as the Bollinger middle band (288.85) - 61.8% ≈ 278.06. Today's close of 275.29 is just below it. - 78.6% ≈ 263.07

4. Trend¶

Moving averages (verified)¶

10 EMA: 293.23. Price is 17.94 below it (−6.1%), so the short-term trend has turned down.
50 SMA: 269.37. Price is 5.92 above it (+2.2%, about 0.33 ATR). Today's low of 270.26 stopped 0.89 above it, so the 50 SMA is being tested now.
The 50 SMA bottomed at 261.05 on 09-21 and has risen every day since.
From the change between 10-07 and 10-08, I worked out which closes drop out of the 50-day average next: 241.54, 239.69 and 239.06 over the next three sessions. The SMA should keep rising unless price falls to around 240.
From about 10-14 the closes dropping out are 280.56, 274.58, 286.68 and so on, so the SMA will flatten if price stays near 275.
200 SMA: 219.35. Price is 25.5% above it, and the 50 SMA is above the 200 SMA. The long-term uptrend is intact.

SuperTrend (14-period, 3x ATR)¶

Timeframe	Direction	Stop level	Price vs stop
Weekly (main signal)	DOWN	383.15	−28.15%
Monthly (background)	UP	198.17	+38.91%
Daily (timing)	DOWN	331.79	−17.03%

The weekly reading carries the most weight, and it points down. Even the September spike to 336.98 never got near the 383.15 weekly flip level.
The daily stop at 331.79 sits almost on the 09-22/23 high zone (333.20 close, 334.66 and 336.98 highs). A close above roughly 332–337 would flip the daily trend back up.
The monthly trend is still up, with its stop at 198.17, below both the 200 SMA and the August low. The bull market backdrop has not broken.

ADX (trend strength)¶

ADX was 12.45 on 10-08. It peaked at 40.30 on 09-23 and has fallen almost every session since: 38.37, 36.99, 29.13, 23.51, 18.77, 15.59 … 14.84, 12.45.
ADX kept falling even on today's −6.5% day. That means buying and selling pressure are roughly balanced and no new downtrend has formed yet.
What this means for trading: below 20, ADX signals a range. Breakouts are more likely to fail, and buying near the bottom of the range or selling near the top works better. The bearish SuperTrend readings should be treated as context, not confirmed trends, until ADX rises back above about 20–25.

5. Momentum¶

MACD¶

Bearish cross on 10-07: the histogram turned negative for the first time in the window (−0.27) and widened to −2.12 on 10-08.
The histogram peaked at 10.86 on 09-23 and has shrunk steadily since. This was an early warning, ahead of the price breakdown.
The MACD line (7.55) is still above zero. It crossed above zero on 09-21 and peaked at 14.71 on 09-25. Momentum is slowing but has not turned negative. A drop below zero would be the next bearish step.

RSI¶

RSI is 46.66, its first reading below 50 since 09-16 (45.23).
Each RSI peak has been lower: 71.36 (09-22), 61.19 (09-25), 58.52 (10-02). Price's own lower highs confirm this.
RSI is neutral, not oversold. It has about 17 points of room before reaching 30, so it gives no reason to buy here.

6. Volatility and How Stretched Price Is¶

ATR is 17.76, about 6.45% of price. It peaked at 19.83 on 09-28, eased to 17.28 on 10-07 and rose again today.
Price minus 1 ATR is about 257.53. Minus 2 ATR is about 239.77, which matches the mid-September close cluster (239.01–243.98).
Price plus 1 ATR is about 293.05, which matches the 10 EMA (293.23).
Bollinger Bands: upper 344.77, middle 288.85, lower 232.93.
The bands are very wide, about 38.7% of the middle band, because of the September spike.
Price sits in the lower half, about 38% of the way from the lower band to the upper band. The lower band is 42.36 (about 15%) below price.
Z-scores:

Timeframe	Z-score	Reading
Weekly	−0.46	Near average
Monthly	+1.12	Above average, not extreme
Daily	−0.49	Near average

Taken together: nothing is statistically stretched. The selloff has not reached an oversold extreme, so a bounce is not supported on statistical grounds. A reading of −2 on the daily chart would put price near the lower band, around 233.

7. Volume (OBV)¶

OBV peaked at 437.66M on 09-22, the same day as the closing high. It is now 414.17M, down 23.49M.
OBV is now slightly below its 09-18 level (417.24M, before the gap), while price is about the same (275.29 vs 275.61). All the buying volume from the gap rally has been given back. OBV is moving with price, so it shows no bullish divergence.
Since the 08-24 low (376.85M), OBV is still up 37.3M. Buying since late August has not been fully reversed.
Volume on up and down days since the peak:
Down days were heavier: 09-24 (9.56M), 09-28 (9.10M), 10-08 (6.16M).
Up days were lighter: 09-25 (6.99M), 09-29 (6.02M), 10-02 (5.90M).
This leans toward selling. Today's above-average volume on the drop adds to that.

8. Exhaustion (TD Sequential, 9-count)¶

Timeframe	Count	Reading
Weekly (main)	−4	Sell setup 4 of 9 (counts an advance)
Monthly	+2	Buy setup 2 of 9 (counts a decline)
Daily	+1	Buy setup 1 of 9 (counts a decline)

Weekly −4: each of the last four weekly closes was above the close four weeks earlier (275.61, 310.32, 307.49, and 275.29 for this week so far).
This week's close (Friday 10-09) needs to stay above 264.79 (the 09-11 weekly close) to keep the count going.
A weekly close below 264.79 would end the sell setup and start a buy count. That would confirm weekly momentum has turned down.
Monthly +2: the September (289.66) and October-so-far (275.29) closes are both below their closes four months earlier (May 353.29, June 354.57). This is an early count, consistent with the slide from the June peak.
Daily +1: today's 275.29 is below the 10-02 close of 307.49. If every close stays below the close four sessions earlier, the earliest a daily 9 could complete is about 10-20. That would be the first exhaustion-based buy signal, so it is not one yet.

9. Key Levels¶

Resistance, from nearest: 1. 286.73–290.50: unfilled gap from today (today's high vs the 10-07 low). It overlaps the Bollinger middle band (288.85) and the 50% retracement (about 288.6). 2. 293.23: 10 EMA, roughly 1 ATR above price. 3. 307.49 / 318.36: the 10-02 close and high, the most recent lower high. 4. 331.79–336.98: daily SuperTrend stop plus the 09-22/23 peak zone. A close above here would flip the daily trend up. 5. 383.15: weekly SuperTrend flip level.

Support, from nearest: 1. 269.37–270.26: rising 50 SMA plus today's low. This is the key level to watch. 2. 263–265: 78.6% retracement (about 263.07) and the weekly TD reference close (264.79). 3. 252–254: the 09-04 close (252.09) and 09-10 close (254.18). 4. 238–244: the mid-September closes and low (238.03), which is also about 2 ATR below price. 5. 232.93: lower Bollinger band, where the daily z-score would be about −2. 6. 219.35–225.46: 200 SMA, the August–September lows and the 07-29 close (224.89). 7. 198.17: monthly SuperTrend stop. The long-term bull regime fails below it.

10. Possible Scenarios¶

A. Breakdown (main risk, favoured by the weekly SuperTrend, the MACD cross and the volume pattern) - Trigger: a daily close below about 269 (the 50 SMA), especially on volume above 6M. - Targets: first 263–265, then 252–254. The 238–244 cluster and the 232.93 lower band are the levels where a stretched, oversold setup would line up. - What would confirm it: MACD falling below zero, ADX rising back above about 20 with the move, and a weekly close below 264.79.

B. Range holds (fits the low ADX and the higher lows) - The 50 SMA holds, and price swings between about 270 and 293. - Rallies into 286.7–293.2 face a gap, the Bollinger middle band and the 10 EMA all at the same zone. That makes it a low-risk area to trim longs or test a short, with a stop above 307.49 (about 1 ATR above 293).

C. Bullish recovery (needs confirmation) - Needed: the 50 SMA holds, then a daily close back above 293.23, with the MACD histogram turning back up and RSI back above 50. - Next levels: 307–318, then a retest of 331.79–336.98. - Only a close above about 337 would turn the daily trend up and make the September high a real breakout.

Practical notes for the trading agent: - Position size: with ATR at 6.45% of price, a 2-ATR stop (about 35.5 points) is about 12.9% of the price. Size positions for that. 1.5 ATR is about 26.6 points. - Don't chase in either direction. Price is in the middle of a wide range, and no exhaustion or stretch signal has fired. - Higher-probability long setups: - (a) price holds 269–270 and then retakes 293, or - (b) price drops to 233–244, where the lower Bollinger band, the higher-low structure and a z-score near −2 would all line up. - Events to watch: - Friday 10-09: does the weekly close hold 264.79? - Does the 50 SMA hold on a closing basis? - Is the MACD line moving toward zero? - Not covered: I can't see news or fundamentals. The 09-21 gap on 13.0M shares looks like it had a catalyst, but another agent would need to check that.

11. Key Points¶

Category	Indicator / Data	Latest Value	Reading	Effect on bias
Price	Close (2026-10-08)	275.29	−6.48% day. Opened at its high, closed 31% up the day's range. Gap from 09-21 fully filled.	Bearish
Volume	10-08 volume	6.16M	About 1.9x the prior three sessions; heavier down days since the peak	Bearish
Short-term trend	10 EMA	293.23	Price 6.1% below	Bearish
Medium-term trend	50 SMA	269.37 (rising)	Price 2.2% above; today's low 0.89 above it	Neutral to bullish (key support)
Long-term trend	200 SMA	219.35	Price 25.5% above; 50 SMA above 200 SMA	Bullish
Weekly trend (main)	SuperTrend	DOWN, stop 383.15	Price 28.15% below the flip level	Bearish
Monthly trend	SuperTrend	UP, stop 198.17	Price 38.91% above the stop	Bullish background
Daily trend	SuperTrend	DOWN, stop 331.79	Stop sits at the September peak zone	Bearish
Trend strength	ADX	12.45	Down from 40.30 (09-23); no trend, range-bound	Range tactics favoured
Momentum	MACD / signal / histogram	7.55 / 9.67 / −2.12	Bearish cross 10-07; MACD still above zero	Bearish, weakening
Momentum	RSI	46.66	Below 50; lower peaks 71.4, 61.2, 58.5; not oversold	Bearish to neutral
Volatility	ATR	17.76 (6.45%)	1 ATR ≈ 257.5 / 293.1; 2 ATR down ≈ 239.8	Size positions down
Volatility	Bollinger upper / middle / lower	344.77 / 288.85 / 232.93	Price in lower half; bands about 38.7% wide	Middle band is resistance
Stretch	Z-score (weekly / monthly / daily)	−0.46 / +1.12 / −0.49	Nothing stretched	No oversold signal
Volume trend	OBV	414.17M	Peak 437.66M (09-22); rally volume given back; no divergence	Neutral to bearish
Exhaustion	TD count (weekly / monthly / daily)	−4 / +2 / +1	Weekly count breaks if this week closes below 264.79; earliest daily 9 about 10-20	No signal yet
Resistance	Gap + middle band + 10 EMA	286.73–293.23	Strong overlapping levels	Sell or trim zone
Resistance	Daily stop + September peak	331.79–336.98	Daily trend flips above	Breakout trigger
Support	50 SMA + today's low	269.37–270.26	Key level	Breakdown trigger below
Support	Retracement + weekly TD reference	263.07–264.79	Second line of support	Weekly confirmation level
Support	Mid-September cluster + lower band	232.93–244	Where a stretched, oversold setup would form	Possible buy zone
Overall	Timeframes combined	—	Weekly and daily down, monthly up, ADX shows a range	Short-term bearish to neutral in a long-term uptrend. Wait for 269 to break or 293 to be reclaimed.

Sentiment Analyst¶

Overall Sentiment: Mildly Bearish (Score: 4.0/10) Confidence: Low

ARM Sentiment Report: 2026-10-01 to 2026-10-08¶

Bottom line: Sentiment on ARM (Arm Holdings plc) leans mildly bearish. News flow is dominated by two things: a sector-wide semiconductor and AI-trade sell-off tied to worries about OpenAI's revenue, and ARM-specific legal overhang from Qualcomm trials over royalties and chip testing tools. StockTwits shows a nominal 57% Bullish / 7% Bearish label split, but on 2026-10-08 the message content is mostly frustration and distress over a roughly 7-7.5% intraday drop. The labels therefore overstate retail optimism considerably. Reddit was disabled by configuration, so no community-discussion layer is available.

1. Source-by-source breakdown¶

A. News headlines (Yahoo Finance, 13 items) Caveat: only headlines and outlets were provided. There are no article bodies and no publication timestamps, so the sequence of events cannot be reconstructed and the framing is inferred from titles alone.

Sector/macro, bearish (2):
Investopedia, 'Worries About OpenAI's Revenue Rattle the AI Trade'.
MT Newswires, 'US Equity Indexes Drop as Sharp Sell-Off in Semiconductor Heavyweights Sinks Technology While Crude Oil Surges'.
Together these set a risk-off backdrop for AI-exposed chip names.
ARM-specific, negative (2):
Insider Monkey, 'Semiconductor Sector Sell-Off and Supply Execution Questions Weigh on Stock'.
GuruFocus, 'Arm Stocks Fall as Microsoft Brings Agentic AI to Laptops'. The headline does not explain why this is negative for ARM; the mechanism is unknown from the data.
ARM-specific legal events (2):
Simply Wall St., 'Arm Holdings (ARM) Heads To Trial Over Billions In Royalty Payments'.
Investing.com, 'Qualcomm and Arm begin new trial over chip testing tools'.
These are events, not opinions. They confirm active litigation with Qualcomm. The headlines alone cannot confirm whether they describe one proceeding or two related ones.
ARM-specific, constructive (2):
24/7 Wall St., 'Wall Street May Be Underestimating Arm's AI Opportunity' (bullish thesis).
Zacks, 'ARM Stock Rebounds 11.5% in a Month: Is it a Buy Right Now?' (neutral-to-positive; confirms strong prior momentum).
Neutral/comparative (1): Motley Fool, ARM vs. Marvell revenue trends.
Ambiguous/cautionary (1): 24/7 Wall St., 'The Highest-Beta Name in Big Tech Just Ran. Here's the Risk'. The headline does not name the company, so it cannot be confirmed as ARM.
Tangential (1): MarketBeat, Qualcomm's Huawei deal. It is relevant only because Qualcomm is ARM's counterparty in the trials.
Off-topic (2): ACM Research automation stocks; fusion power.
Net tone: of roughly 10 relevant headlines, about 4 are negative and 2 are legal-risk events, against 2 constructive. Institutional framing skews negative over the window.

B. StockTwits (30 most-recent messages, 21 unique authors) - Coverage: messages span only about 2026-10-07 15:56Z to 2026-10-08 21:18Z, roughly 30 hours of the 8-day window. They are heavily concentrated on the 2026-10-08 sell-off session. - Raw labels: 17 Bullish (57%), 2 Bearish (7%), 11 unlabeled (37%). - Among labeled posts only, the ratio is about 89/11. That is near the over-extension zone on its face. - However, the labels are a poor guide to tone here. - Label inflation: - 5 of the 17 Bullish tags come from a single user, @AutoAZTrader. All five are expletive-laden complaints about the decline ('Already down 7%', 'new LOD', 'Fucking manipulation', 'Seven percent down? Why the fuck now'). The Bullish tag reflects a held position, not a constructive outlook. - @hAeNa posted 'wtf happened why so sudden dropped' (distress), though the same user also posted 'added more'. - Another 4 Bullish tags carry no ARM thesis: two bare ticker lists from @Monty_Roysiin, @TopPi writing mainly about JKS, and @JumpnJack about a CoreWeave India deal. - @Essence's Bullish-tagged 'This CEO needs to play the right card in front of the media soon' reads as frustration. - Genuinely constructive posts (about 7): - @Ron_Burn: there is 'more demand with ticker' than initially anticipated, and he expects the gap to stay open this cycle. - @hAeNa: added more. - @jd4308: expects a bounce and dismisses the Qualcomm suit. - @theRooster007: 'when cleared $ARM may hit $400', implying upside if the litigation resolves. - @SwingPlay: 'all loaded' in a basket with NBIS, SOXL, AVGO and CRWV. - @Essence: notes a Lattice collaboration with Arm on secure AI data center infrastructure. - @Xorao121 (unlabeled, 10/7): '300 by the end of the day'. - Negative or skeptical content, mostly unlabeled (about 7): - @beztwits: 'ARM's CEO is a dirtbag and Judge Noreika has his number. ARM will end up paying Qualcomm a substantial amount'. - @19d (Bearish): ARM 'has habit of back stabbing its own customers', 'not trust worthy'. - @Baazigar123 (Bearish): 'Tariff risk', with no detail given. - @brahms1833: 'garbage'. - @Essence: 'What is wrong with this company? Communication'. - @devilinblue: AMD and ARM 'taken down approximately 25 bucks'. - @chessNwine: 'One of the hottest names in semiconductor space since the 9/16 FOMC rally began, now rolling back over... bigger risk is lower high vs. June'. - Informational posts: - @ace_of_king attributes the 10/8 drop specifically to the Qualcomm legal battle. He cites a 10/7 close of $294.37 and about $284-286 on the morning of 10/8, down roughly 3-4%. - @theoptionsplug reports -7.5% intraday, price testing the 50DMA, and $270 as key support after the daily gap was filled. - All of these price levels are user-reported and unverified. - Noise: two promotional @KryptonResearch14 posts. One frames the 'OpenAI news' chip sell-off as a buying opportunity, but for a memory-focused company, not ARM. - Content-adjusted read: roughly balanced between constructive and negative posts, with a large block of distress. The underlying tone is materially weaker than the 57/7 headline split.

C. Reddit (r/wallstreetbets, r/stocks, r/investing) - Not available: the feed was skipped because it is disabled by the sentiment_include_reddit config. - There is no read on measured (r/stocks) or longer-horizon (r/investing) discussion. - This is a meaningful gap, given that the key debate (litigation outcome versus long-term AI thesis) is exactly what those communities tend to discuss.

2. Cross-source divergences and alignments¶

Main divergence (within StockTwits): the label ratio says bullish while the message content says distressed. Treat the 57% Bullish figure as heavily inflated by one user's repeated venting and by off-topic ticker lists.
News vs. StockTwits labels:
On the surface they diverge: news is negative, labels are bullish.
After adjusting for content, they align on the same two drivers: (1) the AI and semiconductor sell-off linked to OpenAI revenue worries, and (2) Qualcomm litigation.
Retail confirms both. KryptonResearch references the 'OpenAI news' chip sell-off, and ace_of_king attributes the move to Qualcomm.
Retail is split on what caused the drop:
Some attribute it to ARM-specific legal risk (ace_of_king, beztwits).
Others blame 'manipulation' (AutoAZTrader, devilinblue).
The news flow supports a combination of sector beta and an idiosyncratic legal headline.
Agreement on prior momentum:
Zacks (11.5% monthly rebound) and chessNwine ('one of the hottest names... since the 9/16 FOMC rally') both confirm a strong run into the window.
That raises give-back risk and is consistent with the high-beta caution headline, if it refers to ARM.
Disagreement on the legal outcome: jd4308 expects the suit to 'amount to nothing', while beztwits expects ARM to pay Qualcomm 'a substantial amount'. Neither offers evidence beyond opinion.
Internal inconsistency on the gap: theoptionsplug and chessNwine say a daily gap was filled, while Ron_Burn says 'the gap... will remain open'. They may be referring to different gaps. This cannot be resolved from the data.

3. Dominant narrative themes¶

Qualcomm litigation overhang. This is the most recurring ARM-specific theme: two trial headlines plus about five StockTwits posts (beztwits, 19d, ace_of_king, jd4308, theRooster007's 'when cleared'). It frames ARM's near-term path as hostage to courtroom developments.
AI-trade and semiconductor risk-off. OpenAI revenue worries and a 'sharp sell-off in semiconductor heavyweights' hit high-multiple AI names broadly.
Momentum give-back and technical damage. After a strong run (11.5% monthly rebound, a hot name since 9/16), traders flag a gap fill, a test of the 50DMA and $270, and the risk of a lower high versus June.
Long-term AI opportunity. This is the bullish counter-narrative: 24/7 Wall St. argues the AI opportunity is underestimated, the Lattice secure AI data center collaboration, and dip-buyers adding exposure.
Management credibility and communication. Several retail posts criticize the CEO and the company's communication or customer relations (Essence twice, beztwits, 19d). This is a soft but recurring reputational thread linked to the Qualcomm dispute.
Competitive and product headline risk. 'Arm Stocks Fall as Microsoft Brings Agentic AI to Laptops'. The mechanism is unclear from the headline alone.

4. Catalysts and risks surfaced by the data¶

Potential upside catalysts: - Favorable trial developments or resolution of the Qualcomm litigation. The '$400 when cleared' thesis is retail opinion, not evidence. - Recognition of the AI opportunity (24/7 Wall St. thesis). - AI data center partnerships such as the Lattice collaboration (user-reported). - Holding the $270 / 50DMA support zone that traders are watching. - A rebound in the broader semiconductor complex if AI-trade worries ease.

Key risks: - An adverse ruling or damages in the royalty trial ('billions in royalty payments'). - A second front in the chip-testing-tools trial. - Continued AI capex skepticism tied to OpenAI revenue concerns. - High beta to semiconductor sector moves. - The Microsoft agentic AI on laptops headline. - 'Supply execution questions' (Insider Monkey; no detail provided). - Tariff risk (a single unsupported post; low weight). - Macro pressure from surging crude oil. - Technical risk of a lower high versus June, after a failed push toward $300 on 10/7.

Missing information: - No earnings date, guidance, analyst rating changes or price targets appear in the data. - No trial schedule or ruling dates are provided.

5. Summary of key sentiment signals¶

Signal	Direction	Source	Supporting evidence
AI-trade / semiconductor sell-off	Bearish	News (Investopedia, MT Newswires); StockTwits (KryptonResearch)	'Worries About OpenAI's Revenue Rattle the AI Trade'; 'Sharp Sell-Off in Semiconductor Heavyweights'
Qualcomm litigation	Bearish (binary event risk)	News (Simply Wall St., Investing.com); StockTwits	Trial over 'billions in royalty payments'; new trial over chip testing tools; beztwits, 19d, ace_of_king attribute weakness to the legal battle
ARM-specific negative headlines	Bearish	News (Insider Monkey, GuruFocus)	'Supply Execution Questions Weigh on Stock'; 'Arm Stocks Fall as Microsoft Brings Agentic AI to Laptops'
Long-term AI thesis	Bullish	News (24/7 Wall St.); StockTwits (Essence)	'Wall Street May Be Underestimating Arm's AI Opportunity'; Lattice secure AI data center collaboration
Prior momentum	Mixed (supportive but give-back risk)	News (Zacks, 24/7 Wall St.); StockTwits (chessNwine)	11.5% monthly rebound; 'hottest names... since 9/16'; 'now rolling back over'; high-beta caution headline
StockTwits label ratio	Bullish (nominal)	StockTwits	17 Bullish / 2 Bearish / 11 unlabeled of 30
StockTwits content tone	Bearish / distressed	StockTwits	5 of the 17 Bullish tags are @AutoAZTrader venting about a 7% drop; hAeNa 'why so sudden dropped'; 'garbage'; 'what is wrong with this company'
Dip-buying cohort	Mildly bullish	StockTwits	hAeNa 'added more'; SwingPlay 'loaded'; jd4308 'expecting a bounce'
Technical setup	Bearish-to-neutral	StockTwits (theoptionsplug, chessNwine, ace_of_king)	10/7 close $294.37, then -7 to -7.5% on 10/8; testing 50DMA and $270 support; lower-high risk vs June (all user-reported)
Management credibility	Bearish (soft)	StockTwits	CEO criticism (beztwits, Essence); 'back stabbing its own customers' (19d)
Tariff exposure	Bearish (low weight)	StockTwits (Baazigar123)	Single two-word post, no detail
Reddit community read	Unavailable	Reddit	Disabled by sentiment_include_reddit config

Confidence rationale¶

Confidence is low for four reasons: - Reddit is unavailable: it returned a disabled placeholder. - News is headlines only: no bodies or timestamps were provided. - StockTwits coverage is narrow: it spans only about 30 hours of the 8-day window and is dominated by a single sell-off session. - StockTwits is skewed by one user: a single account produced 5 of the 17 Bullish tags, which distorts the label ratio.

The mildly bearish read rests mainly on negative news framing plus content-adjusted retail distress. It is partly offset by a persistent long-term AI bull thesis and visible dip-buying. This is sentiment signal for the trader to weigh alongside fundamentals and technicals, not a price forecast.

News Analyst¶

ARM (Arm Holdings plc) news and macro report, as of October 8, 2026¶

1. Summary¶

ARM is a high-multiple, high-beta AI semiconductor stock, and the macro picture this week is unfriendly to stocks like it:

The Fed has started raising rates again. The market expects at least one more hike.
The 10-year Treasury yield is around 5.3%, up 115 bp in a year.
Oil is above $100.
Worries about OpenAI's revenue have hit the AI trade.

On the stock itself:

A rebound has stalled. ARM had bounced about 11.5% over the past month, but a broad chip-stock sell-off this week has stalled it.
There is new legal risk. A new Arm vs. Qualcomm trial has started, with billions in royalty payments reportedly at stake.

The offset is that the market sees little crisis risk. Recession odds are 6%, the odds the "AI bubble" bursts in 2026 are 6%, and the VIX volatility index is low at about 15. Prices look like an orderly pullback in an AI trade that is still intact, not a collapse. The main risk is that long-term rates keep climbing and squeeze valuation multiples.

2. Macro backdrop: the Fed is hiking again¶

2.1 Fed policy¶

Data (FRED / Polymarket)	Reading	What it means
Effective Fed funds rate (monthly average)	3.75% in Sep 2026, up from 3.63% in Aug	First increase after holding at about 3.63–3.64% from Jan to Aug. The average fits a ~25 bp hike in mid-September, which would put the current rate near ~3.85–3.9% (my inference).
"No Fed cuts in 2026" (Polymarket, $8.8M volume)	96%	Rate cuts are effectively off the table this year.
"2 Fed hikes in 2026"	70% (+10.5 pp this week)	The market expects the September hike plus one more.
"Another Fed hike in 2026" (resolves Dec 10)	78% (+1.5 pp)	The next hike is most likely in December.
October FOMC: no change / +25 bp	84% / 16% (no-change odds +10 pp this week)	The late-October meeting is likely a hold, but the press conference tone matters.

Takeaway: The policy path is clearly hawkish. There is some near-term relief, since odds of an October hike fell 9 pp this week. A December hike is the base case.

2.2 Inflation is sticky, and energy is pushing headline inflation up¶

CPI: 334.131 in Aug 2026, up 2.79% since Nov 2025, about 3.7% annualized. The jump came mostly in Mar–May (+~2.0% in three months), which fits an oil and geopolitical shock. June fell 0.4%, then Aug rose 0.40% month over month, so momentum picked up again.
Core PCE (the Fed's preferred inflation measure, excluding food and energy): Aug +0.25% m/m. That is about 2.7% annualized over six months and about 3.1% annualized since Oct 2025. It is not spiraling, but it is clearly above the Fed's 2% target.
Real policy rate: about +0.8 to +1.2% (Fed funds minus core PCE). That is restrictive and getting tighter.

2.3 Labor market¶

Unemployment: 4.2% in Sep, up slightly from 4.1% in Jul–Aug but down from 4.5% in Nov 2025. That is firm enough for the Fed to keep hiking without much worry about growth.

2.4 Rates: the most important macro variable for ARM¶

10-year Treasury yield: 5.28% (Oct 7). It peaked at 5.31% on Oct 5. It was 4.68% in mid-August and 4.13% a year ago.
10-year minus 2-year spread: +0.47% (Oct 8), widening from +0.20% on Sep 21.
Implied 2-year yield (10-year minus spread, my calculation): about 4.15% on Aug 13, about 4.76% on Sep 21, and about 4.77% on Oct 7.
The rate move has two phases:
Mid-Aug to late Sep: short-term yields led (2-year +~60 bp) as markets priced in the Fed hike.
Since Sep 21: the 2-year is flat and the 10-year is up ~32 bp. Long-term yields are rising faster than short-term ones (a "bear steepener"), driven by inflation, fiscal, or term-premium worries rather than Fed expectations.
Why phase 2 matters: this kind of move does the most damage to stocks valued on profits far in the future, like ARM. Yahoo Finance's Chart of the Day this week also noted that "rapid bond yield moves have preceded nearly every major financial blowup."
Side effect: mortgage rates are at their highest in nearly three years, a drag on housing and consumers.

2.5 Volatility, commodities and geopolitics¶

VIX at 15.08 (Oct 7), in a 14–18 range for two months. Stock-market volatility looks calm compared with how fast yields are moving. That gap usually closes through stocks repricing, not bonds.
Oil at about $103, falling after President Trump said the US will not attack Iran before the midterms. The odds of a US invasion of Iran before 2027 are 16% (+2 pp this week; $72.9M volume). Oil above $100 keeps headline inflation, and so Fed hike odds, high.
Gold settled at $4,131.80 (+0.44%), consistent with ongoing demand for protection against inflation and geopolitical risk.
Taiwan: invasion odds by end-2026 are 2%, and a military clash before 2027 is 5%. This is a small but very damaging tail risk for the chip supply chain.
US midterms (Nov 3): Democrats are 90% likely to win the House, and a Democratic sweep of both chambers is 62%. Divided government or a Democratic Congress lowers the odds of new fiscal stimulus, and policy uncertainty around tariffs and chips could pick up after the election.
Recession: US recession by end-2026 is priced at 6% (−2 pp). Growth is not the worry; rates and valuations are.

3. Semiconductors and the AI trade¶

OpenAI revenue worries are shaking the AI trade (Investopedia). This hits ARM directly in two ways:
Indirectly through demand: OpenAI-linked data-center buildouts use Arm-based server CPUs.
Through SoftBank (background, not from this week's news): SoftBank owns about 90% of ARM, is one of OpenAI's largest backers, and has borrowed against its ARM shares. Stress on OpenAI's finances can turn into pressure on ARM through SoftBank's need for cash.
Sharp sell-off in chip heavyweights while crude oil surged (MT Newswires). US indexes fell as semis led technology lower. This is the combination of higher rates and higher oil working against long-duration tech.
Chip stocks fell despite Samsung guiding to record profit (Yahoo AlphaCheck). When strong news gets sold, the trade is usually crowded and investors are fatigued. Chip stocks are reacting to rates and positioning more than to fundamentals.
Prediction markets do not see a crash. "AI bubble burst in 2026" is 6% (−1.9 pp) and "by mid-2027" is 18%. OpenAI's eventual IPO valued above $1T is 72% (−2.5 pp this week). Confidence in AI's long-term value is slipping slightly, not breaking.

4. ARM company news (Oct 1–8)¶

I only had headlines, not full articles, so details should be checked.

Theme	Headline / source	Read-through for ARM
Price action	"ARM Stock Rebounds 11.5% in a Month: Is it a Buy?" (Zacks)	Positive momentum into October, now being tested by the sector sell-off.
Sector pressure and execution	"Semiconductor Sector Sell-Off and Supply Execution Questions Weigh on Stock" (Insider Monkey)	New concern. "Supply execution" probably relates to Arm's push to sell its own chips rather than only license designs. If so, that adds risks around manufacturing, inventory and customer conflict to a business that has been licensing-only with high margins. Unconfirmed.
Legal	"Arm Heads To Trial Over Billions In Royalty Payments" (Simply Wall St); "Qualcomm and Arm begin new trial over chip testing tools" (Investing.com)	A new trial with Qualcomm, a major licensee, is underway. Background: the Dec 2024 Delaware jury verdict on the Nuvia licensing dispute largely went Qualcomm's way. A ruling against Arm could hurt royalty assumptions and its pricing power with licensees. Expect sharp moves on trial headlines.
PC exposure	"Arm Stocks Fall as Microsoft Brings Agentic AI to Laptops" (GuruFocus)	The market read Microsoft's AI-laptop push as not favoring Arm, or as favoring rival x86 chips. Windows-on-Arm PCs are a growth area, so this needs watching.
Competition and licensees	"Qualcomm's Huawei Deal Adds Strategic Depth to Its AI Expansion" (MarketBeat)	Qualcomm is both Arm's licensee and its courtroom opponent. Its broader AI and China partnerships strengthen its hand in the dispute.
Bull case	"Wall Street May Be Underestimating Arm's AI Opportunity" (24/7 Wall St); "ARM vs. Marvell: Revenue Trends" (Motley Fool)	The long-term story is still accepted: Arm-based data-center CPUs, higher royalty rates per chip with its v9 and compute-subsystem designs, and AI at the edge. Bulls are still writing about it.
Beta warning	"The Highest-Beta Name in Big Tech Just Ran. Here's the Risk" (24/7 Wall St)	Appeared in ARM's news feed; it is unclear whether it is about ARM. Either way, ARM's high beta (sensitivity to market moves) works against it in a sell-off driven by rising yields.

Upcoming catalysts¶

Mid-October: September CPI. A second hot month in a row (after Aug's +0.40%) would raise December hike odds above 78% and push the 10-year toward or above 5.3%.
Ongoing: Qualcomm trial. Expect headline risk in both directions, with a large gap move on a verdict.
Oct 27–28: FOMC. 84% hold. Watch for a hawkish signal on December.
Nov 3: US midterms.
Early November (estimate based on past timing, not confirmed): ARM fiscal Q2 FY27 results. Watch data-center royalty growth, any commentary on its own silicon and supply, guidance, and any legal reserves.

5. What this means for trading¶

The 10-year yield is the main driver for ARM. A long-term-led rise in yields (2-year flat, 10-year +32 bp since Sep 21) hurts high-multiple stocks most. If the 10-year holds above about 5.3%, expect ARM to lag the semiconductor index; a drop back below about 5.0% would be the clearest signal for multiples to recover.
Low VIX next to fast-rising yields is a mismatch. Equity options look cheap compared with rate volatility. With the trial, CPI, FOMC, midterms and earnings all within about four weeks, owning volatility or protection on ARM, or hedging existing positions, is better value than usual.
Watch reactions more than news. If chip stocks keep falling on good news like Samsung's record guidance, positioning, not fundamentals, is setting prices. If ARM can't hold its rally when good AI news arrives, that is a warning sign.
Price in legal risk separately. The Qualcomm trial can cause large single-stock moves regardless of macro. Single-name exposure should account for that risk around the verdict.
Watch SoftBank and OpenAI. ARM can be hit by SoftBank's finances and by OpenAI funding or revenue headlines even when its own fundamentals are fine.
What would turn this around:
a softer September CPI that cuts December hike odds,
oil continuing to fall on easing Iran risk,
a favorable trial outcome,
strong data-center royalty numbers at earnings.

The 11.5% one-month rebound shows buyers are still there.

Data gaps: FRED rate-limited my requests for WTI oil, the 2-year yield and breakeven inflation, so oil comes from news ($103) and the 2-year is derived from the 10-year and the spread. ARM's price, valuation multiples and technical indicators were outside my tools and should come from another agent. The ARM news search returned nothing for Sep 20–30; the tool said this was a search limitation, not a sign there was no news.

6. Key points¶

Category	Indicator / Event	Latest reading	Direction / change	Impact on ARM
Fed policy	Effective Fed funds rate	3.75% (Sep avg), up from 3.63%	First hike of the cycle (mid-Sep, inferred)	🔴 Negative
Fed outlook	"2 hikes in 2026" / "Another hike by Dec 10"	70% / 78%	+10.5 pp / +1.5 pp this week	🔴 Negative
Fed outlook	Oct FOMC hold	84%	+10 pp (less risk of an October hike)	🟡 Mildly positive near term
Fed outlook	"No cuts in 2026"	96%	Firm	🔴 Negative
Rates	10-year Treasury	5.28% (peak 5.31% Oct 5)	+115 bp YoY; +32 bp since Sep 21	🔴 Strongly negative (long-duration stock)
Rates	10-year minus 2-year	+0.47%	Widened from +0.20% (Sep 21), long-term yields leading	🔴 Negative
Inflation	CPI	+0.40% m/m (Aug); ~3.7% annualized since Nov 2025	Re-accelerating	🔴 Negative
Inflation	Core PCE	+0.25% m/m (Aug); ~2.7% annualized over 6 months	Sticky above target	🟡 Neutral to negative
Labor	Unemployment	4.2% (Sep)	+0.1 pp from Aug	🟡 Neutral (doesn't stop hikes)
Volatility	VIX	15.08	Range 14–18; calm next to rate moves	🟡 Complacency risk; hedges cheap
Commodities	Oil / gold	~$103 / $4,131.80	Oil easing on Iran comments; gold firm	🟡 Oil above $100 keeps inflation high
Geopolitics	US invades Iran before 2027 / China invades Taiwan in 2026	16% / 2%	+2.0 pp / −0.5 pp	🟡 Tail risks
Growth	US recession by end-2026	6%	−2 pp	🟢 Supportive
AI sentiment	AI bubble bursts in 2026 / OpenAI IPO above $1T	6% / 72%	−1.9 pp / −2.5 pp	🟡 Slipping, not breaking
Sector	Chip-stock sell-off; Samsung record guidance sold	Semis led indexes lower	Crowded trade	🔴 Negative
ARM: momentum	One-month rebound	+11.5% (Zacks)	Stalling in sector sell-off	🟡 Being tested
ARM: legal	New Qualcomm trial (royalties, "billions")	Trial underway	Verdict could cause a large gap move	🔴 Event risk
ARM: execution	"Supply execution questions"	New concern (Insider Monkey)	Unclear; likely own-chip push	🔴 Watch
ARM: PC	Microsoft agentic AI laptops	ARM fell on the news	Windows-on-Arm risk	🔴 Mildly negative
ARM: ownership	SoftBank (~90% owner, large OpenAI backer)	OpenAI revenue worries	Risk spreads through SoftBank	🔴 Watch
Catalysts	Sep CPI (mid-Oct), FOMC (Oct 27–28), midterms (Nov 3), ARM fiscal Q2 earnings (early Nov, estimated)	—	Four big events in ~4 weeks	⚠️ High volatility window
Bottom line	Macro and sector trends work against ARM; long-term AI story intact	—	Main swing factors: 10-year yield and Qualcomm trial	Cautious near term; buy volatility or hedge rather than chase

Fundamentals Analyst¶

ARM (Arm Holdings plc): Fundamental Analysis Report¶

As of 2026-10-08 · Technology / Semiconductors · Exchange: NMS (Nasdaq) · Fiscal year ends March 31

1. Summary¶

ARM is a high-quality business with a very high valuation. Revenue has grown about 20–23% a year for three years. Gross margin is about 97%. The balance sheet holds about $3.06B in cash and no meaningful financial debt. Over the last twelve months the company produced roughly $1.5B in free cash flow.

There are two problems: 1. Operating leverage has turned negative. Operating expenses are growing about 28% a year while revenue grows about 22%. In the latest quarter (Q1 FY27, June 2026) operating margin fell to 7.1%, the lowest of any quarter in the dataset outside the IPO-charge quarter. 2. The price assumes strong future growth. The stock trades at about 300x trailing GAAP EPS, ~90x forward EPS, ~57x TTM sales, with a free cash flow yield of about 0.5% and a beta of 3.79.

Insiders sold about $72M of stock between March and September 2026 and made no open-market purchases.

No insider transactions or new financial filings appear in the tool data for the past week (Oct 1–8, 2026). The most recent data points are the June 2026 quarterly report and a CFO stock sale on 2026-09-21.

2. Company Profile and Market Data¶

Metric	Value
Market Cap	$294.0B
Implied share price	~$275.3 (calculated from P/E × EPS and P/B × book value; the two agree)
Implied shares outstanding	~1.068B
52-Week High / Low	$452.70 / $100.02
Distance from 52W High / Low	~39% below the high / ~175% above the low
50-Day / 200-Day Average	$268.36 / $218.54
Price vs 50DMA / 200DMA	+2.6% / +26% (50DMA is above the 200DMA)
Beta	3.79 (very high)
Dividend	None

Business model: ARM licenses CPU and system designs and collects royalties on chips that use them. That is why cost of revenue is only about $30–36M a quarter against more than $1.2B of revenue.

Price path, reconstructed from insider sale prices: about $148 (late March 2026) → $160–180 (April) → $207–$257 (mid-May) → $384–$416 (June 1), with the 52-week high at $452.70 → about $242–$255 (late August) → $300 (Sep 21) → about $275 now. That is a rise of roughly 3x and then a drop of about 45% from the peak within six months, which fits the 3.79 beta.

3. Income Statement Analysis¶

3a. Annual trend (fiscal years end March 31)¶

FY	Revenue	YoY	Gross Margin	Op Income	Op Margin	Net Income	Diluted EPS
FY22	$2,703M	—	95.2%	$633M	23.4%	$549M	$0.54
FY23	$2,679M	-0.9%	96.0%	$671M	25.0%	$524M	$0.51
FY24	$3,233M	+20.7%	95.2%	$111M	3.4%*	$306M	$0.29
FY25	$4,007M	+23.9%	97.0%	$831M	20.7%	$792M	$0.75
FY26	$4,920M	+22.8%	97.5%	$900M	18.3%	$904M	$0.85

*FY24 was depressed by the IPO-quarter charge (September 2023 quarter operating loss of -$156M).

Revenue grew at about a 22% compound annual rate from FY23 to FY26.
In FY26, operating income grew only +8.3% against revenue growth of +22.8%. Operating expenses rose from about $3.06B to about $3.90B (+27.6%).
FY26 EPS was $0.85, up 13%. Earnings are growing much more slowly than revenue.

3b. Quarterly trend (Q4 figures calculated as annual minus the first nine months)¶

Quarter	Revenue	YoY	OpEx (GP − OI)	Op Income	Op Margin	Net Income	EPS
Q1 FY26 (Jun-25)	$1,053M	+12.1%	$909M	$114M	10.8%	$130M	$0.12
Q2 FY26 (Sep-25)	$1,135M	+34.5%	$943M	$163M	14.4%	$238M	$0.22
Q3 FY26 (Dec-25)	$1,242M	+26.3%	$1,027M	$185M	14.9%	$223M	$0.21
Q4 FY26 (Mar-26)†	$1,490M	+20.1%	$1,020M	$438M	29.4%	$313M	$0.30
Q1 FY27 (Jun-26)	$1,289M	+22.4%	$1,162M	$91M	7.1%	$270M	$0.25

†Calculated. TTM revenue ($5,156M) and TTM net income ($1,044M) match the reported fundamentals exactly, which confirms these figures.

Points from the quarterly data: 1. Revenue growth has held above 20% for four straight quarters. The drop from Q4 to Q1 is seasonal (-13.5% this year versus -15.1% a year earlier), because the March quarter usually carries more licensing revenue. 2. Operating expenses jumped. Q1 FY27 opex was $1,162M, up 27.8% year over year and up 13.9% from the prior quarter. Opex now equals about 90% of revenue. Operating income fell 20% year over year even though revenue grew 22%. 3. Earnings quality was weak. Q1 FY27 net income of $270M was about 3x operating income of $91M. A year earlier, the gap between net income and operating income was only $16M. About $179M of the net income therefore came from items below operating income, such as interest income, investment gains or tax benefits. The tools do not provide a breakdown. One plausible contributor is tax deductions from shares vesting during the May rally. Year-over-year EPS growth of +108% overstates the improvement in the core business. 4. Gross margin is stable at about 97%, so pricing and royalty economics are intact. The margin pressure comes entirely from spending.

4. Cash Flow Analysis¶

The tool reports cash flows as year-to-date totals, so single quarters were calculated by subtraction.

Period	Operating CF	CapEx	FCF (OCF − CapEx)
FY23	$739M	$64M	$675M
FY24	$1,090M	$92M	$998M
FY25	$397M	$219M	$178M
FY26	$1,524M	$545M	$979M
Q1 FY26 (Jun-25)	$332M	$154M	$178M
Q2 FY26	$567M	$138M	$429M
Q3 FY26	$365M	$179M	$186M
Q4 FY26	$260M	$74M	$186M
Q1 FY27 (Jun-26)	$902M (record)	$197M	$705M
TTM	~$2,094M	~$588M	~$1,506M (29% margin)

(The fundamentals feed lists FCF at $1,334.5M. It likely uses a different "levered FCF" method.)

Points from the cash flow data: - Free cash flow converts well: TTM FCF of about $1.5B is about 1.44x TTM net income. Non-cash stock compensation is one reason. - The record Q1 FY27 operating cash flow was partly a working-capital effect. Non-cash current assets fell about $204M from March to June (likely collection of receivables from the strong Q4), and current liabilities rose $167M. Together that adds about $370M, so underlying operating cash flow was probably closer to $500–550M. Investors should not treat $900M a quarter as the new normal. - Capital spending has risen sharply: $92M (FY24) → $219M → $545M (FY26, +149%), and $197M in Q1 FY27. That is 11–15% of revenue, up from about 3%. ARM appears to be becoming more capital-intensive. This likely reflects spending on compute infrastructure and a move toward selling more complete compute designs. The tools do not provide a breakdown. - Financing outflows are growing: -$548M in FY26 and -$326M in Q1 FY27, up from -$123M a year earlier. There is no dividend and no meaningful debt. The likely cause is tax paid on employees' behalf when restricted stock vests, which was large in May 2026. In effect, stock compensation is costing real cash.

5. Balance Sheet Analysis¶

Item	Jun-25	Mar-26	Jun-26	1-yr change
Total Assets	$9,395M	$10,703M	$11,196M	+19%
Current Assets	$5,173M	$6,236M	$6,339M	+23%
Cash & Equivalents	$1,956M	$2,751M	$3,058M (highest in dataset)	+56%
Total Liabilities	$2,388M	$2,417M	$2,566M	+7%
Current Liabilities	$1,037M	$1,040M	$1,207M	+16%
Stockholders' Equity	$7,007M	$8,286M	$8,630M	+23%

Liquidity is very strong: the current ratio is 5.25 and working capital is about $5.1B.
Leverage is minimal: debt-to-equity is 0.06x (about $485M, probably mostly lease obligations). Liabilities are only about 23% of assets.
Equity has more than doubled since March 2023 ($4.05B → $8.63B), driven by retained earnings and stock compensation.
Returns are modest for the valuation: ROE is 13.4% and ROA is 5.4%. Book value is $8.08 per share, so price-to-book is 34x.
Enterprise value is about $291B ($294B market cap − $3.06B cash + ~$0.49B debt). Short-term investments are not broken out, so this may slightly overstate EV.

6. Valuation¶

Metric	Value	Comment
P/E (TTM, GAAP)	302.5x (281x on summed quarterly EPS of $0.98)	Extreme
Forward P/E	89.9x (forward EPS $3.06)	Forward EPS is likely a non-GAAP consensus that excludes stock compensation. The jump from $0.91 to $3.06 is mostly accounting basis, not growth.
PEG	2.48	Expensive even after adjusting for growth
P/S (TTM)	~57x
EV / TTM operating income	~330x
P/FCF (TTM)	~195–220x	FCF yield about 0.45–0.51%
P/B	34.1x

What the price implies: for ARM to trade at 30x GAAP earnings at today's price, EPS would need to rise about 10x to roughly $9.20. The valuation depends on ARM's role in AI and data-center chips and on royalty rates continuing to rise. The financials show steady 20–23% growth, not acceleration, so there is little cushion if growth or margins disappoint. Combined with a 3.79 beta, large swings in both directions should be expected.

7. Insider Activity (March 25 – September 21, 2026)¶

No open-market purchases. There were 18 sales by 7 insiders: about 323,700 shares for about $72.2M.

Insider	Role	Shares Sold	Value	Price Range
Jason Child	CFO	95,280	~$20.0M	$148 → $180 → $227 → $255 → $300
Spencer Collins	Officer (CLO)	92,902	~$19.8M	$208–$215
William Abbey	Officer	43,831	~$12.0M	$199–$416
Rene Haas	CEO	41,152	~$6.6M	$160–$163 (Mar/Apr only)
Richard Grisenthwaite	Officer	24,339	~$5.1M	$209
Charlotte Eaton	Officer	14,905	~$4.2M	$252–$291
Laura Bartels	Officer	11,306	~$4.4M	$393

How to read this: - Most sales clustered right after the May 15, 2026 vesting and grant date. That day the CEO received 265,643 shares, the CFO 81,359 and Collins 69,117. Several entries dated May 15 have no price, which usually means shares were withheld for taxes. Much of the selling was routine diversification after vesting, not a sign of bad news. - The CFO sold at steadily higher prices. His sales ran $148 → $180 → $227 → $255 → $300, in fixed lot sizes and at partly round prices. That pattern fits a pre-arranged trading plan with price triggers. His latest sale was 10,400 shares at $300 on Sep 21. If the plan continues, more stock may be sold if the price moves back above $300. - Slightly positive: CEO Haas has not sold since April 14 (at about $160), including during the run to more than $400. - Negative: nobody bought in the late-August dip to about $242–$255. - Director Jeffrey Sine gifted 9,572 shares on Aug 7. Gifts are not an economic signal. - The total sold is immaterial relative to about 1.07B shares outstanding. Note that, as general background not taken from these tools, SoftBank owns about 90% of ARM. The small public float adds to volatility.

8. Takeaways for Traders¶

Next catalyst: Q2 FY27 earnings (September quarter), likely in early November 2026. The year-ago figures to compare against are revenue $1,135M, operating income $163M (14.4% margin) and EPS $0.22. About 22% growth would mean revenue of roughly $1.38B.
Signs of strength: revenue growth of 22% or more, opex growth slowing below 25%, and operating margin back above 14%. That would support the forward multiple.
Signs of weakness: operating margin staying in single digits, or net income again relying on non-operating items. That would undermine the forward EPS of about $3.06, and with a beta of 3.79 the downside move could be large.
Look past headline EPS. The +108% EPS jump in Q1 FY27 was driven by items below operating income. Operating income actually fell 20%. Focus on operating margin and opex growth.
Watch capital spending and stock-compensation cash costs. Capex at 11–15% of revenue and financing outflows of $300M or more per quarter reduce how much free cash flow is left for shareholders. This changes the "asset-light royalty" story.
The balance sheet sharply limits failure risk: $3.06B cash, no meaningful debt, current ratio of 5.25. The risk is in the valuation, not solvency.
Price context: the stock is about $275, slightly above its 50-day average ($268) and well above its 200-day average ($219), but 39% below the June peak. The late-August range of about $242–$255 is a recent low area. Around $300, the CFO's trading plan and the September high may bring selling.
Position sizing: with a beta of 3.79 and a 52-week range of $100–$453, position size should reflect very high volatility. On fundamentals, the stock is fairly valued to expensive.

Overall view: strong fundamentals and balance sheet, deteriorating operating margins, an extreme valuation, and insiders consistently selling. The next earnings report is the key test. The final trade decision is left to the decision-making agent.

Data limitations: the tools do not provide revenue split by licensing vs. royalty, stock-compensation expense, R&D detail, short-term investments, receivables (including related-party Arm China balances), or a breakdown of items below operating income. No news or filings dated within the past week appeared in the tool data.

Key Metrics Summary Table¶

Category	Metric	Value	Signal
Valuation	Market Cap / Implied Price	$294.0B / ~$275.3	—
	Trailing P/E (GAAP)	~281–303x	🔴 Extreme
	Forward P/E / PEG	89.9x / 2.48	🔴 Expensive
	P/S (TTM) / P/B	~57x / 34.1x	🔴 Expensive
	FCF Yield (TTM)	~0.5%	🔴 Very low
Growth	FY26 Revenue / YoY	$4,920M / +22.8%	🟢 Strong
	TTM Revenue	$5,156M	🟢
	Q1 FY27 Revenue / YoY	$1,289M / +22.4%	🟢 Steady
	FY23–FY26 Revenue CAGR	~22%	🟢
Profitability	Gross Margin	~97%	🟢 Very high
	Q1 FY27 Operating Margin	7.1% (vs 10.8% a year earlier)	🔴 Falling
	Q1 FY27 OpEx Growth (YoY / QoQ)	+27.8% / +13.9%	🔴 Outpacing revenue
	FY26 Op Income Growth	+8.3% vs revenue +22.8%	🟠 Negative operating leverage
	Q1 FY27 Net Income vs Op Income	$270M vs $91M	🟠 Weak earnings quality
	TTM Net Margin / ROE / ROA	20.2% / 13.4% / 5.4%	🟡 Moderate
Cash Flow	TTM OCF / FCF	~$2.09B / ~$1.51B	🟢 Strong
	Q1 FY27 OCF / FCF	$902M / $705M (record)	🟢, partly working capital
	FY26 CapEx / % of revenue	$545M / 11% (vs 3% in FY24)	🟠 Rising capital needs
	Financing outflow Q1 FY27	-$326M (likely vesting taxes)	🟠 Stock comp costs cash
Balance Sheet	Cash (Jun-26)	$3,058M (+56% YoY)	🟢
	Current Ratio / Debt-to-Equity	5.25 / 0.06x	🟢 Very strong
	Equity / Book Value per Share	$8,630M / $8.08	🟢 Growing
Market / Risk	Beta	3.79	🔴 Very volatile
	52W Range / Distance from High	$100.02–$452.70 / -39%	🟠
	Price vs 50DMA / 200DMA	+2.6% / +26%	🟡 Moderately positive trend
Insiders	Mar–Sep 2026 activity	18 sales, ~$72.2M, 0 buys	🔴 Net selling
	Latest transaction	CFO sold 10,400 @ $300 (Sep 21)	🟠 Likely planned sales
	CEO activity	Last sale Apr 14 @ ~$160	🟡 No selling into the rally
Catalyst	Next earnings (Q2 FY27, est. early Nov)	Year-ago: revenue $1,135M, op margin 14.4%, EPS $0.22	⚠️ Key test of operating margin

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Opening: ARM

The bear hasn't spoken yet, so I'll make the case and then answer the objections I expect.

The setup¶

ARM fell 6.48% today to $275.29. That fully filled the September 21 gap. I see that as a good entry, not a broken thesis.

The selling was sector-wide. OpenAI revenue worries pulled down semiconductor leaders across the board. Chip stocks fell even after Samsung guided to record profit. When good news gets sold, positioning is driving prices, not fundamentals.
The trend held. Today's low of $270.26 stopped $0.89 above a rising 50-day SMA ($269.37). Price is still 25.5% above the 200-day, the 50-day is above the 200-day, and the monthly SuperTrend points up with its stop at $198.

1. The business keeps compounding¶

Revenue growth is steady. Revenue grew about 22% a year from FY23 to FY26, and the last four quarters each grew more than 20%. Q1 FY27 revenue was $1,289M, up 22.4%.
Gross margin is rising. It went from 95.2% in FY22 to 97.5% in FY26. A company losing pricing power doesn't widen gross margin.
The royalty model is hard to replicate. Cost of revenue runs about $30–36M against quarterly revenue above $1.2B. Each chip shipped on Arm pays ARM, whether it goes into phones, Windows-on-Arm PCs, edge AI devices or data-center CPUs. Newer designs (v9 and the compute subsystems) earn higher royalty rates per chip.
Even its opponent depends on it. Qualcomm is suing ARM and still builds its products on Arm architecture. The dispute is about contract terms. Nobody is leaving the ecosystem.

2. The balance sheet removes solvency risk¶

Metric	Value
Cash	$3.06B, a record, up 56% year over year
Debt-to-equity	0.06x
Current ratio	5.25
TTM free cash flow	about $1.5B, a 29% margin and about 1.44x net income
Equity	more than doubled since March 2023 ($4.05B to $8.63B)

When the 10-year yield sits at 5.3%, it matters that this company never needs to raise money.

3. The valuation has already come down¶

The bear will cite 300x trailing earnings. I'd point to how the multiple has moved: - At the June 18 close, ARM was worth about $469B, roughly 95x sales. - Today it is worth $294B, about 57x sales.

The multiple has fallen about 40% while revenue kept growing 22%. Much of the rate and AI-froth risk the bear will raise has already been priced out. ARM isn't cheap, and I won't claim it is. It is a scarce asset whose price has been reset while the business kept growing.

Answers to the bear points I expect¶

"Operating margin fell to 7.1% and operating expenses are growing 28%." That spending is a choice. Gross margin is stable at 97%, so the pressure is entirely investment: compute subsystems, a possible move into ARM's own silicon, and capex rising from $92M to $545M. Q4 FY26 showed the model can still deliver a 29.4% operating margin. The year-ago comparison for the November report is undemanding: revenue of $1,135M and a 14.4% margin.

"Q1 net income was propped up by items below the operating line." That's fair, so look at cash instead. Strip the roughly $370M working-capital benefit out of Q1 operating cash flow and you still get about $500–550M, against $332M a year earlier. Cash generation is rising.

"The Qualcomm trial." It is a real binary risk, and I'd size the position for it. But ARM has absorbed an adverse Nuvia verdict before. It then went from $100 to $452 within this 52-week range. The worst realistic outcome is a cash and royalty-terms hit that $3B of cash can absorb, not the loss of a customer.

"Insiders are selling." About $72M of sales against roughly 1.07B shares is immaterial. Most of it followed the May 15 vesting date. The CFO's sales at $148, $180, $227, $255 and $300 look like a pre-set plan with price triggers. The CEO hasn't sold a share since April at about $160, including through the run above $400.

"Rates at 5.3% kill long-duration stocks." That is the strongest bear argument, and I accept it is the main headwind. But recession odds are 6%, the odds of the AI bubble bursting in 2026 are 6%, the VIX is 15, an October Fed hold is priced at 84%, and oil is easing on the Iran comments. A softer September CPI print is the clearest trigger for multiples to re-expand.

Why the technical picture favors buyers here¶

Higher lows: $219.39, then $225.46, then $238.03. Buyers keep stepping in earlier.
ADX is 12.45 and still falling, even on a 6.5% down day. That means no new downtrend has formed. The bearish weekly and daily SuperTrend readings are signals for a trending market, applied to a market that isn't trending.
The 50-day will keep rising. The closes rolling out of it over the next three sessions are $239–$241.
The rally isn't fully undone. OBV is still up 37M since the August low.
Retail is in distress. StockTwits content is full of frustration. That is usually how pullbacks end, not how they start.

The trade¶

Accumulate ARM in tranches, sized for a 6.45% average daily range.

Tranche 1: buy at $270–$275. Exit on a daily close below about $263, where the 78.6% retracement sits near the weekly TD reference of $264.79. That risks about 4.5%.
Tranche 2: add on a close back above $293, which reclaims the 10-day EMA and the gap.
Tranche 3: if price flushes to $233–$244, buy more. That zone lines up the lower Bollinger band, a z-score near −2 and the higher-low structure.
Targets: $307–$318 first (about 12–15% upside), then $331–$337 (about 21%). That gives roughly 2.5 to 4.5 times the risk at the first stop.

What would change my mind: - a weekly close below $264.79 combined with a heavy-volume break below the 50-day; - the November report showing operating margin still in single digits and operating expense growth still above 25%.

Until then, I see a growing business with no debt and a multiple already cut by about 40%, sitting on rising support. Bear, your turn. Bull Analyst: # Bull Rebuttal: ARM

You found real flaws in my trade plan, and I'll fix them before defending anything else. Your conclusion, though, was "don't buy, short the bounce," and several of the data readings behind it don't hold up against the reports we're both using.

1. What I concede¶

My stop was inside normal daily movement. $263 is 0.7 ATR away, and today's range alone was $16.47.
My tranches contradicted each other. A stop at $263 and a buy zone at $233–244 can't sit in the same plan. One position needs one stop.
My November test was too easy. Your math is right. A 14.4% margin needs Q2 operating expenses at or below about $1.15B, and Q1 was already $1,162M. A 10% margin shouldn't pass a thesis check. I've replaced the test below.
The Nuvia link was sloppy. The move from $100 to $452 came long after the December 2024 verdict, and I implied a cause I can't show.
Valuation hasn't been "priced out." Anchoring to the June high was as convenient for me as late March is for you. 57x sales is expensive, and I'm not buying ARM because it's cheap.
OBV. The buying volume from the gap rally is gone. That is what a filled gap looks like.

Here is what I don't concede.

2. The Qualcomm risk has been tested once, and pricing power held up¶

Your correction actually strengthens my case. If the December 2024 verdict went Qualcomm's way, we've already seen what a courtroom loss does to ARM's pricing power. FY26 runs from April 2025 to March 2026, entirely after that verdict: - Revenue grew 22.8%. - Gross margin hit a record 97.5%. - The March quarter set a revenue record at $1,490M, and the June quarter then grew another 22.4%.

You argue that losing to Qualcomm gives every licensee more bargaining power. If that were how it works, FY26 is where it would have shown up, and it didn't.

That doesn't make this trial harmless. A verdict is gap risk, and you're right that a stop can't manage it. I've changed the trade structure for that reason (section 7). Also, the sentiment report says the headlines can't confirm whether there are one or two separate proceedings, so don't count the risk twice.

3. Rates haven't been the main driver¶

I still treat rates as a headwind. But look at the 12-month record you cited: - The 10-year went from 4.13% to 5.28%. - Over the same period ARM went from about $100 to $275, and its sales multiple more than doubled.

You call that froth. I'd call it evidence that ARM's multiple is set by the AI and royalty story more than by the discount rate. If a stock's multiple doubled through a 115bp rise in long yields, the 10-year isn't its main lever.

Your "down 17% since the steepener began" framing has the same problem: - ARM ran from $243.98 to $333.20 (+37%) in four sessions on a 13M-share gap, then gave it all back. - Today's close of $275.29 is 32 cents below the September 18 close. - That is a spike unwinding. The base underneath hasn't been repriced.

The near-term rate picture is easing slightly, not worsening: - October hold odds rose 10 points this week to 84%. - The 10-year has edged off its 5.31% peak. - Oil is easing on the Iran comments.

On SoftBank, the news report itself labels the margin-loan channel as background, not this week's news. And the markets that would price OpenAI distress aren't pricing it: an OpenAI IPO above $1T is at 72%, and an AI bubble bursting in 2026 is at 6%.

4. Fundamentals: look at where each series starts¶

"Growth is slowing." - Your series starts at 34.5%, but that quarter was compared against a September 2024 quarter of about $844M, which was itself below the quarter before it (about $939M). - Add one more quarter and the series reads 12.1%, 34.5%, 26.3%, 20.1%, 22.4%. - That is noise around the low 20s, and the latest reading ticked up.

The 7.1% margin is already in the price. The stock made its higher lows of $225.46 (Sept 3) and $238.03 (Sept 14) after that quarter was reported. The market has seen the worst margin quarter in the dataset and built a base on top of it.

"$10 left for shareholders." - You picked the one quarter that contains the annual May 15 vest, after the stock rose 40–75% into it. - The financing outflow was $123M a year earlier and $326M this year. It tracks the share price at vesting. - I accept it as a real cost of stock compensation. But it isn't cash leaving shareholders. Paying the withholding tax in cash instead of issuing those shares works like a buyback: shareholders get it back as shares that never exist. - TTM operating cash flow is a record $2.09B. The March and June quarters together, which cancels out the receivables timing you adjusted for, averaged $581M a quarter.

"Spending to move away from royalties." The financials don't show a hardware business yet. - Q1 gross margin was about 97.2%, on roughly $36M of cost of revenue. - The fundamentals report ties the capex to compute infrastructure and more complete designs, not inventory. - Operating cash flow covers TTM capex about 3.6 times. - If ARM turns into a chip vendor with inventory and lower margins, gross margin will show it first, and it hasn't moved.

Insiders. The CEO received 265,643 shares on May 15. Executives paid that much in stock rarely buy more on the open market, so zero purchases is normal here. What he hasn't done is sell: nothing since April at about $160, all the way through a run above $400.

5. Sentiment and the chart¶

Retail. You quoted the 57% bullish label, but the sentiment report says that number is inflated: - 5 of the 17 bullish tags come from one user complaining about the drop. - Its content-adjusted read is balanced to distressed, with an overall score of 4.0/10, mildly bearish.

It's also only 30 messages over 30 hours, so I'll withdraw "capitulation." The source doesn't support "a market still long and hoping" either.

Headlines. The same report says the mechanism behind the Microsoft laptop headline "is unknown from the data," and the "supply execution questions" headline comes with no detail. You've given both a specific meaning the sources don't contain.

The chart. Lower highs and higher lows are both true. Together they form a narrowing range, which is exactly what an ADX of 12.45 describes. That makes us both range traders: - You want to sell at $287–293, and I want to buy near $269–275. - I'm using the 50-day as a support level, the same way you're using $287–293 as a resistance level. - Today's close is 6 points above support and 12–18 points below your resistance. - When the range breaks, I use the higher timeframe as the tiebreaker: the monthly SuperTrend is up, the 50-day is above the 200-day, and price is 25.5% above the 200-day.

6. Your short has the same flaw you found in my long¶

The stop is just as tight. Entry at $287–293 with a stop above $307.49 is 14.5 to 20.5 points, or 0.8 to 1.15 ATR. By your own standard, a normal day stops you out.
Gap risk runs both ways. A favorable ruling gaps over a short stop just as an adverse one gaps under a long stop. Here that would happen in a stock with a 3.79 beta and about 90% held by SoftBank. You flagged the squeeze risk yourself.
Both your plans need a rally first. Trimming or shorting at $287–293 requires a 4–6% bounce, so you're implicitly forecasting the bounce I'm positioning for.

7. The revised trade¶

One position, one stop: a daily close below $230. That is below the lower Bollinger band ($232.93) and the bottom of the technical report's own oversold buy zone. Below that level the base is failing, and I don't buy lower.

Tranche	Size	Entry	Notes
1	25%	$270–278	Only if Friday's weekly close holds $264.79; otherwise skip it and wait for tranche 2. This tranche gets ahead of the report's confirmation setup, which is why it's small. Through the trial, CPI and FOMC window, hold it as calls or a call spread expiring after the November report, so a verdict gap costs the premium and nothing more.
2	50%	$238–252	The roughly 2-ATR band near $240, the mid-September closes and low ($238–244), and the Sept 4 and 10 closes ($252–254). It overlaps the upper half of the report's $233–244 zone.
3	25%	Daily close above $293, with the MACD histogram turning up and RSI above 50	This is your own "step aside" condition and the report's first setup. Once it fills, raise the stop on the whole position to below $263.

Reward to risk: - Tranche 1 alone is about 1:1 to $318. That's why it's a quarter of the size and held in options. - With tranches 1 and 2 filled, the average entry is about $255 and the risk to $230 is about 10%. That's roughly 2 to 2.5 times the risk to $307–318, and about 3 times to $331–337. - The targets are resistance, which is why they're where I take profit, not where I expect a breakout. The CFO's last $300 sale was 10,400 shares, about $3M. That isn't enough selling to cap a $294B stock.

Sizing for the gap you raised: I size the full position so a gap to $219 (the 200-day and the August low) is survivable, rather than sizing to the stop.

The November test, replaced: - Exit if revenue growth is below 20%, operating margin is below Q1's 7.1%, or opex growth is above 30%. - Hold with no more adds if we get your base case: about a 10% margin with opex up about 28%. That would mean the investment phase is running longer than I'd like. - Thesis confirmed if operating income is at or above last year's $163M, which needs opex roughly flat from Q1. In that case I hold for the $331–337 target.

What would change my mind: - a daily close below $230; - any of the November exit triggers; - a Qualcomm verdict that resets royalty rates across licensees, rather than awarding a one-time payment.

Bottom line¶

We agree on more than it looks: - the range is roughly $263–293; - rates are a headwind; - the valuation is rich; - November decides the medium term.

The disagreement is what to do about it. ARM is growing 22% a year with 97% gross margins and no debt. It sits on a rising 50-day average, 39% below its June high, with retail sentiment mildly bearish. You'd short a bounce with a 1-ATR stop going into a binary verdict. I'd rather own a small, defined-risk position near support and put the real size where the reward is two to three times the risk. Above $293 I'll pay up for confirmation, which is the same confirmation you're waiting for. Bear, your turn. Bull Analyst: # Bull Rebuttal: ARM (Round 3)

Most of your critique of my plan's mechanics is right, and I'll fix it. But look at what's left of your case. You've dropped insiders, sentiment, the Microsoft and supply headlines, SoftBank, and "growth is slowing." What remains is valuation and timing. On timing, your own advice to holders says ARM should be owned at $275.

1. What I concede¶

Tranche 2's stop was inside one ATR. I flagged the same flaw in your short. It's fixed below.
I called $263–293 "the range" and then put half my size below it. The wording was bad and the zone was too wide. At $252 the z-score is only −1.3, which isn't stretched.
The blended 2–2.5x mixed option premium with share price. Each tranche now gets its own math.
Sizing for a gap to $219 was convenient. I'll size for $198, the level you named.
Tranche 1 at 1:1 needed better-than-even odds. It's been restructured.
My November test only exited on a collapse. Your base case now forces a cut.
Gross margin can't measure royalty pricing. Revenue is the only thing we can observe, and neither of us can see per-chip rates.

2. Your advice to holders is my tranche 1¶

Your plan for holders at $275 is to keep the stock, hedge now, and reduce on a weekly close below $264.79.

Holding stock plus a put is, by put-call parity, the same as holding a call plus cash. If the holder funds the put by selling an upside call (a collar), it becomes a call spread plus cash.
My tranche 1 is a call spread, opened at Friday's close if the weekly close holds $264.79.

That's the same exposure on the same trigger. The stock doesn't know anyone's cost basis. If a hedged long is the right position for someone who already owns ARM at $275, it's the right position for someone who doesn't. The only consistent bear answer would be to tell holders to sell today, and you didn't.

You also said premium makes my payoff worse. The macro report says that with the VIX at 15, "owning volatility or protection on ARM… is better value than usual." Options can't be cheap enough to hedge with and too expensive to own upside with.

3. Your buy plan is built not to fire¶

Your entry is $233–244, after the Qualcomm outcome is known and Q2 shows opex growth under 25%.

Opex growth under 25% means Q2 opex below about $1.179B ($943M × 1.25). That is my "confirmed" case (opex at or below about $1.18B), which you just called unlikely.
Your long therefore needs an outcome you rate unlikely. It then also needs ARM to sit 11–15% below today right after that good print and a known verdict.
Those two conditions mostly rule each other out. The only path is good company news overwhelmed by bad macro.

"Pay up for confirmation" sounds prudent, but it's expensive in this stock. Three of your four confirmations are gap events: the verdict, CPI and the Q2 print. The last catalyst gap, on September 21, opened 6.8% above the prior close, and by the next day's close ARM was up 21% ($275.61 → $333.20). That's what waiting costs in a stock with a 3.79 beta.

4. The fixed plan¶

Tranche	Share of risk budget	Vehicle and entry	Exit and risk
1	25%	Call spread: buy the $280 call, sell the $320 call, expiring after the November report. Open at Friday's close only if (a) the weekly close holds $264.79 and (b) the spread costs no more than a third of its width, about $13. Otherwise skip.	Maximum loss is the premium. The payoff is at least 2:1, so it needs roughly one-in-three odds, not better than even. Breakeven at expiry is about $293, the same level we both call confirmation.
2	50%	Stock at $233–245 (midpoint about $239). This is the technical report's oversold zone and your own buy zone. On today's bands that's a z-score of −1.6 to −2.0.	Exit on a weekly close below $219, the level of the 200-day ($219.35) and the August 3 low ($219.39). Size as if the exit fills at $198, the monthly SuperTrend, which is 17% below the midpoint.
3	25%	Stock on a daily close above $293, with the MACD histogram turning up and RSI above 50.	Exit on a daily close below $263, about 1.7 ATR from entry. When tranche 3 fills, any tranche 2 stock also moves its stop up to $263.

Tranche 2 on its own, from $239: - Targets: first the $286.7–290.5 gap and 50% retracement (+20%), then $307–318 (+28–33%). - Reward to risk against the planned $219 exit: about 2.5x to the first target and 3.4–4.0x to the second. - Against the $198 worst case I size for: 1.2x and 1.7–1.9x. The realistic figure sits between those two, and it's positive either way. - Is the rally realistic? You said the payoff needs a 25–30% rally back through every level. Last month ARM went from a $243.98 close on September 16 to $333.20 on September 22. That's +37% in four sessions, starting from this exact zone.

On "half your size sits below your range": - $263–293 is the range that formed after the gap, which is what the low ADX describes. - Tranche 2 instead buys the lower third of the six-week base that existed before the gap. Closes ran $234–287, and the lows kept rising: $219.39, then $225.46, then $238.03. - A base fails when it breaks below its lows, and that's where my stop now sits.

5. A November test with a real exit (for any stock held into the print)¶

Q2 FY27 operating income	What it means	Action
$163M or more (opex at or below about $1.18B)	Thesis confirmed	Hold for $331–337
$130–163M	Your base case (about $138M, roughly a 10% margin)	Cut the stock position in half; no adds
Below $130M, or revenue growth below 20%, or opex growth above 30%	Operating income falls 20%+ year over year for a second straight quarter	Exit

The Qualcomm rule is unchanged: exit if a verdict resets royalty rates across licensees, and hold if it's a one-time payment.

Why I don't treat your base case as "what probably happens": - Q1 contained the May 15 vest. Prices at that vest were 40–75% above late March. - The same quarter shows three related distortions: - a 13.9% sequential jump in opex; - a $179M boost below operating income, which the fundamentals report suggests may include tax effects from the vesting; - a $326M outflow for tax on vesting shares. - Some of the opex jump may be timing. Employer payroll taxes on vesting shares are booked as operating expense when the shares vest. The data can't confirm this, so I won't lean on it. - Q2 is a clean test. The big May vest isn't in the September quarter, so Q2 will show the underlying trend either way, and my plan now acts on the answer.

6. Where your numbers overreach¶

"17% a year over two years." Two-year comparisons of single quarters are distorted here by FY25's uneven timing: Q1 FY25 ($939M) was larger than the $844M quarter after it. You caught me starting from a soft base, and this comparison starts from a firm one. Full fiscal years remove the problem: revenue grew 23.4% a year from FY24 to FY26.
Qualcomm's "billions" vs. $877M of operating income. You argued an adverse verdict means "not getting a rate increase," not losing existing revenue. If so, the billions are mostly upside ARM doesn't collect today, not a hole in the current earnings base. The stock can still gap down on a loss. That's why tranche 1 has defined risk and tranche 2 is sized for $198.
The weekly SuperTrend. You dismissed the monthly signal because its stop sits 14% past my exit. The weekly's flip level of $383.15 sits 20% past your short stop at $318.36, so by your standard it can't settle your trade either. The report's guidance applies to both of us: with ADX at 12.45, treat SuperTrend readings as context "until ADX rises back above about 20–25." I do use the weekly as the main timeframe. It decides tranche 1 and sets tranche 2's stop.
The failed breakout. It fell back to where it launched ($275.29 vs. $275.61) and held the 50-day. If this is a real top, price will break the base lows and my stop takes me out. If the base holds, I own it near the bottom.
Rates. I agree this week was net hawkish on the expected rate path. Still, ARM trades above its late-August $242–255 range even though the 10-year is 60bp higher than in mid-August and the Fed has made its first hike. My core buy zone is within about 4–12% of where the market priced the 7.1% quarter.

7. Why own ARM at all¶

Steady growth with a very high margin. Revenue has grown more than 20% for four straight quarters, about 22% a year from FY23 to FY26, with a 97% gross margin.
Rising royalty per chip. The v9 architecture and compute subsystems earn more per chip, across phones, PCs, data centers and edge AI.
No funding risk. ARM has $3.06B of cash, 0.06x debt-to-equity and a record $2.09B of trailing operating cash flow.
The long-term trend is intact. The monthly SuperTrend is up, the 50-day is above the 200-day, price is 25.5% above the 200-day, and lows have been rising since August.
Low odds of a broad crash. The market prices 6% odds of a recession and 6% odds of the AI bubble bursting in 2026.

We agree the valuation is rich. That's why no tranche is full-size stock at $275, and why the stock purchases come either 11–15% lower or on confirmation.

Bottom line¶

We agree there should be no full-size stock purchase at $275.
We disagree on holding zero upside into four catalysts. Your own holder advice, hold and hedge keyed to Friday's $264.79 close, is the same exposure as my tranche 1.
Your only long entry requires an opex result you call unlikely, plus a price that result would probably prevent.
My plan:
a defined-risk starter at Friday's close if the weekly level holds;
the core position in the base at $233–245, with a weekly-close stop and sizing for $198;
the rest above $293;
a cut in half on your base case and an exit on a real miss.

Bear, your turn. Bull Analyst: # Bull Rebuttal: ARM (Round 4)

Your options math is right, and your tranche 2 table found a real sequencing flaw. I'll concede both and fix the second.

This round also showed something about your case. Your remaining objection is valuation, yet each of your long entries pays close to, or more than, the multiple you've spent four rounds calling unpayable. So we aren't really debating whether ARM deserves 57x sales. We're debating one quarter of revenue and opex, and how to position before it.

1. What I concede¶

The call spread is fairly priced. I reran your Black-Scholes estimate and get about $12.70 at 65% implied volatility and $13.50 at 90%. The spread is close to vega-neutral, so cheap VIX doesn't help it. Its edge has to come from direction. I withdraw the volatility argument.
The verdict rule can't act before the gap. Only position sizing protects against a ruling. That's why the core is sized for $198.
The payroll-tax point is out. I said I wouldn't lean on it, then did.
Your tranche 2 table is right about sequencing. Most fills happen before the print, so my halving rule would mostly sell after a gap down. I've restructured it in section 7.
Your holder advice is now consistent with parity. Whether it's good advice is section 6.

2. Your valuation case doesn't survive your own entry plan¶

Entry	Price	Price-to-sales	EV / trailing operating income
Your price path (after a base-case Q2)	$219–225	~44x	~275x
My pre-print core	$233–245	~48–51x	~280–295x
Today	$275	~57x	~330x
Your confirmation path (after a confirmed Q2)	$293 or higher	~58x or more	~355x or more

Notes on the table: - Post-print rows use trailing revenue that includes a Q2 of about $1.39B. - A confirmed Q2 of $163M operating income exactly replaces last year's $163M, so trailing operating income stays at $877M.

What the table shows: - On confirmation you'd pay more than today on every measure. That includes roughly 300x trailing GAAP earnings if Q2 EPS matches last year's $0.22, and a lower free-cash-flow yield. A confirmed quarter doesn't change trailing operating income at all. - So 300x isn't really your objection. Your objection is uncertainty about the print and the verdict. You'll pay the full multiple to remove that uncertainty. I'll accept part of it in exchange for a lower price. - Your two entries are about a third apart in price ($222 versus $293+). What decides between them is one quarterly report. That's a forecast about Q2, not a valuation verdict. - Late March isn't your anchor either. Neither of your entries pays anything like 32x sales.

3. "Confirmed" is a revenue question too¶

You framed confirmation as opex growth collapsing from +13.9% QoQ to under 2%, and called that unlikely. But operating income has two inputs.

Keep your opex: up 3.7% QoQ, to about $1,205M.
Change one input: revenue grows 24% instead of 22%. That's $1,407M of revenue, about $1,368M of gross profit at 97.2%, and about $163M of operating income. That's my confirmed case.
The gap is small. It's about $23M of revenue, or 1.6% of the quarter. The last five quarters grew 12.1%, 34.5%, 26.3%, 20.1% and 22.4%; two of the last four beat 24%.
Q1 shows the same sensitivity. If opex had grown at revenue's 22.4% instead of 27.8%, Q1 operating income would have been about $140M, up 23% year over year instead of down 20%.
This is the convexity the multiple pays for. You showed opex growth has held near 28% for five quarters, and I agree. So the whole "operating profit is falling" story is a steady 5–6 point gap between two growth rates. With a 97% gross margin, a small change in that gap swings operating income hard in either direction.
Your base case is a sequential improvement. It takes operating margin from 7.1% to about 10%.
Your own options model calls the outcome balanced. It puts the odds of ARM finishing above $293 by November 20 at about one in three. At the same volatilities, that's roughly the same as the odds of finishing below $239. The market isn't calling confirmation unlikely.

Your extra condition, opex growth under 25%, would reject a quarter that earns $163M through revenue. That condition demands a particular story, not a level of profit.

4. Tranche 1: three ways to get paid¶

"Fair price" cuts both ways. At a fair price no instrument has an edge, and that includes your put spreads. "Fair" here means risk-neutral pricing, which assumes the stock drifts at the risk-free rate. If a 3.79-beta stock earns any equity risk premium, the real-world odds of finishing above $293 are a little above 35%. The edge is small, but it favors the long side and works against your puts.
It doesn't need the confirmed print alone. Any one of these by November 20 pays:
a confirmed print, about two points of revenue growth away (section 3);
a soft CPI print that pulls the 10-year back under 5%;
a Qualcomm outcome that leaves royalty terms intact.

The last two are on your own list of things that would change your mind. - The trigger is a filter, not a signal. A weekly close below $264.79 is the state the technical report says "would confirm weekly momentum has turned down." The filter's only job is to keep the starter out of that state.

5. Waiting paid off for gap buyers, not base buyers¶

Entry type	Example	Return at $275.29
Catalyst gap	Sep 21 open, $294.36	−6.5%
Catalyst gap	Sep 22 close, $333.20	−17.4%
Base	Sep 16 close, $243.98	+12.8%
Base	Sep 14 low, $238.03	+15.7%
Base	Sep 3 low, $225.46	+22.1%
Base	Aug 3 low, $219.39	+25.5%

Your examples are catalyst-gap buys, and so is your confirmation path. Your plan says to "buy on the print, even above $293." You also pointed out that both volume surges, June 18 and September 21, marked tops within days. Your evidence for waiting is evidence against how you plan to enter.
My tranche 3 has the same weakness. That's why it's my smallest stock piece. Your confirmation path is nearly your entire long.
The rally template isn't a contradiction.
The spike unwound to where the gap started ($275.29 versus $275.61), not to where the move started ($243.98).
The pre-gap leg, +13% in two sessions from September 16 to 18, is intact, and so is the base beneath it.
My first target, $287–290, is the top of the August–September base, where closes reached $287 without any squeeze. From $239 that's 2.7 ATR.

6. Holders: you've moved the sale down to support¶

Your sell level keeps dropping. In Round 1 you said trim into $287–293. Now you say reduce at $275, which is 2% above the 50-day and near the bottom of the range we both mapped.
Your own range rule says hold. In Round 2 you wrote: "In a range, a break of support is where you exit." Support hasn't broken.
The technical report says "Don't chase in either direction." Selling at $275 is chasing to the downside.
You won't short here either. Your put spreads wait for a failed rally. A level you won't short is a poor level to tell holders to sell.

Parity made your advice consistent. It didn't make $275 a good place to sell.

My advice for holders: - Hold. - Trim into $287–293 if overweight. - Hedge the event cluster with a put spread that expires after the print. The macro report says protection is better value than usual with the VIX at 15. - Exit on a weekly close below $219, a Q2 miss, or a royalty-reset verdict.

7. The revised plan¶

Tranche 2 is now split, so only half its stock faces the print. The base-case halving rule is replaced by holding that second half back until after the print.

Piece	Risk budget	Entry	Exit
1	25%	$280/$320 call spread, expiring after the November report. Open at Friday's close only if the weekly close holds $264.79 and the cost is no more than ~$13.	Maximum loss is the premium
2a	25%	Stock at $233–245 before the print, only if no company-specific exit trigger has fired	Weekly close below $219; sized for $198
2b	25%	Stock after the print and the verdict, only if neither triggers an exit. Base case: buy $225–233. Confirmed: buy the first pullback into $287–293, not the gap.	Weekly close below $219; after a confirmed-path entry, daily close below $263
3	25%	Stock on a daily close above $293 with the MACD histogram turning up and RSI above 50	Daily close below $263; once filled, all stock moves to that stop

November rules for all stock:

Q2 outcome	What happens
Confirmed (operating income ≥ $163M)	Hold 2a for $331–337
Base case ($130–163M)	Hold 2a with no adds above $233; 2b buys only at $225–233
Miss (operating income below $130M, revenue growth below 20%, or opex growth above 30%), or a royalty-reset verdict	Exit all stock; 2b never fills

What the change costs and buys: - Through the base case I carry 25% of the risk budget in stock. That's the same exposure the Round 3 halving rule left, but I no longer sell into a gap to get there. - On the confirmed path I own less cheap stock than before. That's the price of the fix, and I accept it.

Reward to risk:

Piece	Entry	Planned exit / sizing level	Target	Reward-to-risk
2a	~$239	$219 (−8.4%) / $198 (−17%)	$287–290	~2.5x / ~1.2x
2a	~$239	$219 / $198	$307–318	3.4–3.9x / 1.7–1.9x
2b (base case)	~$229	$219 (−4.4%) / $198 (−13.5%)	$287–290 (+26%)	~6x / ~1.9x

The 2b stop is tight even on a weekly close. Sizing is set to $198, so a whipsaw costs about 4%, not the plan. That entry sits within 2–4% of your own price-path entry.

What changes my mind: - a weekly close below $219; - any of the three Q2 miss triggers; - a Qualcomm verdict that resets royalty rates across licensees.

Bottom line¶

We agree on a lot: - no full-size stock at $275; - the valuation is rich; - the chart is a range; - November decides.

Your plan: - pays about 58x sales and about 300x earnings on a catalyst gap after one good quarter, or buys at about 44x after a weak one; - tells holders to sell at support.

My plan: - a fairly priced, capped-loss call spread with three independent ways to pay; - a quarter of the risk in stock at the base before the print; - a quarter after the print, within a few percent of your own price-path entry; - a quarter on confirmation.

In this stock, buying the base has paid and buying the gap hasn't. ARM grows revenue 22–23% a year with a 97% gross margin, $3.06B of cash and essentially no debt. Two points of revenue growth decide whether operating profit is "falling" or growing 20%+. I'd rather own a measured, rule-bound position in that business than own nothing and buy the gap later at a higher multiple.

Bear, your turn. Bull Analyst: # Bull Rebuttal: ARM (Round 5)

Your sensitivity table is right, and so is your critique of my holder advice. Both have the same fix: no unhedged stock goes into the print, for new money or for holders.

That leaves one question. Should anyone own defined-risk upside in ARM through the print, or own nothing and pay for the answer afterward? You've now agreed that 300x is payable if the trajectory turns. So we're no longer arguing about whether ARM is worth owning. We're arguing about the cheapest way to pay for the November answer. Your plan pays through a higher entry price, and the one test case we have shows how much that can cost.

1. What I concede¶

My miss line sits inside the noise. $130M is $11M below your base case, and confirmation is $22M above it. Sequential opex has ranged from −0.7% to +13.9% in four quarters. Holding unhedged stock into that, with an exit so close, was poor design. Tranche 2a no longer holds stock before the print.
Paths aren't payoffs. The spread is judged only on the post-print price. A CPI rally counts only if it survives the report.
The timing risk is real. The earnings date is an estimate, so the expiry moves to late November or later. By the same Black-Scholes model, at 65–90% vol a December $280/$320 spread prices at about $12.50–14. If it's over the $13 cap, I skip it.
My holder advice failed my own parity test. A full unhedged holder at $275 owns more than my plan would open, and a put spread leaves the gap uncovered. Section 5 fixes this.
Tranche 3 is tied for smallest, not smallest.
The equity premium is small. I won't lean on it.

2. Your confirmation entry, tested on the gap you called confirmation¶

In Round 3 you called the September 21 gap "confirmation" and used it to show what waiting saves. Run your current entry rule through it:

Pre-gap close: $275.61 (September 18).
Entry: the first pullback that holds above that close. It came on September 24, a heavy-volume down day. The next day closed at $310.32, 12.6% above the pre-gap close. A buyer of that pullback paid roughly $300–310.
Stop: a daily close below the pre-gap close. Today's $275.29 is below $275.61, so the stop fires.
Result: a loss of about 8–11%, depending on the fill.

So "paying 6–7% more to remove a binary" is a floor, not an estimate. In the one gap we have, the first pullback sat about 10% above the pre-gap close, and your rule bought it and was stopped out today.

Every plan pays for the November answer. I pay a fixed premium of about $13 on a $40 spread. You pay with the gap, and you can't know its size in advance.

3. Your base-case entry needs a verdict that has no date¶

Your price path needs three things: a base-case print, a verdict, and a price of $219–225.

Neither report gives a trial schedule or ruling date. You used this against my spread: "A verdict in December doesn't pay a November spread." My spread doesn't need a verdict. Your price path does, and your confirmation path runs at half size until one arrives.
Under your rules, the last cycle produced no fills.
The September 3 low ($225.46) and September 14 low ($238.03) are both outside $219–225.
The August 3 low ($219.39) is inside the zone, but there was no verdict.
So the post-print base buyers in my table weren't buyers under your rules.
On hindsight, you're right that lows only look like lows afterward. That's why 2a now requires an objective stretch signal: a daily z-score near −2, or a completed daily TD buy 9, which could come as early as about October 20.
Even poor base entries beat the gap entries. By your own numbers, a buyer at the base midpoint (around $260) is up about 6%. A buyer at the top ($287) is down about 4%. Both did better than the two gap buyers, at −6.5% and −17.4%.

4. "No edge" applies to you too¶

A fairly priced spread has zero edge only if my view matches the market's. Your view doesn't match the market's either, and you've shown which way it leans:

You won't short at $275. Your put spreads wait for a failed rally into $287–293. If you thought the market was overpricing ARM's upside here, $275 would be a short.
You conceded that real-world odds sit a few points above risk-neutral ones. That tilt is small, but it favors my side.
The deciding input is ARM's most reliable one. Confirmation is two points of revenue growth away. Revenue is the steadiest line in the model: four straight quarters above 20%, 23.4% a year from FY24 to FY26, and 22.8% growth in FY26, the year after the 2024 Qualcomm loss. The noise sits in opex, which is ARM's own investment choice.

You're right that a miss is closer than confirmation. That's why my downside is now capped at the premium. The print is a coin flip with large swings either way. Your answer is to own none of it. Mine is to own a small, capped piece of the upside, where the worst case is the premium rather than a −17% gap followed by a forced sale.

5. Holders: collar, size to budget, cap at $320¶

Parity cuts both ways. A holder should hold what they'd open today, and what I'd open today is defined-risk upside. For a holder, that means a collar:

Structure: buy a put near $240 and sell a call at $320, both expiring after the print. By my Black-Scholes estimate at about 70% vol over about six weeks, the two premiums roughly offset before skew. Expect a small net cost after skew.
Effect:
The floor is about 13% below $275, instead of 28% down to $198.
Unlike a put spread, a full put covers the gap.
Size: trim until a 13% loss fits what you'd risk on ARM before the print. Some holders will need to cut and some won't. "Half or less" for everyone isn't a sizing rule.

Our remaining disagreement is the call strike. You'd sell calls at $293–307 against puts near the 50-day, after cutting to half. That leaves a holder close to flat. It's your view on new money applied to holders, so it's consistent, but it amounts to selling, not hedging. If the print is genuinely two-sided, as your own options math says, a cap at $293 is a bet that the print fails. A cap at $320 keeps the confirmed-print path open while the put handles the gap.

6. The revised plan¶

Piece	Risk budget	Entry	Maximum loss / exit
1	25%	$280/$320 call spread, expiring late November or later. Open at Friday's close only if the weekly close holds $264.79 and the cost is $13 or less.	Premium
2a	25%	Before the print, only if ARM reaches $233–245 with a stretch signal (daily z near −2 or a completed daily TD buy 9) and no company-specific exit has fired: a $240/$290 call spread, same expiry, cost of about $17 or less (a third of the width)	Premium; nothing to sell after a gap
2b	25%	Stock after the print, unchanged. Base case: buy at $225–233. Confirmed: buy the first pullback into $287–293.	Weekly close below $219; after a confirmed-path entry, a daily close below $263
3	25%	Stock after the print, on a daily close above $293 with MACD and RSI turning up. Before the print, tranche 1 already covers that move.	Daily close below $263

Rules after the print:

Outcome	Stock purchases
Miss or royalty-reset verdict	None
Base case	2b only, at $225–233
Confirmed	2b and tranche 3

What this change costs: on the path where 2a gains most (a macro dip followed by a confirmed print), the spread caps the gain at about $33 per share, where stock had open-ended upside. You named that path as my advantage, and I'm giving up part of it to remove the gap risk.

7. Where each plan wins¶

Path	My plan	Your plan
Confirmed print	Spreads pay up to $27 (tranche 1) and about $33 (2a). Stock is added on the pullback and above $293.	Buy the first pullback at whatever premium the gap sets. Half size if the trial is still open.
Base-case print, no verdict	Spreads lose some or all of their premium. 2b buys only at $225–233.	No entry: the price path needs a verdict, and confirmation isn't met.
Miss or royalty-reset verdict	Lose the premium: at most half the ARM risk budget, with nothing beyond it	Lose nothing

You win the third row outright and I win the first. In the second, you own nothing and I've paid a capped premium for upside.

On the confirmed path, half my stock is bought at the multiples you quoted. The difference is that by then I already hold spreads bought from below.

My worst-case cost is a number I set before Friday's close. Yours is the size of the next gap. On the last one, your entry rule lost 8–11% and stopped out today.

8. Why the upside is worth owning¶

The royalty model: about $36M of cost of revenue against $1.29B of revenue. Every chip built on Arm pays, across phones, PCs, data centers and edge AI.
Growth held through a legal loss: revenue grew 22.8% in FY26 after the 2024 Qualcomm verdict, including a record $1,490M quarter. Qualcomm is still building on Arm while it litigates.
Upside convexity: you showed that two points of revenue growth swing operating income sharply. That works upward too. Revenue is the line ARM delivers most reliably.
No funding risk: $3.06B of cash, 0.06x debt-to-equity and $2.09B of trailing operating cash flow.
The trend is intact:
The 50-day held on a −6.5% day.
The monthly SuperTrend is up and the lows are rising.
ADX describes a range, not a downtrend.

What would change my mind¶

A weekly close below $264.79 on Friday: tranche 1 doesn't open.
A miss or a royalty-reset verdict: no stock is bought, and any stock bought after the print exits.
A weekly close below $219.

Bottom line¶

We now agree on most of this: - no unhedged stock before the print; - 300x is payable only if the trajectory turns; - the chart is a range; - November decides.

The remaining choice is whether to own a capped piece of the upside through a print the options market prices as two-sided, or to own none and pay the gap afterward. In September, your entry rule paid that gap and was stopped out today, and your base-case entry needs a verdict with no date.

ARM is compounding revenue at 22–23% a year with a 97% gross margin. I'd rather fix my maximum cost on that business before Friday's close than learn the cost of waiting from the next gap. Bear, your turn.

Bear Researcher¶

Bear Analyst: # Bear Rebuttal: ARM

I agree with part of the bull's case. ARM is not going bankrupt, its 97% gross margin is exceptional, and revenue is growing about 22%. I'm not arguing against any of that.

My argument has three parts: - Price: at $275, ARM is still priced for profits its income statement isn't producing. - Macro: interest rates are moving in the direction that hurts this kind of stock most. - Trade plan: the bull's stop sits inside a normal day's trading range, and four binary events land in the next four weeks.

1. "The multiple already came down" only holds if you measure from the top¶

Reference point	ARM price	Approx. price-to-sales (trailing)
52-week low	~$100	low-to-mid 20s
Late March 2026 (CFO sale)	~$148	~32x
June 18 peak	$439	~95x
Today	$275	~57x

Measuring from the June bubble high is anchoring. Since late March, ARM's sales multiple has risen about 75–80%. Over the past year the 10-year yield rose from 4.13% to 5.28%. Rates went up and the multiple went up with them. That is froth that has not been priced out.

The earnings-based measures are worse: - Earnings multiples: about 300x trailing GAAP earnings and about 90x forward. PEG is 2.48, and enterprise value is about 330x operating income. - Free cash flow yield: about 0.5%, against 5.28% on a risk-free Treasury. A buyer gives up about 4.8 points of yield today in exchange for growth that is steady, not accelerating. - What it takes to look reasonable: for $275 to equal 30x GAAP earnings, EPS has to reach about $9.20, roughly 10x today's level. - At 22% annual growth, that takes about 11 years. - At the roughly 12% a year ARM has actually grown EPS since FY22, it takes about 20 years.

2. Revenue compounds, but profit doesn't¶

You pointed to gross margin rising from 95.2% to 97.5%. Over the same period, operating margin fell: - 23.4% in FY22 - 18.3% in FY26 - 7.1% in Q1 FY27

EPS went from $0.54 to $0.85 in four years. That is ordinary earnings growth priced at an extraordinary multiple.

The 29.4% Q4 margin is a seasonal peak. The March quarter carries the most licensing revenue, so it is always the strongest. Trailing-twelve-month operating margin is about 17% and still falling.
Revenue growth has slowed. The last four quarters grew 34.5%, 26.3%, 20.1% and 22.4%. That is steady at best.
"Spending is a choice." Agreed, so look at what the money buys. Capex has gone from 3% of revenue to 11–15%. ARM is pushing into its own silicon, and there are new reports of "supply execution questions."
The royalty model you praised, with $30–36M of cost against $1.2B or more of revenue, is the model ARM is spending to move away from.
Its own chips would mean lower margins, inventory risk, and competing with its own licensees. That last point is exactly what fuels the Qualcomm fight.

3. The November "undemanding comparison" is a trap¶

Here is what Q2 FY27 needs to beat last year's 14.4% operating margin: - At about $1.38B in revenue (22% growth), gross profit is about $1.345B. - To reach a 14.4% margin, operating expenses must stay at or below about $1.15B. - Q1 operating expenses were already $1,162M. So ARM would need to cut spending from one quarter to the next.

Last year, operating expenses rose about 4% from Q1 to Q2. If that repeats, the margin lands near 10%, below last year's level, with expense growth around 28%.

Your thesis breaks only if the margin is in single digits and expense growth is above 25%. A 10% margin passes that test. That isn't a real check on the thesis. It is a low bar the stock is likely to clear while the business still gets worse. It also arrives after the trial, CPI, the Fed meeting and the midterms.

4. Cash flow: account for stock compensation and almost nothing is left¶

You conceded the net income point and moved to cash. Using those figures:

Q1 FY27	$M
Reported operating cash flow	902
Less working-capital timing	~(370)
Underlying operating cash flow	~530
Less capex	(197)
Underlying free cash flow	~335
Less financing outflow (most likely tax paid on vesting shares)	(326)
Left for shareholders	~10

On a trailing basis: - Free cash flow is about $1.5B, minus about $750M of financing outflows, which leaves roughly $750M. - Against a $294B market cap, that is a yield of about 0.26%.

On the balance sheet: I never said ARM had a solvency problem. Its $3.06B in cash is about 1% of its market value. It can't protect the multiple.

5. Qualcomm: the risk is to the growth story, not the cash¶

The verdict history doesn't show what you say it shows. The December 2024 Nuvia verdict largely went Qualcomm's way. The move from $100 to $452 came about a year later, during an AI rally with the 10-year near 4.1%. That rally doesn't show ARM shrugging off legal losses. It shows a rising market.

The real risk is to royalty rates. Your growth engine is "newer designs earn higher royalty rates per chip." Two trials are now under way, one reportedly over billions in royalties and one over chip-testing tools. - If ARM can't enforce its terms on its largest smartphone licensee, every other licensee gains bargaining power. - Pricing power is what the 90x forward multiple is paying for.

The competitive signals are pointing the wrong way: - Qualcomm's Huawei deal strengthens its hand. - ARM fell this week on Microsoft's agentic-AI laptop news, which puts Windows-on-Arm, part of your thesis, in question.

On sizing: you can't size for a binary verdict with a 4.5% stop. A ruling gaps straight through it.

6. Rates: the bear case doesn't need a recession¶

Low recession odds (6%), low AI-bubble odds (6%) and a VIX of 15 answer a crash question I'm not asking. Low recession odds give the Fed room to keep raising rates: - 96% odds of no cuts in 2026 - 78% odds of another hike by December - 70% odds of two hikes this year

The shape of the rate move matters: - Since September 21, the 2-year yield is flat and the 10-year is up 32 basis points. Long-term yields rising faster than short-term ones is the worst pattern for stocks valued on distant profits. - ARM's closing high came on September 22, one day into that phase. It is down 17% since.

Inflation isn't helping: - August CPI rose 0.40% for the month, and oil is around $103. - "A softer CPI print" is a hope, not evidence. - A VIX of 15 alongside fast-moving yields is a mismatch. These gaps usually close by stocks repricing.

There is also a channel through ARM's owner: - SoftBank owns about 90% of ARM, is one of OpenAI's largest backers, and has borrowed against its ARM shares. - This week's OpenAI revenue worries reach ARM through that route. - You read Samsung's record guidance being sold as "just positioning." I read it as a crowded trade starting to unwind, and those unwinds don't finish in one day.

7. The chart: you read the lows and skip the highs¶

Lower closing highs: $439.46, then $333.20, $310.32 and $307.49. Today's close also broke the 61.8% retracement ($278.06) and fully filled the September gap.
Momentum is fading: RSI peaks went 71.4, then 61.2, then 58.5, and RSI is now below 50. MACD has crossed bearish, and the gap below its signal line is widening.
The OBV point leaves out the key part. OBV is now 414.17M, below its September 18 reading of 417.24M. All the buying volume from the gap rally is gone. Down days have also been heavier than up days: 9.56M, 9.10M and 6.16M versus 6.99M, 6.02M and 5.90M.
The rising 50-day is arithmetic. The closes dropping out of the average for the next three sessions are $239–241. From about October 14, the closes dropping out are $275–287, so the average flattens just as price sits on it.
The ADX argument is selective. You dismiss SuperTrend as a trend signal in a market with no trend. But you lean on the 50-day average, which is also a trend signal, and your targets assume a breakout.
The technical report doesn't support buying here. It says: "Don't chase in either direction… Wait for 269 to break or 293 to be reclaimed." RSI is 46.7 and the z-score is −0.49, so price isn't oversold. Your first tranche meets neither of the report's two higher-probability long setups.
Retail isn't capitulating. StockTwits labels are still 57% bullish and 7% bearish, with posts like "added more" and "all loaded with SOXL." A market that is still long and hoping hasn't flushed out yet.

8. The trade plan doesn't hold up against its own numbers¶

The stop is too tight. $263 is about 0.7 ATR below $275. Today's range alone was $16.47. Ordinary daily movement would stop you out.
The tranches contradict each other. Tranche 3, at $233–244, sits below tranche 1's stop at $263. Either you exit at $263 and then buy back 7–11% lower, which means the stop was never a thesis break, or you ignore the stop.
The realistic reward-to-risk is about 1:1. With the report's 2-ATR sizing (about 12.9%, a stop near $240), the 12–15% upside to $307–318 gives roughly 1:1, not 2.5–4.5:1.
The targets sit in resistance. $307–318 is the most recent lower high. $300 is where the CFO's trading plan has been selling. $331–337 is the September peak and the daily SuperTrend stop.

Insiders: I agree $72M is small relative to the share count. What matters is the zero. Seven insiders made no open-market purchases, not at $242–255 in August and not now. Management sells into strength and doesn't buy on weakness. With SoftBank holding about 90%, the small public float helps explain the 3.79 beta.

My position¶

Don't buy ARM here. - If you hold: trim into $287–293, where the gap, the Bollinger middle band, the 50% retracement and the 10-day EMA all overlap. Or hedge, since a VIX of 15 makes protection cheap ahead of CPI, the trial, the Fed meeting, the midterms and earnings. - If you want to be aggressive: take a small short on a rally into $287–293, with a stop above $307.49, or use put spreads. Keep the size small, because a favorable ruling could cause a sharp short squeeze.

Downside levels: - $263–265 - $252–254 - $238–244 - $219–225, the 200-day average and the August lows. Even $219 is about 45x sales.

What would change my mind: - November operating margin above 14.4%, with expense growth below 25% and net income not propped up by non-operating items - A Qualcomm outcome that keeps ARM's royalty terms intact - The 10-year back below 5% after a soft CPI print - A daily close above $293 with MACD and RSI turning up. I'd step aside there, and above $337 I'm wrong on the near term.

You're asking investors to buy a stock at 300x earnings with a 3.79 beta, on the day it filled its gap. The stop sits inside a normal day's range, and a trial verdict and a hawkish Fed are both ahead. I'd rather pay more later for confirmation than pay this price now on hope. Bull, your turn. Bear Analyst: # Bear Rebuttal: ARM (Round 2)

Your revisions were honest and they fixed the mechanics. But look at what the revised plan does at today's price:

Tranche 1 waits for Friday's weekly close, and then buys only calls.
Tranche 2 needs ARM to fall another 8–14%.
Tranche 3 needs a close above $293.

At $275.29, your plan buys nothing today. This debate is about whether to buy ARM here, and your answer is now "not yet." I agree. Two disagreements remain: - whether a small call position is worth holding through the verdict, CPI, the FOMC meeting and earnings; - whether half a position should go in below the range you defined yourself.

I think both are mistakes.

1. What I concede¶

Sentiment. The 57% bullish label is inflated, the content-adjusted read is balanced to distressed, and it's only 30 messages. I withdraw "long and hoping." Neither of us should lean on it.
Headlines. The Microsoft mechanism is unknown, and "supply execution" is unconfirmed. I'm dropping both as evidence. My concern about ARM building its own chips rests on the opex and capex numbers.
My short stop. By my own standard, 0.8–1.15 ATR is too tight. Revised below.
Insiders. A $3M CFO sale won't cap a $294B stock. Zero open-market purchases means little when the CEO just received 265,643 shares. I'm dropping insiders from the case.
Growth. Low-20s growth is steady. My argument was never that it's collapsing. It's that steady isn't enough at 300x earnings.
SoftBank. It's background risk, not this week's catalyst.

2. Your revised plan, judged by your own standards¶

Tranche 2 has the stop you criticized in my short. - Entries are $238–252 and the stop is a close below $230. That's 8 to 22 points, or 0.45–1.24 ATR, about 0.85 ATR at the midpoint. - You called 0.8–1.15 ATR a normal-day stop-out. Your largest tranche has the same distance. - On paper the ratio looks good. In practice, ordinary noise hits that stop.

Half your size sits below your own range. - You said we're both range traders and the range is $263–293. In a range, a break of support is where you exit, not where you add. - $252–254 is the report's second breakdown target in the scenario it calls the "main risk." - Only the bottom half of your zone overlaps the report's oversold zone ($233–244). At $252, the daily z-score on today's bands is about −1.3, which isn't stretched.

The blended 2–2.5x mixes option premium with share price. - Tranche 1 is calls, so it has no $274 cost basis to average with stock at $245. - The tranche 2 payoff only exists on one path. ARM first has to break the 50-day, the 78.6% retracement, the weekly TD level and the range floor. Then it has to rally 25–30% back through all of them.

Your gap sizing assumes the gap stops at support. - ARM fell 49% in six weeks, from June 18 to July 29. - The monthly SuperTrend sits at $198. - An adverse verdict plus a hot CPI print doesn't have to stop at the 200-day. From $245, a gap to $200 is −18%, not −11%.

Tranche 1 is 1:1 by your own count. A 1:1 trade needs better than even odds. The report names the weekly as its main signal, and it points down. Paying option premium on top makes the payoff worse.

3. The November test still has no realistic exit¶

Outcome	What it requires	Your action
Confirmed	Operating income ≥ $163M, so opex ≤ ~$1.18B (under +2% QoQ)	Hold for $331–337
My base case	Opex +3.7% QoQ as last year (~$1.205B). Operating income ~$140M, margin ~10%, opex +28% YoY	Hold, no adds
Exit	Margin < 7.1%, revenue growth < 20%, or opex growth > 30%	Exit

"Confirmed" is unlikely. It needs opex growth to fall from +13.9% QoQ to under 2%.
The margin exit only fires on a collapse. The September quarter is seasonally stronger than June: 14.4% versus 10.8% last year. A margin below 7.1% would be a disaster, not a warning.
The base case is what probably happens. Operating income would fall about 15% after falling 20% in Q1. That's two straight quarters of shrinking operating profit at 300x earnings, and your plan holds through it.

4. Qualcomm: gross margin can't measure royalty pricing¶

Your test says that if the 2024 loss had hurt pricing power, FY26 would show it. Gross margin is the wrong tool for that.

Gross margin barely moves with price. Cost of revenue is about $36M a quarter. Remove $100M of royalty revenue from Q1 and gross margin goes from 97.2% to about 97.0%. It measures cost structure, not pricing power.
We can't see royalty rates. The data has no licensing/royalty split. Neither of us can show what happened to rates per chip in FY26.
A lost increase doesn't show up in revenue. Losing a dispute over terms means not getting a rate increase. It doesn't mean losing existing revenue. That's why FY26 looks fine.
Scale. The headline says "billions in royalty payments." TTM operating income is $877M. Whichever way the case goes, that's more than two years of operating profit.

5. Growth, "priced in," and cash¶

The uptick came against the weakest quarter. Your added data point, Q1 FY26 at +12.1%, means Q1 FY27's 22.4% was measured against the weakest quarter in the dataset. Compared with two years earlier, revenue is up about 37%, roughly 17% a year.

"Priced in." - The market priced the 7.1% quarter at $219–225. You're paying 22–25% more for the same quarter, with a second soft one likely. - The run to $333 after the print priced in a margin recovery, and that rally has now fully failed.

The buyback analogy. I agree net share settlement works like a buyback. Then look at what kind of buyback it is: - It was done at roughly 240–300x earnings (mid-May prices of $207–257 against $0.85 EPS). - It doesn't shrink the share count. It only stops it from growing. - It grows as the stock rises: from $123M to $326M. The more the bull case works, the more free cash flow stock compensation consumes.

Even on your best number: - $581M a quarter of operating cash flow annualizes to about $2.3B. - After capex, free cash flow is about $1.74B, a 0.59% yield. - After about $750M of tax paid on vesting shares, it's about $1.0B, a 0.34% yield. - Treasuries pay 5.28%.

Gross margin will be the last place a chip business shows up. The spending lands in opex and capex first, and both are already rising: opex +27.8%, capex up from 3% to 11–15% of revenue. The fundamentals report says the capex "likely" reflects compute infrastructure and that "the tools do not provide a breakdown." It does not say "not inventory." That's the standard you applied to my headlines.

6. Rates: this week was net hawkish¶

The hike moved; it didn't disappear. October hold odds rose 10 points to 84%. In the same week, "two hikes in 2026" rose 10.5 points to 70%, and "another hike by December 10" rose to 78%.
The 10-year has barely moved. It has edged off its peak by only 3bp (5.31% to 5.28%). Oil is easing but still about $103.
"The multiple doubled through rising yields" cuts against you. It means the multiple rests on the AI story, not on rates, so there's no rate cushion underneath it. You've moved the risk from the discount rate to the story. This week the story is being questioned on three fronts: OpenAI's revenue, royalty terms with your largest phone licensee, and Windows-on-Arm.
The bubble odds aren't that low over a longer horizon. The market pricing a 6% bubble burst in 2026 prices 18% by mid-2027.
CPI comes first. September CPI lands in mid-October, following August's +0.40%.

7. The chart: you picked the timeframe that agrees with you¶

The weekly points down. The report names the weekly as its main signal. You used the monthly as a tiebreaker, but its stop is $198, which is $32 below your own exit. A signal that can't flip until 14% past your stop can't settle a trade with a $230 stop.
Your support loses its slope. The 50-day flattens from about October 14, when closes of $275–287 roll out. That happens within four sessions, while price sits on it.
The breakout failed. The September 21 gap came on 13.0M shares, the most since the June 18 top (34.2M). Both volume surges marked tops within days. The September breakout reversed completely in 13 sessions. A breakout that fails that cleanly is a warning, not a base.

8. My revised plan¶

New money: don't buy at $275. Your plan doesn't either.

Holders. You said both my plans needed a rally. This one doesn't: - Hedge now. That works whether or not a bounce comes. - Reduce on a weekly close below $264.79 or a daily close below $263. - Trim into $287–293 only if a bounce comes first.

Aggressive bears: - Use put spreads expiring after the November report, opened on a failed rally into $287–293. That's defined risk, the same fix you used for gap risk. - If you must short the stock, stop out on a daily close above $318.36 (1.4–1.8 ATR) and size smaller.

Where I'd buy: $233–244, with the daily z-score near −2, once the Qualcomm outcome is known and Q2 shows opex growth under 25%. That's the report's oversold zone without the event risk on top.

What changes my mind: - Q2 operating income at or above $163M with opex growth under 25% - a Qualcomm outcome that leaves royalty terms intact - the 10-year back under 5% after a soft September CPI print - a daily close above $293 with MACD and RSI turning up. I step aside there, and above $337 the near-term bear case is wrong.

Bottom line¶

We now agree on what to do at $275: don't put real money in. Your plan waits for Friday, for a breakdown, or for confirmation. Mine waits for confirmation, or for a stretched price after the verdict.

The difference is your largest tranche. It: - buys into a broken range; - sits ahead of a binary verdict; - has a stop within one ATR; - is sized for a gap that conveniently stops at the 200-day.

And the November test meant to protect it only fires on a collapse.

ARM is a great business. At 300x earnings, with a 0.34–0.59% cash yield to owners, operating profit falling for a likely second straight quarter, and four major events in four weeks, it isn't a buy here. Wait for confirmation and pay up for it. Bull, your turn. Bear Analyst: # Bear Rebuttal: ARM (Round 3)

Your two sharpest points land. Put-call parity shows my holder advice was too soft. My buy plan also stacked two conditions that rarely happen together. I'll fix both.

But the test you used on my plan, "conditions that mostly rule each other out," also breaks yours: - Tranche 1 pays mainly on the November print you don't expect. - Tranche 2 fills mainly on paths where your own rules tell you to exit or stop adding.

1. What I concede¶

Parity is right. Stock plus a put equals a call plus cash, and the stock doesn't know anyone's cost basis. My holder advice didn't match "don't buy here." The fix is in section 2.
My buy plan was badly built. Opex growth under 25% is your "confirmed" case, and a confirmed print rarely leaves ARM at $233–244. I've split it into two paths below.
SuperTrend. By my own standard, the weekly flip at $383 can't settle my short either. With ADX at 12.45, it's only context for both of us, so I'm dropping it.
Growth. My two-year comparison started from a firm base. FY24–FY26 at 23.4% a year is the cleaner figure. Growth is steady in the low 20s. My case is that steady growth doesn't justify this price.
Qualcomm scale. If a loss only means not getting a rate increase, it doesn't damage current earnings. Section 6 covers where it does hurt.

2. Parity says holders should cut, not that new money should buy¶

If cost basis is irrelevant, the consistent rule is to hold only the exposure you'd open today. I wouldn't open upside exposure here, so: - Holders should reduce now. They shouldn't wait for a weekly close below $264.79. - Holders with large gains (anyone who bought below $200) have one valid reason to keep shares rather than sell, and that's tax. For them, a tight collar that brings exposure close to neutral is the right tool, not a hedge that keeps the upside.

That makes my advice consistent. It doesn't validate tranche 1. It just moves the question to whether your call spread is a good bet on its own merits.

3. Tranche 1 is fairly priced, and it mostly pays on the print you don't expect¶

What the market charges. None of our reports include options prices, so this is my own Black-Scholes estimate. - ARM's daily range implies roughly 65% realized volatility, and more with earnings and a verdict inside the window. - At 60–90% implied volatility, a $280/$320 spread expiring around November 20 costs about $12.50–14 at $275. That's right at your $13 cap. - That price implies about a 35% chance of finishing above the ~$293 breakeven and about a 25% chance of collecting the full $40.

"It only needs one-in-three odds" means it needs about the odds the market already charges for. At a fair price, a 2:1 payoff has no edge, so the edge has to come from direction. Low VIX doesn't change that: you're short the $320 call. This is a directional bet, not a cheap-volatility trade.

What direction needs. - The spread expires after the report, and its breakeven sits on the $286.7–293.2 resistance we both identified. - On my base case (about $138M operating income), your own rule cuts stock in half, so you're treating that outcome as bad news. - That leaves the spread mostly needing the confirmed print (opex roughly flat from Q1), or a macro rally big enough to carry a weak print. - You said that confirmed outcome is the one my buy plan "unlikely" needed. The difference is that I'd pay for it after seeing it. You pay about $13 for it beforehand.

The trigger adds little. A weekly close above $264.79 isn't a bullish signal. It only means one more bearish signal didn't fire, while MACD, OBV and down-day volume still lean the other way.

To be fair, your spread is a disciplined way to be wrong cheaply, and far better than buying stock here. My objection is to its edge, not its risk control.

4. Tranche 2 fails the test you used on my plan¶

Here is every route to $233–245 and what your rules say happens:

How ARM gets to $233–245	Your rule	Result
Verdict that resets royalty terms	Exit	No fill
Base-case Q2 (operating income $130–163M)	Cut in half, no adds	No fill
Miss (below $130M)	Exit	No fill
Confirmed Q2 (≥ $163M)	—	ARM unlikely to be at $239
One-time-payment verdict, hot CPI, hawkish FOMC, or an AI-trade unwind before the print	Buy	Fills, then has to get through November

What that means for the 2.5x ratio. - Tranche 2 mainly fills on macro weakness over the next three weeks. - It then goes into a print where the base case, which matches last year's seasonal pattern (section 5), makes you sell half. You'd likely sell lower, since the base case means a second straight quarter of falling operating income. - The 2.5x ratio assumes you hold to $287–290. The most likely path cuts the position in half before it gets there.

Two more problems. - The verdict rule can't act before the gap. Telling "resets rates across licensees" apart from "one-time payment" takes reading the ruling, and the stock gaps first. - Your rally template contradicts Round 2. There you called the move from $243.98 to $333.20 "a spike unwinding." Now it's your evidence that a 25–30% rally from this zone is realistic. It was one squeeze on a 13M-share gap, and it fully reversed in 13 sessions.

The "base" price isn't cheap. At $239, ARM is worth about $255B: - about 50x trailing sales, against about 32x at $148 in late March; - about 245–265x trailing GAAP earnings; - a 0.6% FCF yield, or 0.3% after vesting taxes.

Over those six months, trailing operating income fell, from $900M in FY26 to $877M. Your core entry pays about 55% more per dollar of sales than in late March, for a business earning less operating profit.

5. The base case is last year's pattern, not a vesting quirk¶

Q1 opex was on trend. It grew 27.8% year over year, against 27.6% for FY26 as a whole. The 13.9% jump from Q4 only looks large because March-quarter opex is seasonally flat; Q3 to Q4 opex fell 0.7%.
The May vest happens every year. Q1 FY26 contained it too, with $123M of financing outflow. Q2 FY26 opex still rose 3.7% from that base. My base case assumes the same 3.7%.
You said the payroll-tax idea can't be confirmed and that you wouldn't lean on it. Then you used it as the reason my base case isn't likely.

If Q2 is the clean test, as you say, that's an argument for waiting to see it.

6. Qualcomm: the billions aren't in earnings, they're in the price¶

I agree a loss mostly removes future upside rather than current revenue. But that upside is what roughly 300x earnings pays for. - "Rising royalty per chip" is a core growth bullet in your own case. - The 90x forward multiple is based on non-GAAP EPS that excludes stock compensation. Stock compensation cost $326M in cash last quarter alone. - If ARM can't enforce its terms on its largest phone licensee, the earnings base survives but the growth premium doesn't. Multiples compress when expected upside disappears.

7. Waiting in this stock has been a refund, not a cost¶

The record: anyone who bought the September 21 confirmation at the $294.36 open is down 6.5%. Anyone who bought at the next day's $333.20 close is down 17%. Waiting cost nothing.
We both pay up. Your tranche 3 buys at $293, so we both accept paying for confirmation. I want that confirmation to be fundamental (Q2 opex and the verdict), not a chart close.
Gaps run both ways. With a 3.79 beta, a base-case print can gap down as hard as September 21 gapped up. Waiting caps my cost at the upside I miss.
Macro hasn't helped you.
September CPI comes next, after August's +0.40%.
Oil is about $103 and the 10-year is at 5.28%.
The market prices 78% odds of another Fed hike by December.

8. My revised plan¶

New money: no position at $275.

Holders: - Reduce now. - If taxes make selling costly, collar the remainder close to neutral: sell calls into $293–307 to pay for puts near the 50-day.

Aggressive bears: buy put spreads expiring after the report, but only on a failed rally into $287–293. Otherwise stand aside.

Where I'd buy, as two separate paths: - Confirmation path: - Conditions: Q2 operating income of $163M or more, opex growth under 25%, and no verdict that resets royalty terms. - Action: buy on the print, even above $293, with a stop below $263. I accept paying up for this. - Price path: if Q2 matches my base case, I'd buy only at $219–225 (the 200-day and the August lows) or lower, after the verdict and in small size. Even there, ARM trades around 45x sales.

What changes my mind: - the confirmation path above; - the 10-year back under 5% after a soft CPI print; - a daily close above $293 with MACD and RSI turning up. I'd step aside there, and above $337 the near-term bear case is wrong.

Bottom line¶

We agree on most of this: no full-size stock purchase at $275, a rich valuation, a stock stuck in a range, and November as the deciding event. What's left is your plan, and each piece depends on an outcome you don't expect.

Tranche 1 is a fairly priced bet that mostly pays on a confirmed print.
Tranche 2 mostly fills on paths your own rules exit or freeze, and the likely print then cuts it in half.

The price is roughly 300x earnings with a 0.3–0.6% cash yield to owners. The base case is a second straight decline in operating income. I'd rather pay up after the evidence than pay a premium before it. Bull, your turn. Bear Analyst: # Bear Rebuttal: ARM (Round 4)

Two of your points land. My confirmation entry pays at least today's multiple, and my "opex growth under 25%" condition demanded a particular story instead of a profit level. I'll concede both and fix them.

That leaves us in an interesting place. After the print, our plans now buy in nearly the same places. What separates us is the half of your risk budget that goes in before the print: the call spread and tranche 2a. Your own sensitivity math is the best argument I've seen against that half.

1. What I concede¶

My valuation objection is conditional. 300x is unpayable on the current trajectory, not in every possible outcome. Section 3 explains why that isn't just "uncertainty dressed up as valuation."
The opex condition was a story. A $163M quarter is a $163M quarter. My confirmation test is now operating income of $163M or more by any route, with net income not mainly coming from below the operating line.
Buying the print-day gap repeats the September 21 mistake. I'll buy confirmation the way your 2b does: on the first pullback after the print, not on the gap.
Fairly priced puts have no edge either. My put spreads were always conditional and small. My recommendation is to stay flat.
The equity premium is real. Real-world odds of finishing above $293 are a few points higher than the risk-neutral odds. Section 5 covers what that's worth.
My base case is a sequential margin improvement. The improvement is seasonal. Last year the same quarter went from 10.8% to 14.4%, and this year's base case lands near 10%, still down year over year.
Late March isn't my entry anchor. It only showed the multiple expanding while rates rose.

2. After the print, we've converged¶

Situation	Your plan	My plan
New money at $275, before the print	Call spread, 25% of risk, if Friday holds $264.79	Nothing
Pre-print drop to $233–245	Stock, 25% of risk (2a)	Nothing
Base-case print	2b buys $225–233	Buy $219–225, small
Confirmed print	2b buys first pullback; tranche 3 above $293	Buy first pullback (adopted)
Miss or royalty-reset verdict	Exit all stock	Nothing to exit
Holders at $275	Hold, hedge with a put spread	Cut to half or less; collar the rest if taxes bind

You said my two entries were "a forecast about Q2." It's the reverse. Conditional entries respond to the print. The first two rows of your plan are the forecast. Holders are our third disagreement.

3. Yes, the objection is conditional. That's what a multiple is.¶

The same trailing multiple can describe two different bets. A growth multiple is a bet on trajectory. - At $275 today you pay about 330x trailing operating income for a business whose operating profit fell 20% year over year last quarter, with the next print undecided. - After a confirmed print, I'd pay about 355x for the same trailing number, but the decline would have stopped and I'd have a defined stop. - Paying 6–7% more to remove a binary outcome isn't hidden uncertainty aversion. It's how you price a conditional asset.

Your table describes half your own stock plan. On the confirmed path, 2b and tranche 3 buy at $287 or higher. If ARM doesn't dip before the print, 2a never fills, and every share you own was bought at the multiples in your table.

You also called tranche 3 "my smallest stock piece." In your Round 4 table, 2a, 2b and 3 are each 25%. It's tied for smallest, not smallest.

Look at what "confirmed" means. - A $163M quarter equals last year's $163M, so operating income is flat year over year. - Operating margin would be 11.6% via your revenue route ($1,407M) and 11.8% via the opex route, against 14.4% last year. That is still down about 260–280 bp, with opex still growing faster than revenue. - By your own note, trailing operating income stays at $877M, below FY26's $900M. - Your bottom line says two points of revenue growth decide whether operating profit is "falling or growing 20%+." The 20%+ figure was your Q1 counterfactual. For Q2, two points of revenue take operating income from about −14% to flat.

So "thesis confirmed" means operating profit stops falling. That's the minimum I need before paying up, which is why I'll buy it once it happens. It isn't evidence that 300x is cheap, which is why I won't pay for it in advance.

4. Your sensitivity math puts the exit closer than the confirmation¶

This table holds opex at last year's +3.7% sequential pace and gross margin at 97.2%:

Q2 outcome	Revenue growth	Opex	Operating income	Distance from base case
Confirmed	+24% ($1,407M)	$1,205M	$163M	+$22M (2 pts more revenue growth)
Base case	+22% ($1,385M)	$1,205M	~$140M	—
Your miss trigger (revenue)	+21% ($1,373M)	$1,205M	$130M	−$11M (1 pt less revenue growth)
Your miss trigger (opex)	+22%	$1,216M (+4.6% QoQ)	$130M	−$11M (0.9 pts more opex growth)

The miss is half as far away as confirmation. One point of revenue growth, or under one point of sequential opex growth, triggers your exit. Confirmation needs two points of revenue growth.
That distance is within normal noise. Sequential opex over the last four quarters ran +3.7%, +8.9%, −0.7% and +13.9%. My base case already uses the gentlest seasonal comparison.
Convexity cuts both ways. With opex at 90% of revenue, a small change swings operating income hard in either direction. You described the upside convexity the multiple pays for. You didn't mention that your exit sits on the near side of it.
"Balanced" supports my case. You read the options as giving about 35% odds of finishing above $293 by November 20, roughly the same as finishing below $239. That's the probability of a price, not of a print result. Even taken at face value, a coin flip at 330x with gap risk in both directions is a reason not to position early.

5. Tranche 1 has three paths up and one final test¶

Paths aren't payoffs. The spread expires after the print, so its value depends on where ARM sits after the print. Suppose a soft CPI rallies ARM to $300 and then a base-case print arrives, which your own rules treat as bad news. The spread ends below breakeven. Your three paths up collapse into one: the post-print price.
The paths down count too. These include:
hot CPI following August's +0.40%;
a hawkish FOMC on October 27–28;
an adverse verdict;
a base-case or miss print;
policy noise after the November 3 midterms.

The roughly $13 price nets all of them against your three upside paths, which is why it's fair. - Two of your three paths may not arrive in time. Neither report gives a trial schedule or ruling date, and the earnings date is an estimate based on past timing. A verdict in December doesn't pay a November spread. - The equity premium is small. Even generously, a 3.79 beta adds about 2% of drift over six weeks. That's a few points of probability, earned by carrying about four times market exposure through CPI and an FOMC while long yields rise faster than short ones. It's compensation for the macro risk both reports flag, not a timing edge. - Soft CPI and a clean verdict are on my list of things that would change my mind. That's the real difference between us: I act after they happen, and you pay $13 for them beforehand.

6. 2a keeps the flaw you fixed in 2b¶

You split tranche 2 because my table showed that most fills come before the print, and a miss then forces a sale after the gap. That's still true of 2a.

The filter screens the wrong risk. "No company-specific exit trigger" still lets 2a buy after a hot CPI, a hawkish FOMC or an AI-trade unwind. The macro report calls the 10-year yield ARM's main driver, so 2a buys after that driver gets worse.
Then 2a faces the print, where the miss is half as far away as confirmation (section 4).
On a miss, 2a sells after the gap. From $239, a gap to your $198 sizing level is −17%. You fixed this sequencing for 2b, but 2a still has it.
To be fair, on the path where 2a gains most (a macro dip followed by a confirmed print), you buy at $239 and I buy the first post-print pullback wherever it lands. You capture more of that path. On the other paths, you lose on 2a and I lose nothing.

7. The base buyers in your table bought after a print¶

Two of your best dated entries came after the last report. In Round 2 you wrote that the $225.46 (September 3) and $238.03 (September 14) lows formed "after that quarter was reported." Those are post-print entries, which is exactly my price path.
Lows only look like lows in hindsight. Your table lists the best prices in the base. A buyer at the base's midpoint, around $260, is up about 6%. A buyer at its top, $287, is down about 4%.
I've accepted your gap critique and moved my confirmation entry to the first pullback after the print.

8. Holders: apply your own parity and sizing¶

You introduced parity: the stock doesn't know your cost basis. Apply it to your own advice.

Your new-money plan at $275 owns no stock, and at most a call spread worth a quarter of the risk budget. A full-size holder with a put spread holds far more than that. By your test, "hold" doesn't match what you'd open today. That's the same flaw you found in my Round 2 advice.
Your sizing rule says cut. You size 2a for a gap to $198, which is −17% from $239. For a holder at $275, the same gap is −28%.
You conceded that only sizing protects against a verdict. For a holder, sizing means reducing. The macro report says single-name exposure "should account for that risk around the verdict."
A put spread leaves the gap uncovered. Below the lower strike the holder is fully exposed again, and that's exactly the gap scenario.
"Don't chase" is about entries. Reducing ahead of four events isn't chasing. A level where I'd neither buy nor short is a level where the right exposure is small, and cutting to half delivers that.

9. My revised plan¶

New money: none before the print.

Holders: - Cut to half or less now. - If taxes make selling costly, collar the rest: sell calls at $293–307 to fund puts near the 50-day average. - Trim what's left into $287–293 if a bounce comes first.

Confirmation path: - Conditions: Q2 operating income of $163M or more by any route, net income not mainly from below the operating line, and no royalty-reset verdict. - Entry: the first pullback after the print that holds above the pre-print close, wherever that is. - Stop: a daily close below the pre-print close. - If the trial is still open, use half size until a ruling.

Price path: after a base-case print and a verdict, buy $219–225 in small size. Exit on a weekly close below $198, where the monthly SuperTrend says the long-term uptrend has failed.

Aggressive bears: put spreads only on a failed rally into $287–293, kept small. Otherwise stay flat.

What would change my mind: - the confirmation path above; - the 10-year back under 5% after a soft September CPI print; - a daily close above $293 with MACD and RSI turning up. I'd step aside there, and above $337 the near-term bear case is wrong.

Bottom line¶

Side by side, your plan is my plan plus two pieces: - A call spread you concede is fairly priced. Its only edge is a few points of beta premium, earned by holding through CPI, the FOMC and rising long yields. - Tranche 2a, which buys after the macro report's main driver worsens, then holds into a print where your exit trigger is half as far away as your confirmation.

We now agree on everything else. Waiting costs me the small edge in your call spread and 2a's gain on one path. Your extra half costs you a stock position and an option premium carried through four events, with your exit closer than your confirmation.

The bar you call "thesis confirmed" is operating profit flat year over year, margin still down about 270 bp, at 355x trailing operating income. That's worth buying once it's proven. It isn't worth paying for before. Bull, your turn. Bear Analyst: # Bear Rebuttal: ARM (Round 5)

Your September test found a real flaw in my confirmation stop. You're also right that a verdict with no date could leave my price path permanently unfilled. I'll fix both.

Your round narrowed the debate to one question: should anyone pay for defined-risk upside before the print? Your own rules and the sensitivity table we both accept answer it. The answer is no.

1. What I concede¶

My confirmation stop made my risk equal to the gap. With a stop at the pre-print close, the bigger the good news, the bigger my loss if it fades. I called September 21 "confirmation" in Round 3, so I can't object to you testing it. The fix is in section 7.
The verdict condition could leave my price path unfilled. I've dropped it. Defined risk handles the verdict instead.
"Half or less for everyone" isn't a sizing rule. I'll size holders to a budget (section 6).
A full put covers the gap and a put spread doesn't. Your collar fixed what I criticized.
Making 2a a spread removes the forced sale after a gap. That fixes the flaw I raised in Round 4.

2. The September test, run through your own stock rules¶

The September 21 gap ran from $275.78 to $293.08, so that day's low was $293.08.

Tranche 3 buys a daily close above $293 with the MACD histogram turning up and RSI above 50. All three appear to have been met on September 21:
the close was above $293.08;
MACD crossed above zero that day, with the histogram rising toward its September 23 peak;
RSI hit 71 the next day.

It fills at $293 or higher. Today it's down at least 6%, and its $263 stop is another $12 away. - 2b's confirmed path buys the first pullback into $287–293. ARM traded down to $290.50 on October 7 at the latest, so it fills at $293 or below. It's down about 5–6%, with its stop roughly 10% below entry. - On your confirmed path, half your stock budget pays the gap exactly as mine does. On that path, the only thing separating our plans is the spreads. - Your spreads have no profit-taking rule. Take a $280/$320 spread bought at the September 18 close ($275.61). By my Black-Scholes estimate, it cost about $13.50, was worth about $24 at $333, and is worth about $12.75 today. As you said, paths aren't payoffs.

3. Your evidence for buying the base comes from buys your rules now forbid¶

Your miss line is Q2 operating income of $130M, against last year's $163M. That's a 20.2% decline.
Q1 FY27 operating income was $91M, against $114M a year earlier. That's also a 20.2% decline.
In Round 2 you said the $225.46 (Sept 3) and $238.03 (Sept 14) lows formed "after that quarter was reported."
Your Round 5 rule after a miss is "stock purchases: none." So 2b would have bought none of the base entries in your Round 4 table.

That leaves two possibilities: - The miss rule is wrong, and ARM is buyable after a 20% drop in operating income. That undercuts every exit in your plan. - The evidence doesn't describe your plan. "Buying the base has paid" comes from buys your current rules wouldn't make.

Those buys also came after a 49% drawdown, at about 45–50x sales. Today ARM is at 57x, before the next print.

4. The spreads pay mainly in the least likely row¶

What break-even requires. Tranche 1 costs about $13 for a $40 maximum payout. It needs at least a one-in-three chance of paying in full, and better odds if payouts are partial.

Which rows pay. - Your rules treat the base case as "no adds" and the miss as an exit. - In the base case, 2b buys at $225–233. Both spreads are worthless there: their breakevens are about $257 for 2a (at your $17 cap) and $293 for tranche 1. - If a base-case print leaves ARM above $257, 2b doesn't fill. Within the base case you can't have both. - So the spreads pay mainly on confirmation.

How likely confirmation is. You accepted the sensitivity: confirmation sits $22M above the base case, and the miss sits $11M below it. Here is a simple bell curve around the base case:

Noise in Q2 operating income (1 standard deviation)	Odds of confirmation (≥ $163M)	Odds of a miss (< $130M)
$15M	~7%	~23%
$30M	~23%	~36%
$50M	~33%	~41%

Confirmation only reaches tranche 1's break-even at $50M of noise. That's about 3.6% of revenue, and it also assumes a confirmed print lifts ARM above $320 (+16%) by expiry. A confirmed print here means operating income flat year over year and margin down about 270bp.
"Revenue is reliable" works against you either way.
If revenue is as steady as you say, the noise is small and you're in the top row.
If it's noisy enough to make confirmation a one-in-three shot, a miss becomes even more likely.
In every row, a miss is more likely than confirmation.
Calling opex "ARM's own choice" doesn't help. ARM has chosen opex growth near 28% for five straight quarters, which you agreed with. Your miss trigger is less than one point of sequential opex growth above that pace.
Your one argument against the base case was withdrawn. In Round 3 your reason for doubting it was payroll-tax timing, which you dropped in Round 4. Since then, your case for confirmation has been the options market's price distribution. That describes where the price may go, not what the print will show.

To be fair, the stock trades on guidance, the verdict and macro, not only operating income, so a base-case quarter could still rally. But you can't count the base case as a payoff path while your own rules treat it as bad news.

5. My not shorting at $275 doesn't give you the edge¶

My view does lean below the market's. At every noise level in the table, a miss is more likely than confirmation.
I don't short at $275 for two reasons.
A favorable verdict can gap through a short. I flagged that squeeze risk in Round 1.
A few points of edge doesn't cover two bid-ask spreads plus the verdict risk.

Passing on a small edge isn't the same as having none, and it doesn't transfer the edge to your side. - The equity premium doesn't close the gap. It adds a few points of drift. The gap between miss and confirmation in my table is 8–16 points. - A December expiry adds risk. It likely spans the December FOMC, where the market's base case is a hike (78% odds of another hike by December 10). Each extension of the window buys more of the macro risk both reports flag.

6. Holders: parity applied to your collar¶

By parity, your collar is a bigger call spread. Stock plus a $240 put minus a $320 call equals a $240/$320 call spread plus cash. That's about $35 a share at risk.
What you'd open as new money is smaller. Tranche 1 is a $280/$320 spread with about $13 at risk, using a quarter of the budget.
So by your own rule, the holder carries about 2.7 times the per-share risk of what you'd open today.

There are two consistent fixes: - Raise the put. Buy a $265–270 put and sell a $300–307 call to fund most of it. I estimate a net cost of roughly $3–8 a share before skew. - Keep your $240/$320 collar but cut shares until $35 a share at risk fits the budget you'd give new money.

Either way, most holders end up owning less than they do today. That's my advice with your sizing rule attached. I'm also moving my call strike from $293 to $300–307, above the resistance cluster. You were right that a $293 cap was a bet against the print.

7. My revised plan¶

New money: none before the print.

Holders: one of the two parity-consistent options in section 6.

Confirmation path. Conditions: Q2 operating income of $163M or more by any route, net income not mainly coming from below the operating line, and no verdict that resets royalties. - Entry: the first pullback after the print. - Stop: about 1.5 ATR below entry (roughly $27 at today's ATR), sized to the budget. The stop is no longer the pre-print close. - If the trial is still open: buy a call spread instead of stock, so a verdict gap costs only the premium. That's your tool, used after the earnings answer is known.

Price path (base-case print): - Buy $219–225 in small size, verdict or not. - If the verdict is still pending, hold the position as stock plus a put, or as a call spread. - Exit on a weekly close below $198.

Miss or royalty-reset verdict: nothing to do.

Aggressive bears: small put spreads only on a failed rally into $287–293. Otherwise stay flat.

Dates to watch: - Friday's weekly close versus $264.79 - September CPI in mid-October - the earliest daily TD buy 9, around October 20 - FOMC on October 27–28 - midterms on November 3 - the Q2 FY27 report in early November (estimated)

What would change my mind: - the confirmation path above; - the 10-year back under 5% after a soft September CPI print; - a daily close above $293 with MACD and RSI turning up. I'd step aside there, and above $337 the near-term bear case is wrong.

8. The three outcomes, with both plans fixed¶

Q2 outcome	Your plan	My plan
Confirmed	Spreads pay up to $27 and $33. Stock bought on the pullback and above $293, paying the gap just as I do.	Buy the pullback (stock, or a call spread if the trial is open). I miss the spreads' gain.
Base case	Spreads lose most or all of their premium. 2b buys at $225–233.	Buy $219–225, small. No premium lost.
Miss or royalty reset	Lose the premium, up to half the ARM risk budget.	Lose nothing.

You win one row, and by our shared table it's the least likely one.
You pay the premium up front in every row and collect in one. I pay the gap only in the row where the news is good, and I pay it once the answer is known. Yours is a realized loss in two of three outcomes. Mine is an opportunity cost in one.

Bottom line¶

We now agree on almost everything: - no unhedged stock before the print; - the valuation is rich; - the chart is a range; - November decides; - after the print, both plans buy stock at nearly the same levels and pay the same gap on confirmation.

What's left is half your risk budget in two fairly priced spreads. They pay mainly on confirmation, which our shared sensitivity puts at roughly 7–33% depending on noise, always below the odds of a miss. The base buys you cite as proof came after a quarter your own rules now classify as a miss.

ARM is a great business, priced at about 330x trailing operating income, with operating profit likely down again in November. Don't buy it here. Wait for the print, and pay for the answer once it's known. Bull, your turn.

Research Manager¶

Recommendation: Underweight

Rationale: By the end of the debate, the two sides agreed on more than they disagreed. Neither wants unhedged ARM stock at $275 heading into the coming event cluster: Friday's weekly close, September CPI, the Oct 27–28 FOMC, the Nov 3 midterms, a Qualcomm ruling with no date, and an estimated early-November Q2 FY27 print. Both accept that the valuation is rich: about 57x sales, about 300x trailing GAAP earnings, about 330x EV to operating income, and a 0.3–0.6% cash yield to owners against a 5.28% 10-year. Both read the chart as a range of roughly $263–293 with ADX near 12, and both say November decides.

The bull's best material is real. Revenue is compounding 22–23% a year with a 97% gross margin. The balance sheet carries $3.06B of cash and 0.06x debt-to-equity, and trailing operating cash flow is a record $2.09B. Revenue held up through FY26 after the 2024 Nuvia loss. The 50-day held on a −6.5% day, and the long-term trend is intact (50-day above the 200-day, monthly SuperTrend up). That is why this isn't a Sell; both sides want to own ARM after the print under the right conditions.

The bear won the question that matters for positioning now, on four points. - Profit trajectory: operating income fell 20% year over year in Q1 (7.1% margin). The base case for Q2 (opex up 3.7% sequentially as last year, revenue up 22%) gives about $140M, down roughly 14% year over year. - The bull's own sensitivity math: his miss line ($130M) is only $11M below the base case, while confirmation ($163M) is $22M above it. At any reasonable noise level a miss is more likely than confirmation, and even 'confirmed' means flat operating income with margin down about 270bp. - His evidence that buying the base has paid comes from entries after a Q1 that his own rules now classify as a miss. - Macro is net hawkish: 78% odds of another hike by December, the 10-year at 5.28% with the long end leading, and oil around $103. A 3.79 beta and a gap-prone history (−49% in six weeks this summer, a full reversal of the Sept 21 breakout) make event risk large.

Short-term technicals also lean weak. Highs are lower ($439, $333, $310, $307), MACD is bearish with a widening gap, RSI is below 50, OBV is back below its pre-gap level, and weekly momentum is down.

The bull's strongest point was put-call parity: you should hold only what you'd open today. It forced the bear to concede that 'hold and hedge' was inconsistent. But the conclusion cuts the bear's way. Even the bull's final plan opens no unhedged stock before the print, only fairly priced call spreads that pay mainly on the less likely confirmation outcome. A full, unhedged position is therefore oversized against both analysts' own rules.

The call is to trim and hedge, not exit, with re-entry rules set in advance for after the print. Several inputs are missing from the record: no live options quotes (spread and collar costs are Black-Scholes estimates), no trial schedule, an estimated earnings date, no royalty vs. licensing revenue split, and no capex breakdown.

Strategic Actions: 1) Pre-print target: about 50% of a standard allocation (range 40–60%), hedged. Trim the excess now near $275 rather than waiting for a bounce. If a rally into $287–293 comes first, sell any remaining excess there. That zone holds the gap fill, the 50% retracement, the 10-day EMA and the Bollinger middle band. 2) Hedge the remainder with a collar expiring after the Q2 report (late November or later). Buy a ~$265–270 put and sell a ~$300–307 call to fund most of it; estimated net cost is about $3–8 a share before skew, so confirm with live quotes. If you prefer a wider $240 put / $320 call collar, cut shares further so about $35 a share of risk fits the budget. If you won't hedge, hold no more than about 35% of standard, unhedged. 3) No new money before the print: no stock and no standalone call spreads. The collared remainder already works like a defined-risk call spread. No outright shorts; a gap through a short stop on a favorable verdict is a live risk. 4) De-risk triggers: - A weekly close below $264.79 (Fri Oct 9 is the first test) or a daily close below $263: cut to about 25% of standard. - A weekly close below $219 (the 200-day and the August low): exit. - A Qualcomm verdict that resets royalty terms across licensees: exit. 5) Post-print playbook: - Confirmed (Q2 operating income at or above $163M by any route, net income not mainly from below-the-line items, no royalty-reset verdict): rebuild to 100% of standard on the first pullback after the print, not on the gap. Set the stop about 1.5 ATR (~$27) below entry and size to it. If the trial is still open, add the new portion via call spreads. A daily close above $293 with the MACD histogram turning up and RSI above 50 adds confirmation. Above $337 the near-term bear case is invalidated. - Base case ($130–163M): keep the hedged ~50%. Add only at $219–233 in small size, up to about 60–75% of standard, held as stock plus a put while the verdict is pending. Exit on a weekly close below $198. - Miss (below $130M, revenue growth under 20% YoY, or opex growth above 30% YoY): exit what remains. 6) Macro upgrade: if a soft September CPI print pulls the 10-year back under 5%, raise or remove the short call and move toward Hold sizing (75–100%). 7) Calendar: - Fri Oct 9: weekly close vs $264.79 - Mid-October: September CPI - ~Oct 20: earliest possible daily TD buy 9 - Oct 27–28: FOMC - Nov 3: midterms - Early–mid November (estimated): Q2 FY27 report - Qualcomm ruling: date unknown 8) Risk mechanics: the average daily range is about 6.5% (ATR ~$17–18), so never place stops within one ATR. Size every piece for a gap to about $198 (the monthly SuperTrend), not to the stop.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan's Underweight translates to a Sell, meaning trim and hedge rather than a full exit. The upcoming events (weekly close, CPI, FOMC, the Qualcomm ruling and an estimated early-November Q2 FY27 print) carry gap risk against a rich valuation of about 57x sales and 300x trailing GAAP earnings, and a Q2 operating-income miss is more likely than confirmation. Short-term technicals also lean bearish: the weekly and daily SuperTrend point down, MACD has crossed bearish, RSI is 46.7, OBV has given back the gap rally's volume and closing highs keep falling (333, 310, 307). The long-term trend is intact, with price 25.5% above the 200 SMA, the monthly SuperTrend up and the rising 50 SMA at 269.37 holding today, so this is a reduction to about half size, not a liquidation or a short. With ADX at 12.45 the stock is range-bound at roughly 263–293, so sell the excess now near 275 or into a bounce to 287–293, the zone where the gap fill, 50% retracement, Bollinger middle band and 10 EMA overlap.

Entry Price: 275.29

Stop Loss: 307.49

Position Sizing: Cut to about 50% of a standard allocation (range 40–60%) and collar the remainder through the Q2 print: buy a put near 265–270 and sell a call near 300–307. Net cost is estimated at $3–8 a share from Black-Scholes, not live quotes, so confirm pricing before trading. If you won't hedge, hold at most 35% of standard. A daily close above 307.49 invalidates the trim thesis; at that point stop trimming and reassess re-adding toward Hold sizing. Cut to about 25% of standard on a weekly close below 264.79 (first test Fri Oct 9) or a daily close below 263. Exit fully on a weekly close below 219 or a Qualcomm verdict that resets royalty terms. Add no new money and open no shorts before the print. Size what you keep for a gap to about 198 (the monthly SuperTrend stop), and keep stops at least 1 ATR (about $17.8) away. After the print, rebuild to 100% on the first pullback only if Q2 operating income is at or above $163M; exit the rest if it is below $130M.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: I'm backing this Sell, and I think it's the most upside-oriented choice available. It isn't a retreat. It cuts ARM to about half size, buys cheap protection on the rest, and sets clear rules for getting back to 100%. The aim is to own the next leg up at a better price or with better evidence, not to own every dip on the way there.

Why stay exposed at all

The long-term bull case is real. Revenue has grown more than 20% for four straight quarters. Gross margin is about 97%. ARM has $3.06B in cash, no meaningful debt, and about $1.5B of free cash flow over the last twelve months.

The chart's big picture agrees: - The monthly SuperTrend is up, with its stop down at 198. - Price is 25.5% above the 200-day average. - The summer lows kept rising: 219, then 225, then 238.

That's why I would never exit fully. A good Qualcomm outcome or a strong quarter for data-center royalties could re-rate this stock quickly, and with a 3.79 beta you don't want to be buying it back from 330.

Why now is the time to take chips off

The short-term signals all point the same way: - The weekly SuperTrend is down. - MACD crossed bearish on 10-07. - OBV has given back every share of buying from the September gap rally. It now sits slightly below its 09-18 level while price is back where it started. - Closing highs keep falling: 333, then 310, then 307. - Today's close of 275.29 broke the 61.8% retracement at about 278, on 1.9x normal volume.

The macro adds pressure. Since 09-21, the day of the gap-up, the 10-year yield has risen 32 basis points while the 2-year stayed flat. Rising long-term yields are the move that hurts long-duration, high-multiple stocks most, and the 09-21 gap has since fully reversed.

The Q2 earnings bar is the strongest argument for trimming

Here is my own arithmetic, so treat it as an estimate. Revenue growth of 22% puts Q2 revenue near $1.38B, and a 97% gross margin gives gross profit of about $1.34B. To beat last year's $163M of operating income, operating expenses can rise only about 1% from Q1's $1,162M.

That looks unlikely. Opex rose 13.9% last quarter and nearly 28% year over year. At the same 28% annual pace, Q2 operating income comes in around $134M. That falls in the gap between the plan's $130M exit trigger and its $163M rebuild trigger. In other words, the base case is a miss on core profitability, at roughly 300x trailing GAAP earnings and 57x sales.

Answering the conservative case for a full exit

I expect the conservative analyst to point to the 300x multiple, $72M of insider selling with no buys, the Fed hiking, oil above $100, and the Qualcomm trial, and conclude that we should get out entirely. That treats gap risk as unmanageable when it can be bought off cheaply.

The collar sets a floor near 265–270 through the print, whatever the jury or the earnings report does. The estimated net cost is $3–8 a share, about 1–3% of price. That figure comes from Black-Scholes, not live quotes, so it needs confirming before trading. Even so, worst-case loss on the hedged half through the print is roughly 3–6.5%. Unhedged, the plan sizes for a fall toward 198, about 28% lower.

On the other inputs, the conservative read goes too far: - Much of the insider selling was routine selling after the May 15 vesting. The CEO hasn't sold since April at about $160. - Prediction markets give only a 6% chance of a US recession by year-end. That's a valuation squeeze, not a crisis.

A full exit hands the whole rebound to someone else, then forces you to chase if Qualcomm goes ARM's way.

Answering the neutral case for holding

I expect the neutral analyst to argue that the rising 50-day average is holding, ADX at 12.45 says we're in a range, and trimming near support is selling low. I disagree.

This isn't a low. RSI is 46.7, the daily z-score is -0.49, and nothing is oversold. The real oversold zone is 233–244, where the lower Bollinger band, 2 ATR below price and a z-score of -2 line up.

The 50-day support is also weaker than it looks. It rises for the next three sessions only because closes near 240 drop out of the average. From about 10-14, closes of 280, 274 and 286 roll off, and the average flattens.

Meanwhile four catalysts arrive within about four weeks: CPI, the October FOMC meeting, the Qualcomm trial and the earnings print. ATR is $17.8, so a break of 263 can gap past you before you react. Holding full size into that with costs outgrowing revenue isn't balance. It's hoping.

The plan already uses the range the neutral side is pointing to. It sells the excess either now or into 287–293, where the gap, the 50% retracement, the Bollinger middle band and the 10-day average all overlap.

Why this plan offers the best upside

Look at how the remaining position pays off. If Q2 operating income comes in at or above $163M, you rebuild to 100% on the first pullback, with proof in hand instead of hope. If it comes in below $130M, you exit the rest from half size with a put underneath. If ARM flushes to 233–244 before the print, the put gains value, and you can bank that gain to fund the post-print rebuild without adding new money.

Two refinements I'd push for: - Short call strike: sell it at 305–307, not 300. That keeps the extra upside while still collecting premium where the CFO's apparent price-triggered selling plan sold at $300 and the 307.49 lower high sits. - Execution: split the trim, with half at market now and half on limit orders in the 287–293 band. With ADX this low, fading the top of the range is favored. A weekly close below 264.79 cuts you to 25% regardless.

I also agree with not shorting. The monthly trend is up, MACD is still above zero, and a 3.79-beta stock faces a binary court ruling. A short there isn't bold. The bold move is keeping cash and the right to rebuild for when the odds are better.

Whatever your current ARM holding, apply it the same way: cut to 40–60% of your standard allocation, collar what you keep through the print, and be ready to rebuild. Selling here keeps the upside and frees capital to buy back lower or on proof. Aggressive Analyst: I'm still on the Sell. I'll give ground where you've both earned it, because that clears the table for the one argument left. Is this plan built to own ARM's next leg, or does it slowly drift down to 25 percent and stay there? The conservative's version drifts, and that is the expensive mistake.

First, the concessions. The neutral is right that my split trim left us at 75 percent while a jury is out. So I'll sell down to 60 percent at market now and work the last ten points with limit orders in 287 to 293. If those orders haven't filled by the CPI release, or ARM closes below the 50-day near 269, they go at market.

You're both right about the call strike too. By my rough Black-Scholes math, moving it from 300 to 305–307 gives up about $1.50 to $2 a share of premium. That widens the hedged worst case by more than half a point. So sell the 300 call. I'll get the upside back through the neutral's roll, which I only pay for if the verdict has already gone our way. And rolling the put down on a flush beats closing it.

I also accept the rest of the protection rules. The collar expires after the confirmed earnings date, and we roll the put if the verdict is still out. Unhedged exposure is capped at 25 percent while both the verdict and the print are ahead, and rises to 35 once one passes cleanly. Proceeds sit in cash near the Fed funds rate as dry powder for ARM, not in other AI names.

Now the core disagreement. The conservative calls missing the rebound "the cheap risk." Look at how this stock actually moves: - It went from 243.98 to 333.20, up 36.6 percent, in four sessions in September. - It roughly tripled, from 143.86 to 439.46, in ten weeks this spring. - It fell 49 percent in six weeks over June and July.

ARM doesn't drift toward evidence; it gaps on it. So "paying up for the evidence" really means paying the whole gap, because the repricing happens the day the evidence lands. That's why we hold a collared half through these events. The put means we don't pay for the bad gap. The shares mean we're there for the good one.

The 49 percent collapse also started from 439, right after a tripling. Today we're 37 percent below that peak, the monthly z-score is 1.12, and nothing on the daily or weekly chart is stretched. That's a different starting point.

The conservative's rebuild rule is where his caution gets costly. He only goes back to full size once the weekly SuperTrend turns up, and that flips at 383.15, 39 percent above today. Suppose ARM prints a clean quarter, the verdict comes in non-adverse, and the stock runs. Under his rule, the last quarter of the position gets bought back somewhere between 25 and 39 percent above where the neutral's trigger, or today's price, would have bought it. That's roughly 6 to 10 percent of a full allocation given away.

That is about the same size as the loss he's sizing against in a gap to 198. The difference is that his loss case already has a put under it. His missed-gain case has no protection at all.

On 40 versus 50 percent collared, the neutral did my math. Each extra ten points adds about 0.65 points of worst-case loss. With the call at 300 and a $3 to $8 collar, it adds roughly 0.6 to 0.8 points of best case. That's defined risk on both sides. Trimming collared shares doesn't shrink the tail, because the put already did that. It only reduces how much of the rebuild you already own. I'm at 50, not 40, and the collar goes on the core half today.

On the collar cost, I'll take the $8 cap. If the quote comes in above it, I'll take the neutral's fallback: try a put around 255 to 258 before cutting size, and only drop to 25 percent unhedged if that fails too. But the cost worry is overstated. If ARM's own options price in event risk, that also raises the price of the call we sell. The structure is still net long volatility, because the put sits closer to the money. Even so, the short call gets back part of what we pay. That's exactly why a collar is the right tool here instead of a naked put.

Now the earnings bar. The conservative stacked costs onto it that don't belong there: - Capex at 11 to 15 percent of revenue is an investing cash flow, not an operating expense. - Tax withheld on vesting shows up in financing. - Neither touches operating income, so neither moves the $130 million or $163 million triggers. - "Supply execution questions" is a headline with no number behind it. The number we do have points the other way: Q1 gross margin was 97.2 percent, right where it's been, so there's no sign yet that selling its own chips is diluting the model. - The worry that net income was three times operating income is already handled, because the triggers are on operating income, not EPS.

The tough comparison also doesn't hold up under the neutral's seasonal math. The usual Q1-to-Q2 step lands revenue near $1.39 billion, about 22 percent growth.

So my base case of roughly $134 million means operating income up about 47 percent from Q1, with margin rising from 7.1 to about 9.7 percent. Expanding margin by 260 basis points in one quarter is not a miss that justifies cutting to 25 percent. The conservative's middle-zone rule does exactly that.

I'm with the neutral on the middle zone: hold the half and let the price reaction decide. But I'd add a tiebreaker that can push it up as well as down. The fundamentals report names opex growth slowing below 25 percent as the sign of strength. In the middle zone, I'd take the first rebuild step to 75 percent if three things hold: - Management guides opex growth below that 25 percent. - The verdict isn't adverse. - The stock holds 263.

The market pays for where margins are heading, and that guidance is the evidence.

On insiders, fine, not selling isn't buying. But the CEO took a vesting of more than 265,000 shares on May 15. While other insiders were selling at $384 to $416, he sold nothing on the open market, and he has held through a 45 percent drawdown. That's a choice. The CFO's sales look like a pre-set price ladder that reached 300. That tells us there's supply at that level, not what he thinks of the business. It's also why I'm comfortable selling the 300 call: let his plan's selling cap the hedged half, and buy the upside back only once the verdict says it's worth it.

SoftBank is a real tail risk, and the put exists for exactly that. A floor at 265 to 270 doesn't care whether the gap comes from a jury, a hot CPI print, or pressure on SoftBank's loans. And the same 90 percent stake that makes the float thin helped power the run from 144 to 439. A thin float amplifies moves in both directions. That argues for a collar on a meaningful position, not for shrinking below half.

The conservative says a low ADX ahead of five catalysts is a spring that hasn't released. Agreed, and nothing in the data says which way it releases. Several things point to a coiled range inside an uptrend rather than a top: - OBV is still 37 million shares above the late-August low. - The lows have stepped up from 219 to 225 to 238. - The monthly SuperTrend is up, with its stop at 198.

On macro, I won't dispute that a 32-basis-point rise in long yields hurts a stock at 90 times forward earnings. But look at what moved this week: - October hike odds fell to 16 percent, with hold odds up ten points. - The 10-year peaked at 5.31 on Monday and was 5.28 by Wednesday. - Oil is easing after the Iran comments. - Recession odds are 6 percent, and so are AI-bubble odds. - Chip stocks sold off on Samsung's record guidance, which means positioning is setting prices, not fundamentals.

Crowded trades that sell off on positioning tend to snap back once the selling is done.

So I'll adopt the neutral's yield rule and make it count on the upside. If the 10-year closes back below 5 percent, operating income comes in at $163 million or better, and the verdict isn't adverse, skip the 75 percent waypoint and go straight to full. If the yield conditions aren't there, I'll take the neutral's two steps: 75 percent on $163 million with a non-adverse verdict, then full on a close above 307.49 that holds. Every one of those conditions is measurable and reachable, unlike a weekly flip 39 percent away.

Here's my one new idea, and it stays inside every rule we've agreed on. Say ARM flushes to 233 to 244 before the print. We roll the put down toward 235 and bank part of the gain, as you both said. That zone is where the technical report sees a higher-probability long setup forming: - The lower Bollinger band at 232.93. - Two ATRs down near 239.77. - A daily z-score around minus 2. - The 238 higher low. - The window where the earliest daily TD buy signal could complete, around October 20.

So take a slice of the banked put gain, not new money, and buy a call spread expiring after the print, with its upper strike at 300. That way it never adds exposure above where the collar already caps us. The floor stays on, nothing is unhedged, and the most you can lose is part of a gain you wouldn't otherwise have had. That's how you get paid for the flush instead of just surviving it.

Before the print, a close above 307.49 means we stop trimming and roll the call up, not buy stock against a capped position. I'll take that too.

The conservative is protecting the firm against a 28 percent gap that the put already covers. I'm protecting it against the other mistake: sitting at 25 to 40 percent while a 3.79-beta stock reprices on good news in four sessions. Sell, keep the collared half, and keep a path back to full size that can actually be triggered. Aggressive Analyst: Aggressive Analyst: I'm still on the Sell. The neutral's last round did more for the upside case than anything I argued. Two of his points settle most of what's left: splitting the stops by bucket, and showing that a collar is already a call spread. Both cut against the conservative more than against me. So I'll accept what I've lost, then use the rules we've all agreed on to push for one more piece of upside.

First, what I'm dropping. The call spread on a flush goes. The neutral's math is right. At 240, stock plus a 265 put minus a 300 call pays off like cash plus a 265/300 call spread. Buying another one doubles exposure the collar already gives us.

The opex guidance tiebreaker goes too. If $163 million of reported operating income already implies opex growth of about 25 percent, rebuilding on a 25 percent forecast counts the same signal twice. An adjusted forecast could also hide GAAP costs.

I'll keep the 75 percent waypoint even if the 10-year drops under 5 percent. The full-size trigger at 307.49 is only 11.7 percent above today, so a clean print and a clean verdict would fire both steps within days anyway. The waypoint costs almost nothing.

I'll also take sizing to the floor: 50 percent collared with a 265 to 270 put, and about 40 percent with the 255 to 258 fallback. That's my own defined-risk logic applied honestly, and it keeps the amount at risk near 3.3 percent of a full allocation either way.

Now look at what the bucket split does to the conservative's case. His objection to acting after a flush was that our own rules would already have cut us to 25 percent by 240. Under the split, they won't. Price stops govern only the unhedged shares, and the put governs the core. A flush to 240 doesn't force a sale. It hands us a deep in-the-money put we can roll down. That was my whole point about trimming collared shares: you don't pay twice for one floor.

On the roll strike, let the price action set it. Suppose ARM is holding inside 233 to 244, where several supports line up: the lower Bollinger band at 232.93, the 238 higher low, two ATRs down at 239.77, and a daily z-score near minus 2. Then roll toward 235. That banks the most cash and gives full participation from 240 up to the 300 cap, with the floor just under the cluster where buyers stepped in during September. If ARM is slicing through that zone on heavy volume, roll to 245 and bank less. That's where the conservative and I should meet.

Here's my one new point, and it comes straight from the rule you two just wrote. If size follows the floor, it follows it in both directions.

Suppose the live quote comes in cheap: a 270 put against the 300 call for about $4 net or less. The worst case is then about $9.30 a share, or 3.4 percent. Collaring all 60 percent we hold after today's market trim puts about 2 percent of a full allocation at risk. That's well under the 3.3 percent budget we've all agreed to.

Compare that with the base plan. There, the last ten points sit unhedged on limit orders, which is why we've attached three backstops. The CPI deadline can force a sale wherever the stock happens to be. None of the backstops helps if a verdict gaps the stock overnight, and a gap to 198 on that slice costs 2.8 percent of a full allocation on top of the collared half.

So at a cheap quote, collar all 60 and keep the 287 to 293 limit orders working. If they fill, sell those shares and unwind that slice's options. If they don't, nothing gets dumped at a deadline, because there's a floor under it. That lowers the tail, keeps more upside, and stays inside the plan's 40 to 60 percent range.

It also leaves room under the $8 cap. With $4 a share spent, the remaining budget would fund rolling roughly a quarter of the calls if a good verdict gaps ARM to 320. If the quote comes in mid-range or expensive, we go straight back to 50 or 40 percent collared with the backstops. Black-Scholes isn't a quote, so the live market decides, not either of us.

On the verdict, I'll take the neutral's definition. "Decided" means the jury's verdict on the royalty claims, not the end of post-trial motions, and the testing-tools trial alone doesn't count. But the requirement to hold 263 for a week belongs on the unhedged step from 25 to 35 percent, not on the call roll.

The roll is a debit capped inside the hedge budget, so its worst case is already defined. ARM moved 36.6 percent in four sessions in September. A roll that costs about $15 a share at 320 could cost far more a week later at 340, and the budget rule would then cover fewer calls. If ARM gaps and fades, we lose the debit we budgeted. That's the defined-cost bet the hedge budget is there to fund.

On the full-size trigger, I back the neutral's two consecutive daily closes, not a weekly close. A weekly rule can lag four sessions on a stock whose average daily range is 6.45 percent of price. The failures at 310.32 and 307.49 were lower highs in a fading market with no reported numbers behind them. This trigger only fires after the print, once we're already at 75 percent on reported results and a jury verdict. The yield rule then adjusts it: one close is enough if the 10-year is back under 5 percent, and we stop at 75 percent if it's above 5.31 after a hot CPI.

Conservative, on the rebound: your evidence that ARM's gaps fade is September. We don't know what drove September. The news search returned nothing for September 20 to 30. The only explanation in the data is a trader calling it the "9/16 FOMC rally." A rally on rate sentiment fading while the 10-year climbed 32 basis points tells us little about a gap on reported operating income or a royalty verdict.

Still, I'm not fighting the staged rebuild anymore. With these rules, both tails are bounded. The downside is about 2 to 3.3 percent of an allocation on the collared shares. The missed upside is a few points on a quarter of the position. That's the trade I wanted.

On earnings, the neutral's math settles the middle zone. Operating income of $130 to $163 million means opex growing 25 to 29 percent, the same path as Q1's 27.8 percent. So hold, and step to 75 percent only on a weekly close above 293 after the print, with a decided, non-adverse royalty verdict.

Your depreciation point is already in my base case. $134 million implies opex up $47 million from Q1. That's three to five times the $10 to $16 million of new depreciation from Q1's $197 million of capex. And yes, it would be a second straight year-over-year decline in operating income. That's exactly why the middle zone holds rather than adds.

On SoftBank, I'm with the neutral's three observable triggers for rolling the put at expiry: the verdict is still pending, ARM is below the 50-day, or the 10-year is above 5.31. Rolling every six weeks at anything like 1 to 3 percent comes to roughly 9 to 26 percent a year, a drag no upside case survives. SoftBank's stake is worth about $265 billion at today's price, and we don't know the loan size, so we can't measure where a margin call would hit. A risk you can't measure belongs in position size, and staged sizing is what we've built.

On macro, conservative, you're right that a 10-year 3 basis points off its peak isn't relief. That's why the yield rule is conditional. But the same macro report says equity options look cheap next to how fast rates are moving. That's the case for buying the put today, before CPI reprices it.

So here's where I land, in percent of your standard allocation. Sell to 60 percent at market now. Get a live quote today on a 265 to 270 put and a 300 call, expiring after the confirmed print. - If the quote is $4 or less at the 270 strike, collar all 60 and keep the 287 to 293 limits working on the last ten. - If it's within the $8 cap, collar 50. Sell the unhedged ten at CPI, on a close below 269, or if tomorrow's weekly close is below 264.79. - Above the cap, use the 255 to 258 put and collar about 40. - If neither prices, hold 25 percent unhedged.

Price stops govern the unhedged shares, and the put governs the core until expiry. Exit everything on a weekly close below 219 or a verdict that resets royalty terms.

Before the print, a close above 307.49 means stop trimming and roll the call, not buy shares. On a flush, roll the put down with price setting the strike, bank the cash, and skip the call spread. On a good jury verdict, roll calls that day as far as the budget allows, and lift unhedged exposure to 35 percent after a week above 263.

After the print, go to 75 percent at $163 million or more with that verdict. In the middle zone, go to 75 percent on a weekly close above 293. Below $130 million, exit the rest. Go to full size on two closes above 307.49, adjusted by the yield rule. Keep the proceeds in cash.

That's still a Sell. It just makes sure that when ARM gaps the right way, we already own it. Aggressive Analyst: I'm still on the Sell. Both of you checked the arithmetic, and it holds, so I'll concede it first. Then I want to point to three places where the plan still gives up upside by accident rather than by design. None of my fixes adds a share before the print or raises any cap.

What I'm conceding

The roll to 235 is dead. I reran it at the same rough 80 percent volatility. With ARM at 240 and about a month left, the 265 put is worth about $38 and a 235 put costs about $19. The roll banks $18 to $19 while giving up 30 points of floor. Measured from 275, the core's worst case goes from about 5.5 percent a share to nearly 10, which breaks the 3.3 percent budget we all signed. So I'll take the neutral's rule as written. In a flush before the events, hold the put. Roll only if the collar went on cheap, and only as far as the budget allows measured from entry. At 240, the collared core still moves like about a fifth of its share count. That isn't lost upside; it's the insurance doing its job.

The call-roll timing goes to the conservative. My claim that waiting would cost "far more a week later" works out to about $3 a share, from roughly $15 at 320 to about $18 at 340. Rolling on day one risks the whole $15 if the gap fades. So I'll roll only after a non-adverse royalty verdict and two closes above 300. Before that, I'll reserve enough for one post-event re-hedge, priced at post-event levels. That's the same evidence standard I signed for full size, so I can't reject it here.

I'm also dropping the cheap-quote collar on all 60. The neutral's unwind math gives an exit around 279 versus 275 today, about 0.15 percent of an allocation, and spreads on four option legs would eat most of it. Sizing to the floor sets a ceiling, not a target.

First gap: the last ten points

I'm with the neutral here. Work them on limit orders whatever the collar quote is, because the collar's price says nothing about how to sell unhedged shares. The conservative's own evidence supports this: he showed us this stock fills its gaps. Today it left one open at 286.73 to 290.50, and our limits at 287 to 293 sit right inside it. With daily moves around 5 percent, my rough math puts the chance of touching 287 within four sessions closer to two in three than a coin flip.

But there's a hole nobody has flagged. Those limits are resting sell orders, and a jury is out. Suppose the royalty verdict goes ARM's way and the stock gaps from 275 to 310 overnight. Every limit order fills at the open. We'd sell the only uncapped shares in the book at the exact moment the risk we've been hedging clears. Because we've agreed to add nothing before the print, we couldn't buy them back. Our rule says a close above 307.49 means stop trimming, but that rule never gets a chance, because the limits fire at the open, before any close.

The fix is simple. The moment a royalty verdict lands, cancel any unfilled limits. - If the verdict is non-adverse, the ten points stay. That's inside the 25 percent unhedged cap. They get an exit like every other tranche: two daily closes back below 293, which is the gap-fade signal the conservative worries about, plus the existing 269 and 264.79 backstops. - If the verdict is adverse, sell them at market immediately instead of waiting for a close.

That cuts both ways. It's also the cheapest way to own anything above 300 before the print. There's no roll cost and no draw on the hedge budget. That matters, because after the re-hedge reserve, the budget only covers rolling about a seventh to a quarter of the calls at $15 each.

Second gap: the strike on the expiry re-hedge

I back the neutral's version over the conservative's. Re-hedge the excess above 35 once, then either fold it into a rebuild or sell it at the second expiry. The conservative's alternative sells those 15 points on the day the event premium drains out, which is the cheapest moment to hedge them. At the neutral's $2 to $3 a share, re-hedging 15 points costs about 0.15 percent of a full allocation. The 35 percent cap holds either way. One route keeps the shares; the other sells them against an undated SoftBank risk that we've all agreed position size, not options, should carry.

The strike matters, though. If we re-hedge with a 300 call, it conflicts with our own full-size trigger of two closes above 307.49. If that trigger fires during the re-hedge month, the 15 points meant to join the rebuild are capped below the breakout. We'd either pay to buy back in-the-money calls, or "full size" would really mean 85 uncapped plus 15 capped.

The 300 strike was right before the print, when we had lower highs and the CFO's sales triggered at 300. After the print, two closes above 307.49 is our agreed sign that this selling has been absorbed. A re-hedge call below our own breakout trigger contradicts it. So strike it around 310. My rough Black-Scholes at post-event volatility puts that at about $3 a share more than a 300 call, or under 0.2 percent of a full allocation. Confirm it with a live quote.

Third gap: the margin test

The neutral is right to switch the rebuild test from dollars to margin after this print. The conservative's depreciation point means a fixed dollar figure gets easier to miss for reasons that say little about the business. But a flat 14 percent margin threshold would break on ARM's seasonality. Operating margin was: - 7.1 percent in the June quarter - 14.4 percent in September - 14.9 percent in December - 29.4 percent in March

A flat 14 percent gets passed automatically every March and is nearly unreachable every June.

So test it year over year, same quarter. The rebuild evidence is operating margin above the year-ago quarter. That's what "operating leverage has turned positive again" actually means. It absorbs the conservative's depreciation concern because the bar doesn't shift with seasonal mix, and it's reachable in any quarter. For this print it's identical to $163 million at 14.4 percent, so nothing changes now.

Where I side with the neutral on the rest

On the fallback put, no stops on the core. With a 255 to 258 put, a 263 stop sells collared shares 5 to 8 points above a floor we already cut size to 40 to pay for. That locks in the loss and gives up the rebound, which is paying twice for the same protection.

On tranche exits, match the exit to the entry. On a stock with a 6.45 percent daily range, a single close one ATR lower is noise. A whipsaw costs an ATR every time it happens.

On the verdict tiers, I accept them with one clarification. An award against ARM takes cash out; a $1 billion award is about a third of the $3.06 billion cash pile. A denied ARM claim takes nothing out of existing royalty income. For perspective, even $1 billion is about 0.3 percent of a $294 billion market cap. The dollar figure itself barely moves the equity. What moves it is pricing power over licensees, and that's the terms-reset tier. So a denied ARM claim should freeze rebuilds and call rolls, not trigger a full exit of a core that already has a floor under it.

On "good news is getting sold"

Conservative, today's 6.5 percent drop came on the OpenAI-driven chip selloff and the trial headlines, not on ARM-specific good news. The bullish articles were opinion pieces, not catalysts. When positioning sets prices in a crowded trade, a decisive legal resolution is exactly what snaps it. That's why I want the ten points still owned when the verdict lands, not sold into it by an order we placed days earlier. I still accept two closes as cheap confirmation for spending hedge budget.

Practical points

Confirm the earnings date before choosing the expiry. If the print lands in early November as estimated, the November 20 monthly covers the FOMC, the midterms and the print with about two weeks to spare. Don't use a weekly that dies before the print. Buy the collar today, before CPI reprices it. The proceeds sit in cash at roughly the Fed funds rate, so waiting for evidence earns close to 4 percent. And yes, check how much of the rest of your book moves with the 10-year, because this collar doesn't cover that.

The plan

Sell to 60 percent of your standard allocation now. Collar 50 with a 265 to 270 put and a 300 call through a post-print expiry, or about 40 on the fallback put. If neither prices under $8, hold 25 percent unhedged. Work the last ten in 287 to 293 with the CPI, 269 and weekly 264.79 backstops, and cancel those limits the moment a royalty verdict lands: keep the ten on a win, sell at market on a loss.

In a flush, hold the put. Roll calls only after a non-adverse verdict and two closes above 300. At expiry, re-hedge the excess above 35 once, with the call struck above 307.49.

Rebuild: - to 75 percent on $163 million or more with a clean verdict; - in the middle zone, to 75 percent on a post-print weekly close above 293; - to full size on two closes above 307.49, adjusted by the yield rule; - after this print, on year-over-year margin expansion.

It's still a Sell. The difference is that when ARM gaps the right way on the verdict, we still own something that isn't capped. Aggressive Analyst: I'm still on the Sell. This round I'll concede the two places where my arithmetic or my mechanics failed. Then I'll use the rules you've both written to close three holes that would quietly cost us upside.

The last ten points

The last ten go Friday, and the neutral's cancel-rule point is what settles it. Juries read verdicts during court hours, and those overlap the session. A good verdict at two in the afternoon takes ARM through 293 before anyone can cancel, so the limits fill. A bad one triggers my own market sale. Either way the ten get sold. They stay uncapped only if the jury reports after four o'clock. That depends on the court calendar, and I've spent this whole debate arguing against strategies that depend on luck.

The neutral's correction to the conservative cuts the same way. The tail on those ten was never decisive. The 25 percent cap we all signed carries a bigger one. What decides it is that a limit about 4 percent above and a stop about 2 percent below, on a stock with no reliable drift, exit near today's price on average. So sell them Friday, spread through the session.

I back the neutral's sequencing too. Get the quotes first, size the stock sale to whichever collar prices, and put the collar on as one package. I'd add one detail. Work the package once the opening spreads settle, not at the bell after a 1.9-times-volume down day, then sell the ten through the afternoon. And confirm the earnings date before picking November 20 over December.

Conservative, on your Thursday point: fine, call it trial news being priced. That argues for the exposure we're keeping. If part of the legal risk went into a 6.5 percent day, the collared half owns the rebound from 275 to 300. That's about 9 percent on half the position, with the put under whatever isn't priced yet. The verdict upside didn't leave with the ten. It sits in the core up to 300 and in the call roll above it.

The margin test

I was wrong on the margin test. Fourteen point four percent of about $1.385 billion is roughly $199 million. At $163 million the margin is 11.8 percent, down 2.6 points year over year. "Identical" was simply wrong.

The neutral's label is the honest one. At $163 million the year-over-year decline is narrowing, from Q1's 3.7 points to 2.6, not reversing. Reaching $199 million this quarter would need opex to fall from $1,162 million to about $1,144 million. Last year it rose about 4 percent over the same step.

Conservative, look at what your gate does once we accept that. You've shown this print can't show expansion. So your full-size step can't fire before the December-quarter report in early February. That's technically reachable, but in practice it parks the last quarter for three months. This stock rose 36.6 percent in four sessions in September and tripled in ten weeks this spring.

The neutral priced the asymmetry, and I checked it. Buying the breakout near 307.5 and exiting on two closes below 290 is about a 5.7 percent loss. On a quarter of the position, that's roughly 1.4 to 1.6 percent of a full allocation after slippage. Missing a 25 percent run on the same quarter costs about 6 percent. The breakout loss has a defined floor; the missed run doesn't.

So I back the neutral's placement. Margin evidence decides whether the last quarter rides through the next dated event, not whether we buy it. I proposed margin as the post-print test. He put it where it actually protects us.

First hole: full size from the middle zone

His wording leaves a gap I want closed. He writes the full-size step as coming "after a $163 million-plus print and a clean verdict." Read literally, a middle-zone print can reach 75 on a weekly close above 293 but can never reach full size, even if ARM then breaks the chain of lower highs with two closes above 307.49.

Neutral, your own numbers argue against that: - The whole gap between $130 and $163 million is under 3 percent of opex. - Both ends mean opex growing 25 to 29 percent, the same path as Q1's 27.8. - You called the triggers reference points, not precise.

So a $160 million print and a $165 million print are the same business within estimation error. Under your wording, one can reach full size and the other can't until the next print. Both paths already require a decided, non-adverse verdict. The only difference is which side of a line we all agree is approximate the print lands on.

If the middle zone earns 75 on price, let the same two closes above 307.49 earn full size, under the same yield rule. Then the same December-print rule decides whether that quarter gets collared or trimmed before the next report. The conservative's real worry is an unhedged quarter going into a print with margins still down, and that's covered either way. The extra condition only makes us sit out a confirmed breakout over a few million dollars.

Second hole: "whichever prices better"

"Collar the last 25 or trim back to 75, whichever prices better" needs a definition. Otherwise it defaults to the trim, because a trim always costs zero premium.

So spell it out. Before the December-quarter print, collar the last quarter if the package costs no more than about 3 percent of price net, the same ceiling as today's collar. The call should be struck at least one ATR above the breakout trigger, so 325 or higher at today's $17.8 ATR. Otherwise trim to 75.

The strike matters for the same reason it did on the 310 re-hedge you both accepted. A call at the breakout level caps the very shares we just bought for breaking out. If the market wants more than 3 percent for that insurance, the trim wins and nobody argues.

Third hole: the royalty test

On the verdict tiers, the neutral settled the dollar question. A one-time award comes off equity roughly dollar for dollar, so $1 billion is about 94 cents a share, a third of a percent. The conservative is right that the signal matters more than the cash. I accept that an adverse outcome of any kind keeps the unhedged cap at 25, and I accept the middle tier.

But the royalty test has a flaw. "The royalty line grows at least as fast as total revenue" fails for the wrong reason whenever licensing has a big quarter. Licensing is the lumpy line, which is why March quarters run so far above the others.

Suppose ARM signs a stack of licenses right after losing to Qualcomm. Total revenue jumps and royalties lag it on paper. The test would cut us to 25 on the best evidence we could get that other licensees still accept ARM's terms.

Test the royalty line against itself instead: year-over-year royalty growth no slower than what ARM reported for royalties in Q1. That strips out licensing lumpiness and uses a reported number. Our fundamentals tools don't split royalty from licensing, so whoever runs this should pull both quarters from ARM's press releases before the print, not after.

A gap that cuts my way

If neither put prices and we hold 25 unhedged, the 263 and 264.79 cuts do nothing, because they cut to 25 and we're already there. That's correct as written, and I don't want it "fixed" into a deeper cut. We sized the 25 for a gap to 198, about 7 percent of a full allocation, and a weekly close below 219 is the full-exit backstop. Selling below 25 on a 263 close would mean selling a position we already sized for the worst case.

The plan

Here's where I land, in percent of your standard allocation. On Friday, get the quotes first. - If a 265 to 270 put prices within the $8 cap against the 300 call, sell to 50 and collar all 50 as one package. - If only the 255 to 258 put works, sell to 40 and collar 40, with no stop on the core. - If neither prices, sell to 25 and hold it unhedged.

The last ten go Friday in every case, and nothing above 25 points sits unhedged over the weekend.

Through the events: - In a flush, hold the put. - Roll calls only after a non-adverse royalty verdict and two closes above 300, from what's left after the re-hedge reserve. - At expiry after a clean verdict, re-hedge the excess above 35 once, with a call near 310. - After an adverse but contained verdict, keep 50 only on a $163 million print, royalty growth no slower than Q1's, and a weekly close above 293. Otherwise cut to 25.

After the print: - Go to 75 on $163 million or more with a clean verdict, or on a middle-zone print with a weekly close above 293. - Go to full size on two closes above 307.49 from either path. One close is enough if the 10-year is back under 5 percent, and we stop at 75 if it's above 5.31 after a hot CPI. - Before the December-quarter print, collar that last quarter if it costs 3 percent or less with a call at least an ATR above 307.49. Otherwise trim to 75, unless margins have already turned.

Exit everything on a weekly close below 219, a terms reset, or an award above about $1 billion. The proceeds sit in cash earning close to 4 percent while we wait.

It's still a Sell. We give up the ten, we keep the floor, and when ARM proves itself we'll own the breakout instead of sitting it out.

Conservative Analyst¶

Conservative Analyst: I'm with the Sell, and I'm not arguing for a full exit. My problem with the aggressive case is that it agrees the risk is high and then keeps adding exposure back. Each of its refinements does this: the higher call strike, the split trim, cashing the put on a flush, rebuilding straight to 100%. Each one looks small, but together they turn a defensive plan into a bet. Let me take them one at a time.

Start with the split trim. Under that plan, half the excess stays on until price bounces 4 to 6.5 percent into 287–293. But the first weekly test at 264.79 is tomorrow, Friday. That level is only 3.8 percent below today's close, well inside one ATR of 17.8. The low ADX the aggressive analyst cites as a reason to fade the top of the range cuts both ways. A tight range with four catalysts ahead is a spring waiting to release, not a cushion. If the bounce doesn't come, you hold 75 percent of standard size into the weekly close, and the shares waiting on the limit order aren't covered by the collar. I'd do the whole trim now. At minimum, set a time stop: anything not filled in 287–293 by Friday's close gets sold at market.

On the call strike, moving the short call from 300 to 305–307 collects less premium. That raises the net cost of the collar, which raises the worst-case loss on the hedged half. The 3 to 6.5 percent worst case was quoted on the cheaper structure, so the aggressive analyst is quietly widening his own loss figure. And 300 is where the supply sits. The CFO's apparently price-triggered selling plan sold at exactly 300 on September 21, and closing highs have now fallen three times in a row. The trade should be to sell the upside you're least likely to keep and use it to pay for the floor you most need. I'd keep the plan's 300 strike.

The collar cost itself is my bigger worry. The $3 to $8 figure comes from Black-Scholes, not a quote. A stock with a live royalty trial and an earnings report inside the hedge window usually prices extra event risk into its own options. VIX at 15 tells you about the index, not about ARM. So set a ceiling now. If the net cost comes back above roughly $8, or about 3 percent of price, don't pay up, and don't fall back to 35 percent unhedged either. Go to 25 percent.

Timing matters too. The early-November earnings date is an estimate, not confirmed, and nobody has given us a verdict date. If the collar expires before either event, the floor disappears exactly when you need it. Pick an expiry after the confirmed earnings date with some buffer, and plan to roll the put if the verdict hasn't come in.

Here's why I want 25 rather than 35 percent unhedged. The plan sizes for a gap to the monthly SuperTrend stop at 198, which is 28 percent below today. At 35 percent of standard, that gap costs almost 10 percent of a full allocation. At 25 percent it costs 7. At 40 percent collared, the worst case is about 2.6 percent. A 28 percent loss needs a 39 percent gain just to get back to even. The daily and weekly closing triggers don't protect against a gap either. A verdict can land overnight, and a "close below 263" could actually print at 250.

The aggressive analyst warns that you don't want to buy back from 330. Missing that rebound is an opportunity cost, and it's the cheap risk to take. If ARM gets back to 330, it will be because the verdict went its way and the quarter showed profits growing faster than revenue again. Paying up for that evidence is fine. The expensive risk is the other branch. This stock fell from a 439.46 close on June 18 to 224.89 on July 29, about 49 percent in six weeks, with the same $3 billion of cash and the same 97 percent gross margin. The balance sheet protects against insolvency. It doesn't protect against the valuation multiple shrinking, and that is the risk we face.

On insiders, he says the CEO hasn't sold since April. Not selling isn't buying. Seven insiders sold $72 million, and nobody bought a single share in the late-August dip at 242 to 255.

There's also a risk nobody has raised yet. The news report notes, as background, that SoftBank owns about 90 percent of ARM, is one of OpenAI's largest backers, and has borrowed against its ARM shares. This week's selloff started with worries about OpenAI's revenue. If that pressure reaches SoftBank's balance sheet, ARM's own fundamentals won't matter. With a small public float, the move could be violent, and no stop can manage that.

On the 6 percent recession odds, I agree this is a valuation squeeze, not a crisis. But that is exactly the risk for a stock at 300 times earnings. The 10-year yield is 5.28 percent, up 32 basis points since the gap day while the 2-year stayed flat. The Fed is hiking, with 78 percent odds of another hike by December. VIX at 15 looks calm next to how fast yields are moving, and the macro report notes that gaps like this usually close through stocks repricing. A valuation squeeze on a 3.79-beta stock at 57 times sales is enough to take it to 233 or 198 without any recession.

On the earnings bar, the aggressive analyst's own math puts the base case at about $134 million of operating income. That sits between the $130 million exit trigger and the $163 million rebuild trigger, and the plan says nothing about what to do there. Two things make the bar harder than his math shows. Last year's Q2 grew 34.5 percent, the strongest quarter in the table, so 22 percent growth this time is against a tough comparison. And there are costs the plan doesn't account for:

Supply execution questions, likely tied to ARM selling its own chips. Capital spending at 11 to 15 percent of revenue, against 3 percent two years ago. Stock compensation costing over $300 million a quarter in cash.

So the plan needs a rule for that middle zone. If operating income lands between 130 and 163, don't rebuild. When the collar expires, either re-hedge or step down to the 25 percent unhedged cap.

Even on a clean beat, I wouldn't go straight back to 100 percent on the first pullback. Q1 net income was three times operating income, so first confirm the beat came from operations and not from items below the operating line. Then confirm the Qualcomm outcome isn't adverse. Then rebuild in steps: first to 75 percent, and to full size only once the 50-day holds and the weekly trend turns up. Even after a good quarter, the stock will still trade at roughly 90 times forward earnings.

Two more refinements I'd push back on. First, cashing in the put on a flush to 233–244 removes the floor right before the two binary events. If you want to bank that gain, roll the put down to a lower strike rather than closing it. Second, the plan says a close above 307.49 means reassessing a move back toward Hold sizing. I'd add nothing before the print, whatever happens. If you're short a 300 call and price closes above 307, buying more stock on top of a capped position adds risk you can't hedge cleanly. It also means chasing the exact level where the CFO's plan sells.

The neutral analyst hasn't spoken yet, but a hold case will likely lean on the rising 50-day, the range-bound ADX and the strong balance sheet. Today's low held the 50-day by 89 cents, about a twentieth of an ATR. Support that close doesn't protect you, because one ordinary down day takes it out. The 50-day also only keeps rising for three more sessions, because closes near 240 are rolling out of the average. After that it flattens. A low ADX ahead of a verdict, CPI, the FOMC and earnings means the move hasn't started yet, not that it won't come. Nor does the sentiment data show a washout. The 57 percent bullish label on StockTwits is inflated by one user venting, dip-buyers are still adding, and RSI is 46.7. Bottoms usually come after capitulation, and we haven't seen it.

So keep the Sell, but make it tighter:

Do the full trim now.
Take the low end of the range, 40 percent of standard, collared with the call at 300.
Cap what you'll pay for the collar.
Cover the confirmed earnings date, and roll the put if the verdict hasn't landed.
Cap unhedged exposure at 25 percent.
Keep the protection on through the print and add nothing before it.
Have a rule for the 130 to 163 zone.
Rebuild in stages, only on evidence from both the earnings and the court.

Missing the first 20 percent of a rebound is a cost the firm can afford. Riding a 3.79-beta stock at 300 times earnings through a gap to 198 is not. Conservative Analyst: Conservative Analyst: I'm still on the Sell. I'll start by giving ground where it's been earned, because three of my rules didn't hold up.

First, the neutral is right that my full-size rebuild condition, a weekly SuperTrend flip at 383.15, was really a rule never to rebuild. I withdraw it. Second, the aggressive is right that capex and the tax withheld on vesting don't run through operating income, so neither moves the $130 million or $163 million triggers. Third, you're both right that cutting to 25 percent on a middle-zone print was too harsh, since the whole gap between the triggers is under 3 percent of opex.

I'll also drop the Friday time stop. Forcing the last ten points out if a one-day bounce doesn't come would mean selling at the bottom of the range. So I'll take the neutral's execution: - Sell down to 60 percent at market now. - Work the last ten points with limit orders in 287 to 293. - Sell them at market if they haven't filled by the CPI release, or if ARM closes below the 50-day near 269.

I'd add one backstop: a weekly close tomorrow below 264.79. That's already a trigger in the plan, and it arrives before CPI.

With those concessions, what's left is whether the aggressive's additions turn a hedged half into a leveraged bet on the very events we're hedging. I think they do, in four places.

Start with the rebound argument. The aggressive says ARM doesn't drift toward evidence, it gaps on it, so waiting means paying the whole gap. Look at his own example. The stock went from 243.98 to 333.20 in four sessions in September. Today it closed at 275.29, below where that gap started. The 09-21 gap is fully filled, and OBV has given back every share of buying from that rally. Anyone who paid the whole gap at the 09-22 close is down 17 percent in under three weeks. The spring tripling ended in a 49 percent fall.

ARM gaps on evidence and then usually gives a good part of it back. That's exactly why rebuilding in stages works on this stock: you rarely get only one chance to buy it.

His estimate that my rule gives away 6 to 10 percent of a full allocation was built on the 383 trigger I've now dropped. With a reachable trigger, the cost of waiting is a few points on a quarter of the position. Even at his number, the two sides aren't equal. A missed gain leaves the capital intact and ready to redeploy. A 28 percent realized loss needs a 39 percent gain just to get back to even.

The neutral's full-size trigger, "a daily close above 307.49 that holds," needs a definition. I'd make it a weekly close above 307.49, after the print. Closes around 307 to 310 have already failed twice in two weeks, at 310.32 and 307.49. And the CFO's price-triggered selling plan sold at 300. A single daily poke into that supply isn't a breakout.

Second, the 40 versus 50 percent collared question. The aggressive says trimming collared shares doesn't shrink the tail, because the put already did that, and only reduces how much of the rebuild you already own. Both halves of that depend on things we haven't seen.

The put limits the loss to the strike plus whatever we paid, and we don't have a quote yet. He concedes the structure is net long volatility, because the put sits much closer to the money than the call. So if ARM's own options are pricing in the trial and the print, our net cost goes up, and the short call only recovers part of it.

The collared shares also aren't a rebuild position. They're capped at 300, about 9 percent above here. The shares he says we need for the good gap stop participating at the call strike unless we pay to roll.

So I'd stop arguing 40 versus 50 and tie the size to the floor we actually get: - If the put lands at 265 to 270 within the $8 cap, the worst case is roughly 3 to 6.6 percent a share. At 50 percent collared, that's about 3.3 percent of a full allocation at risk. Collar 50. - If we're pushed to the neutral's fallback put at 255 to 258, the worst case moves toward 8 or 9 percent a share. Holding the same risk budget means roughly 40 percent collared, not 50.

Size should follow the floor, not the other way around.

Third, the earnings middle zone. You both now describe $134 million as margin expansion: up 47 percent from Q1, with margin rising from 7.1 to 9.7 percent. That comparison starts from the weakest quarter in the table.

Last year the same seasonal step took margin from 10.8 to 14.4 percent, a 360 basis point lift. A 260-point step this year is below the normal seasonal improvement. Year over year, $134 million is 18 percent below last Q2's $163 million. That would be a second straight quarter of operating income falling while revenue grows 22 percent. It confirms negative operating leverage rather than reversing it.

I've conceded that capex isn't opex today, but it becomes opex over time. Capex went from $92 million in FY24 to $545 million in FY26. If most of that is compute hardware on a three-to-five-year life, FY26's spend alone works out to roughly $27 to $45 million a quarter of depreciation flowing into operating costs. That's about the size of the whole gap between our two triggers. It's one reason I wouldn't assume Q1's 13.9 percent opex jump was a one-off.

So I'll take the neutral's middle-zone rule. Hold the half, re-hedge if the verdict is still out, and cut to 25 percent only through the existing 263 trigger. I reject the aggressive's tiebreaker that steps up to 75 percent on opex guidance. Guidance is management's forecast, not a reported number. If it's given on an adjusted basis that excludes stock compensation, it can look fine while GAAP opex keeps running hot, and GAAP opex is what our triggers measure. Rebuild on the reported quarter, not on the promise of the next one.

Fourth, the call spread on a flush. This is the idea I'd stop outright.

By the time ARM reaches 233 to 244, it has broken the 50-day, 263, and almost certainly the weekly 264.79. Our own rules will already have cut the position to 25 percent. Buying a call spread there puts long exposure back on right after the stop told us to take it off. And because it expires after the print, it's a directional bet on the two binary events this whole plan exists to hedge.

The put gain also isn't money we "wouldn't otherwise have had." At 240, the hedged stock is down about $35 a share, and the put gain is the insurance payout for that damage. It's the firm's capital either way. Spend it on calls and the hedge we paid for nets to a loss.

The technical report calls 233 to 244 the zone where an oversold setup would form, not one where it has formed. The earliest a daily TD buy could complete is around October 20, and only if every close cooperates. So roll the put down and bank the gain as cash. If a real buy signal appears after the binaries clear, it will still be there.

On the yield shortcut, the aggressive wants to skip the 75 percent step if the 10-year closes below 5 percent alongside a beat and a clean verdict. That's the moment I most want the waypoint. All the good news lands at once, and the stock has already gapped.

The macro data also doesn't show the relief he's reading into it: - The 10-year is 3 basis points off its peak. That's not a reversal. - October hike odds fell, but the odds of two hikes this year rose 10.5 points to 70 percent, and a December hike sits at 78 percent. The hike moved later; it didn't go away. - The 10-year/2-year spread has widened from 0.20 to 0.47 since the gap day, with long yields leading. - Chip stocks selling off on Samsung's record guidance is what the macro report calls a crowded, tired trade.

Crowded trades do snap back eventually, but usually after the unwind. OBV and the heavier volume on down days say the unwind is still going.

So use the neutral's yield rule, but give it a defined effect: - If the 10-year is below 5 percent, the second rebuild step can trigger on a daily close above 307.49 instead of waiting for the weekly close. - If it's above 5.31 after a hot CPI, the rebuild stops at 75 percent.

Neither case skips the waypoint.

Neutral, your framework is closest to mine, but two of your rules depend on a word nobody has defined: verdict. The headlines describe one trial over billions in royalty payments and another over chip testing tools, and the sentiment report couldn't tell whether that's one proceeding or two. A win on testing tools while the royalty claims are still open doesn't mean a binary event has passed. The last time these two companies went to a jury, the fight didn't end at the verdict, and post-trial motions dragged on.

So for both the step-up to 35 percent unhedged and the call roll, "non-adverse verdict" should mean three things: - The royalty claims are decided. - Royalty terms aren't reset. - ARM holds 263 through the following week.

Rolling the call up on a good verdict is the right tool, but it has to be priced honestly. If a verdict gaps ARM to 310 or 320, our 300 call is in the money and expensive to buy back. That roll could easily cost more than the whole collar did. Count roll costs against the same hedge budget. If rolling would push total spending past the cap, leave the call where it is. We've already captured the move to 300 on the collared half, and that's a good outcome, not a failure.

On SoftBank, you both say that's what the put is for. The put covers price until expiry, and expiry is set by the earnings date. SoftBank's borrowing against its ARM stake has no expiry. A thin float amplifies moves both ways, but a margin call only ever sells. If OpenAI revenue worries are still moving the sector when the collar expires, roll the put on the core rather than letting the floor lapse.

On insiders, I'll take the neutral's view that they don't change sizing. The one fact that matters is mechanical: there's a price-triggered seller at 300, which is why our call strike sits there. I fully agree with keeping the proceeds in cash at near the Fed funds rate rather than moving them into other AI names.

So here's where I land. Sell to 60 percent now, with the last ten points on limits in 287 to 293 and backstops at CPI, a close below 269, or tomorrow's weekly close below 264.79. Collar the core today with the call at 300 and an expiry that covers the confirmed print, and roll the put if the verdict is still pending.

Size the collar to the floor we actually get. That's 50 percent with a 265 to 270 put inside the $8 cap, about 40 percent if we have to use the 255 to 258 put, and 25 percent unhedged if neither prices.

Keep unhedged exposure at 25 percent until a real royalty verdict or the print has cleared, then 35 percent. Count call rolls against the hedge budget. On a flush, roll the put down and keep the gain as cash, with no call spread.

On earnings, hold the half in the middle zone with no step-up on guidance. Rebuild to 75 percent on reported operating income of $163 million or more with a non-adverse royalty verdict. Go to full size on a weekly close above 307.49 after the print, loosened to a daily close only if the 10-year is back under 5 percent.

That keeps a real path back to full size for the aggressive. It just makes ARM prove itself first, because this stock has already shown us twice this year how quickly it can give a gap back. Conservative Analyst: I'm still on the Sell. A lot of this has been settled fairly, so I'll start with what I accept.

The neutral is right that a collar already works like a call spread, which ends that argument. I'll take two consecutive daily closes above 307.49 for the full-size step, because that step only fires after we're already at 75 percent on reported numbers. I'll also take the neutral's depreciation correction. Q2's new depreciation comes mostly from Q1's $197 million of capex, so it's roughly $10 to $16 million, not another step the size of the trigger gap. My only addition is that capex running near $200 million a quarter makes depreciation climb every quarter. A year out, that could mean $40 to $60 million a quarter of extra cost against a 90x forward multiple. That's a question for future prints, not this one.

I accept the jury verdict as "decided." I accept that rolling puts forever against an undated SoftBank risk costs more than it saves, and that position size is the right tool for that risk. I also accept the neutral's middle-zone upward path: a post-print weekly close above 293 plus a non-adverse royalty verdict. That's a price, not a promise.

Here's where I think the plan still takes on more risk than we agreed to.

First, the roll-down after a flush.

You're both treating the banked gain as if it pays for the new floor. It doesn't. Take the neutral's example: ARM at 240, rolling the 265 put down to 235. I'll use ARM's own ATR, which implies about 80 percent annualized volatility before any event premium, on rough Black-Scholes math:

The 265 put at 240 is worth around $38.
A 235 put, with the verdict and the print still ahead, costs about $19.
So the roll banks roughly $19, not the $30-plus people picture.
The effective floor is 235 plus $19, about 254, down from 265.

Measured from today's 275 and including a $5 collar, the worst case on the core goes from about 5.6 percent a share to about 10. At 50 percent collared, that's 2.8 percent of a full allocation becoming nearly 5. All three of us signed a 3.3 percent budget.

The reason is simple. You'd be selling a put that's mostly intrinsic value and buying one that's almost all time value, at peak implied volatility, with two binary events ahead. That's the most expensive insurance on the board, and any event premium in ARM's options makes it worse.

So the roll strike should come from the budget, measured from entry and counting every premium paid and banked. It shouldn't come from reading the chart mid-flush. On the same rough math:

At a $4 collar with a 270 put, the budget lets you roll to the mid-240s.
At $5 with a 265 put, it's about 255.
At the full $8, there's no room at all, and the put stays where it is.

235 never fits. The aggressive's rule, 235 if it's holding and 245 if it's slicing through, is a judgment made during the worst session of the quarter. The budget rule is arithmetic you can do before the open.

Second, what happens when the collar expires.

Nobody has addressed this. Put three agreed rules together:

The put governs the core until expiry.
The put lapses unless the verdict is pending, ARM is below the 50-day, or the 10-year is above 5.31.
In the middle zone, we hold the half.

Now picture a middle-zone print, a decided verdict, ARM at 280 and the 10-year at 5.2. The put lapses, and we're holding 50 percent unhedged, or 60 in the aggressive's cheap-quote version. The plan's own ceiling for unhedged exposure is 35. Nobody has said why that ceiling stops applying the day the put expires. The neutral's argument that position size carries the SoftBank risk only works if size is actually capped at that moment.

My fix: at expiry, any part of the core that isn't re-hedged must fit the 35 percent cap unless a rebuild trigger has fired. Re-hedging right after the events is the cheapest moment to do it, because the event premium drains out of the options. One post-event roll isn't the endless rolling the neutral objected to. It's a bridge to either a rebuild or a cut.

The bucket split also needs one condition. It's clean only when the put strike sits at or above the stops. With the 255 to 258 fallback put, there are 5 to 8 points of unprotected downside below 263, so in that version the stops should still govern the core.

Third, the aggressive's cheap-quote collar on all 60.

His tail math is right: a 270 put at $4 gives a worst case of about $9.30 a share, or 2 percent of an allocation. Hedging more shares is a conservative instinct, and I won't fight it.

But collaring that slice while leaving limit orders on it gives up most of the bounce. Say the limit fills at 290:

You sell the stock and have to buy back a 300 call that's now nearly at the money.
The 270 put has lost much of its value by then.
On rough math, unwinding costs about $6, plus the $4 paid going in.
Your effective exit is around 280, versus 275 today, before bid-ask spreads on four option legs.

That's a few dollars on a tenth of the position. It also leaves the core at 60 at expiry, which makes the expiry problem worse.

Cleaner: if the quote is that cheap, collar 50 and sell the last 10 at market today. The worst case is 1.7 percent, lower than his 2.0, and nothing is left waiting for a deadline. Before trusting any $4 collar on a stock with two binary events ahead, check that the expiry actually lands after the confirmed print.

Fourth, rolling the call on verdict day.

The aggressive says waiting could cost more if the stock is at 340. Under the budget rule, waiting just means rolling fewer calls, so that cost is bounded. Rolling into a gap that fades costs the whole debit.

The hedge budget is also one pot. If the verdict lands before the print, that same pot may need to re-hedge the core at expiry. So reserve enough for one put re-hedge first, and roll calls only from what's left. And wait for two closes above 300 after the verdict, the same standard he just endorsed for full size. If two closes is enough evidence to buy the last quarter of the position, it's enough evidence to spend hedge budget.

On September, the aggressive says we don't know what drove the gap. That cuts both ways: we don't know a verdict gap will hold either. What we do know is how this stock has traded:

The June peak came on the biggest volume of the year, followed by a 49 percent fall.
The September gap filled within three weeks.
Chip stocks sold off on Samsung's record guidance this week.
ARM fell 6.5 percent today on 1.9 times normal volume, in a week when bullish articles were running.

Right now good news is getting sold. Two closes is cheap protection against that.

Fifth, the rebuild needs its own exits.

Once the collar expires, every rebuild step adds unhedged shares of a 3.79-beta stock. The trader's own rule says stops at least one ATR away, so give each tranche an exit about one ATR below what triggered it:

The middle-zone tranche from the 293 trigger exits on a close below about 275.
The full-size tranche exits on a close below about 290.
The earnings tranche uses the existing 263.

If a gap fades the way September did, we give back roughly one ATR on that tranche, not the whole move.

Two smaller points.

"A verdict that resets royalty terms" is too narrow as the full-exit trigger. If ARM loses a claim it brought or is hit with damages, that's adverse even if the terms don't change. Adverse should mean any outcome that cuts expected royalty income.

I agree with the neutral on the wider book: keep the proceeds in cash, and check how much of the firm moves with long yields. This collar does nothing for that.

Where I land:

Trim: Sell to 60 now and get a live quote today, before CPI reprices it.
Cheap collar: If it's cheap, collar 50 and sell the last 10 at market.
Mid-range collar: If it's mid-range, collar 50 and work the last 10 with the neutral's backstops.
Expensive collar: If it's expensive, collar about 40 on the fallback put.
Flush: Roll the put down only as far as the 3.3 percent budget allows.
Budget order: Fund one put re-hedge before any call roll, and roll calls only after two closes above 300.
Expiry: Re-hedge the core, or bring it down to the 35 percent unhedged cap, unless a rebuild trigger has fired.
Rebuild: Step up in the stages we've agreed on, each tranche with its own one-ATR exit.

That keeps the floor we paid for in place through the events, and keeps a real path back to full size without giving up the risk limits we've already agreed on. Conservative Analyst: I'm still on the Sell. We've narrowed this to a handful of points, so I'll concede what's been earned and then spend my time on the three places where the plan still carries risk nobody has priced.

First, the concessions. The neutral is right about the fallback put. If we use the 255 to 258 strike, we already cut collared size from 50 to about 40 to pay for the deeper floor. Putting a 263 stop on top would sell floored shares a few points above the put and pay twice for the same eight points. I withdraw that condition.

The neutral is also right that my list contradicted itself. The collar quote says nothing about how to sell the unhedged ten. I'll resolve that below, though not the way either of you expects.

I accept the one-time re-hedge of the excess above 35, with the reserve sized at post-event prices for those 15 points. The aggressive is right that a 300 call on that re-hedge conflicts with our own full-size trigger at 307.49. So strike it around 310, provided the live quote keeps total hedge spending inside the cap. I accept tranche exits that mirror their entries, with the daily 263 cut still live underneath every unhedged share as the backstop for the lag a weekly exit can carry. And the aggressive's year-over-year margin test is the right shape, because a flat 14 percent bar breaks on ARM's seasonality.

Now the first disagreement: the last ten points. You both want them on limit orders in 287 to 293 whatever the quote. The aggressive puts the odds of a fill within four sessions at about two in three, and the neutral says better than even. Those odds ignore our own backstops. The 50-day is near 269 and rising about 70 cents a session as the 240 closes roll off, so the close-based stop sits roughly 2 to 3 percent below today's 275.29. The limit sits about 4 percent above. Once both live in the same four-session window, my rough math puts the fill odds closer to a coin flip than two in three. On top of that, Friday's weekly close below 264.79 can end it sooner.

The bigger point is this. On a stock with no reliable drift, a limit above and a stop below don't raise the expected exit price. They only change which way the variance falls. And nothing in our data gives a reliable drift. The low ADX favors fading the top of the range. But the weekly and daily SuperTrend are down, MACD crossed bearish, OBV has given back the whole gap rally, down days carry the heavier volume, and the 10-year is at 5.28. If anything, those lean down.

So working the ten buys us roughly zero expected gain. In exchange, we carry those shares unhedged through four sessions with a jury out and CPI ahead. A gap to 198 on them costs 2.8 percent of a full allocation, which is nearly the entire 3.3 percent budget we set for the whole collared half. That's a bad trade for a desk whose job is protecting capital.

Selling the ten at market now also removes the hole the aggressive just found, and that hole is real. His fix, though, is to cancel the limits the moment a verdict lands. That only works if the verdict comes after the close. A jury reading its decision during market hours moves ARM through 287 to 293 in seconds, and resting orders fill before anyone can cancel. A rule that only works when the news arrives at a convenient time isn't a rule.

And look at what he's protecting. If a verdict gaps ARM to 310 and our limits fill at the open, we've completed the trim 12 percent above today's price. That's the Sell executing better than planned, not an accident. He wants to keep those ten unhedged instead, into an earnings print where his own base case is around $134 million of operating income, a second straight year-over-year decline.

The legal backdrop doesn't support betting on the verdict either. The last jury in this dispute, in Delaware in December 2024, went largely Qualcomm's way, and the sentiment data attributes part of Thursday's drop to this trial's headlines. He says Thursday's selling wasn't good news being sold. Fair. But that makes it bad trial news being priced, which is worse for his case. Sell the ten at market now, whatever the quote. That resolves the neutral's contradiction, removes the verdict-day problem, and costs nothing in expected value.

Second, the margin test, where there's an arithmetic error that matters. The aggressive says that for this print, year-over-year margin expansion is "identical to $163 million at 14.4 percent." It isn't. Last year's Q2 margin was 14.4 percent on $1,135 million of revenue. On this year's expected revenue of about $1.385 billion, 14.4 percent is roughly $199 million of operating income. $163 million on that revenue is an 11.8 percent margin. That's flat operating income on 22 percent more revenue, with margin down about 2.6 points year over year.

By the aggressive's own definition, operating leverage has not turned positive at $163 million. It has just stopped getting worse. The fundamentals report's own sign of strength was margin back above 14 percent, and $163 million misses it.

Reaching $199 million this quarter would mean opex falling sequentially from Q1's $1,162 million to about $1,144 million. Last year it rose about 4 percent over the same step. Realistically, this print cannot show positive operating leverage.

So here's my amendment, and it's built entirely on the aggressive's own framework. Keep the step to 75 percent at $163 million with a non-adverse royalty verdict, as agreed. But the last quarter of the position, the full-size step, should require reported year-over-year margin expansion in addition to the two closes above 307.49. That means either this print clearing about $199 million, or the December-quarter print clearing last year's 14.9 percent.

That bar is reachable. At 22 percent revenue growth, it needs opex growth of about 21 percent, against Q1's 27.8. That's not a 383-style rule that never fires. It's one more print of evidence for the final 25 points of a 3.79-beta stock at 90 times forward earnings.

I accepted the two-close trigger last round because I thought the reported numbers behind the 75 percent step showed the business turning. His own test shows they don't. If ARM runs on a clean verdict and a $163 million print, we're at 75 percent with three-quarters of the upside, and the rest waits in cash at near the Fed funds rate.

Third, the verdict tiers. The aggressive measures a $1 billion award against a $294 billion market cap and calls it 0.3 percent. But that market cap is 300 times earnings, which makes the comparison circular. A $1 billion award is roughly a full year of ARM's GAAP net income of $1,044 million, about two-thirds of its free cash flow, and a third of its cash.

He also says a denied ARM claim "takes nothing out of existing royalty income." That's true of income already booked. It isn't true of the expected royalties the valuation capitalizes. This trial is reportedly over billions in royalty payments. Losing it tells the market ARM can't enforce terms on its largest licensees, and enforcing terms is the whole higher-royalty-per-chip thesis.

I'll accept the neutral's narrow full-exit tier: a terms reset or an award above about $1 billion. A headline shouldn't dump a core that has a floor under it. But we already agreed the unhedged cap rises to 35 only when an event passes without damage. An adverse royalty outcome of any kind, including a denied ARM claim, is damage. So the existing rule already settles it. The step-up never fires, the core comes down to the 25 percent cap at expiry instead of carrying a re-hedge, and rebuilding waits for a print with year-over-year margin expansion. That isn't a new trigger, just our agreed rule applied as written.

Two practical points. Put the collar on as a single package order, not one leg at a time. With a $17.8 ATR, legging into it can cost more than the gap between our cheap and mid-range quotes. And confirm the earnings date before choosing the November 20 expiry. If the print lands after mid-November, use December.

So here's where I land. Sell to 50 now, with the last ten sold at market rather than on limits. Collar the core today as one order, with the 300 call and a 265 to 270 put inside the $8 cap, or about 40 on the fallback put without a core stop. If neither prices, hold 25 unhedged.

In a flush, hold the put. Roll calls only after a non-adverse royalty verdict and two closes above 300. At expiry, re-hedge the excess above 35 once with a call near 310, unless any adverse royalty outcome has landed, in which case cut to the 25 cap.

Rebuild to 75 on $163 million or more with a clean verdict, or in the middle zone on a weekly close above 293. Go to full only on two closes above 307.49 plus reported year-over-year margin expansion. Exit fully on a weekly close below 219, a terms reset, or an award above $1 billion. Keep the proceeds in cash, and check how much of the rest of your book moves with the 10-year.

That costs the aggressive almost nothing in expected value, keeps every floor we paid for, and makes ARM prove operating leverage before we own all of it again. Conservative Analyst: I'm still on the Sell, and we now agree on most of it. The last ten points go today. Quotes come first, the stock sale gets sized to whichever collar actually prices, and nobody goes into the weekend with more than 25 points unhedged.

I'll concede three things: - Neutral, you put the margin gate in the right place. It should decide whether the last quarter rides through the next print, not whether we buy it. That holds only if the downside on that tranche really is bounded, which I'll come back to. - A one-time award does come off equity roughly dollar for dollar. The dollar threshold is a proxy for the legal signal, not the damage itself. - Aggressive, you're right that if neither put prices, the 263 and 264.79 cuts shouldn't push us below 25. We sized the 25 for the gap.

That still leaves six places where the plan either relies on a number that can't tell us what we need, or quietly adds back risk we just decided to cut.

First, today's execution, because it's the only part that's live right now. A quote isn't a fill. On a stock that just fell 6.5 percent on 1.9 times normal volume, with a trial running, the price you're shown at ten in the morning may not be there at two. So work the collar first, as one package with a limit at the $8 cap. The stock is the easy part to sell; the options package is the uncertain part. Then sell stock down to whichever level actually filled. Set deadlines: - If the 265 to 270 package hasn't filled by early afternoon, move to the fallback put. - If that hasn't filled by mid-afternoon, sell to 25. - Be done before the closing auction rather than trading into the weekly close.

On expiry, if ARM hasn't confirmed its earnings date when you trade, buy December, not November 20. If December won't fit under the cap, treat that as the expensive tier, not as a reason to buy a November floor that might expire days before the print. A collar that expires before the event is just a cost.

Second, full size from the middle zone. Aggressive, you say a $160 million and a $165 million print are the same business within estimation error. That's true of our forecast. It isn't true of the reported number. Once ARM reports, the operating margin is a fact.

The middle zone also isn't one thing. Q1's margin was down 3.7 points year over year. On about $1.385 billion of revenue, the same 3.7-point decline works out to roughly $148 million: - Above about $148 million, the decline is narrowing. That's the neutral's "slowing, not reversing." - Below it, the decline is widening. - Your own base case of $134 million is a 9.7 percent margin, down 4.7 points, which is worse than Q1. - At $130 million, margin is down five points.

Calling those a slowing decline contradicts the measure we all just agreed on. So the middle zone can reach full size on two closes above 307.49, as you want, but only if the reported margin decline is narrower than Q1's, roughly $148 million or better. Your $160 and $165 examples both pass. Below about $148 million, the middle zone stops at 75 until the December-quarter print. That's one reported number, measured the same way as everything else. It stops us buying the last quarter of a 3.79-beta stock at 90 times forward earnings in a quarter where margins got worse.

Third, the breakout loss is only bounded once. The entry is two closes above 307.49 and the exit is two closes below 290. That's 17.5 points apart, about one ATR, on a stock that moves 6.45 percent a day and has closed anywhere from 275 to 333 in the last three weeks. Each round trip costs about 5.7 percent on 25 points, roughly 1.4 percent of a full allocation: - Two round trips cost about 2.8 percent. - Three cost over 4 percent, more than the 3.3 percent budget we set for the entire collared half.

The neutral's math compares one bounded loss against one 25 percent run, but in a range you don't get just one loss. So add a one-shot rule: if the full-size tranche is stopped out, it doesn't come back until the next reported quarter. Also remember how this stock's recent peaks ended. The June high at 439 was followed by a 49 percent fall, and the September gap to 333 filled completely. A SoftBank or OpenAI headline won't wait for two closes.

Fourth, the definition of "whichever prices better." I'm glad it's defined now, and a call at 325 or higher is right for the reason the aggressive gave. But he set the call strike and the cost cap and left out the put. Without a put strike, you can always get under 3 percent by pushing the put further down, and then the floor exists in name only.

The put should sit no lower than about one ATR below the trigger, around 290, the same level as the tranche's exit. The reason to collar through a print is that a closing-price stop at 290 can't protect against an earnings gap, so the put has to sit where the stop sits. On rough Black-Scholes, a 290 put against a 325 call with the stock near 310 costs very little. This shouldn't cost the aggressive anything except the loophole, but confirm it with a live quote.

Fifth, the royalty test after an adverse verdict. It breaks in both versions. The neutral wants royalties growing at least as fast as total revenue, and the aggressive wants royalty growth no slower than Q1's. But the quarter ARM reports in early November covers July through September and closed on September 30. The trial headlines are from this month, so whatever the jury decides lands after that quarter closed. The royalty line in that print reflects chips shipped under the old terms. It can't show the damage the test is meant to catch, whatever benchmark you use. We'd be clearing a post-verdict risk with a pre-verdict number. And we don't have Q1's royalty split in our data, so we wouldn't even know the aggressive's bar until we pull it from a press release.

That leaves price as the only post-verdict evidence available by a November expiry. I'll accept price as evidence, just as I accepted the weekly close above 293 in the middle zone. But after an adverse verdict, price alone shouldn't let us hold 50 unhedged, which is double the cap we agreed applies after damage. So mirror the clean-verdict rule: - After a clean verdict, we re-hedge the excess above 35 once. - After an adverse but contained verdict, with a $163 million print and a weekly close above 293, keep 50 but re-hedge the excess above 25 once, at post-event prices. - Otherwise, cut to 25.

Sixth, the yield rule only works in one direction. It can stop us at 75 if the 10-year is above 5.31 after a hot CPI, but once we're at full size, nothing brings us back down if yields break out afterward. The neutral's own principle is that exits should mirror entries. The macro report calls the 10-year ARM's main driver. And a December Fed meeting the market expects to hike at falls right inside the window where that last quarter is unhedged. So if we're at full and the 10-year posts a weekly close above 5.31, trim back to 75. Using a weekly close filters out noise. It's the same condition that blocks the step, applied after the step too.

One last point on the no-collar case. If neither put prices under $8, the options market is pricing ARM's events above the roughly 80 percent volatility we've been using. It's telling us the move could be bigger than our model assumes. And 198 was never a floor; it's the monthly SuperTrend stop. A repeat of the summer's 49 percent fall takes 275 to about 140. On 25 points unhedged, that's about 12 percent of a full allocation, not 7.

I won't reopen the 25. But in that case the full exit should fire on a daily close below 219, where the 200-day and the August low both sit, not on a weekly close. The weekly version made sense with a put under the core. With no put, we already agreed price stops govern unhedged shares right away.

So here's where I land, in percent of your standard allocation: - Today: collar first, with a 265 to 270 put against the 300 call under the $8 cap, using December unless the earnings date is confirmed. Sell down to 50. Use the fallback put at 40, or go to 25 if nothing prices. Hit the deadlines so the book is in one of those states before the close. The last ten go today. - Through the events: hold the put in a flush. Roll calls only after a decided, non-adverse royalty verdict and two closes above 300. - At expiry: re-hedge the excess above 35 after a clean verdict, or above 25 after an adverse but contained one. Otherwise cut to 25. - Rebuild to 75: on $163 million or more with a clean verdict, or on a middle-zone print with a weekly close above 293. - Rebuild to full: on two closes above 307.49. From the middle zone, only at about $148 million or better. Allow one shot at that tranche per quarter. - Before the December-quarter print: collar the last quarter with a put no lower than about 290 and a call at 325 or higher, within 3 percent, or trim to 75. - Yield exit: trim from full back to 75 on a weekly 10-year close above 5.31. - Full exit: a weekly close below 219, or a daily close if we're unhedged; a terms reset; or an award above about $1 billion. - Proceeds: keep them in cash.

None of this takes the breakout away from the aggressive. It makes sure we pay for it once, and only after the business has stopped getting worse.

Neutral Analyst¶

Neutral Analyst: Neutral Analyst: I'm on the Sell as well, so I'll start by setting aside the Hold case the aggressive analyst wrote for me. I'm not going to make it. The 50-day is rising mostly because closes near 240 are dropping out of the average. RSI isn't oversold, and nothing in the data says today was a washout. Trimming to around half is right. Where I differ from both of you is the shape of the plan. The aggressive side is too sure about the road back to 100 percent. The conservative side is too sure that the middle outcomes are bad, and some of its conditions for rebuilding are set so far away they would never be met.

Start with the earnings bar, since you both lean on it. You both treat roughly $134 million of operating income as a base-case miss. But look at how narrow the window is. Every 1 percent of opex is about $12 million of operating income. So the whole gap between the $130 million exit trigger and the $163 million rebuild trigger is less than 3 percent of opex, or about 3 points of revenue growth. That's within the error of the estimate.

The conservative's tough-comparison point doesn't change much either. Last year revenue rose 7.8 percent from Q1 to Q2. The same seasonal step from this year's $1,289 million lands near $1.39 billion, about 22 percent growth. Revenue isn't the problem; costs are. Even so, $134 million would be operating income up about 47 percent from Q1's $91 million, with margin rising from 7.1 to roughly 9.7 percent. Whether the market calls that a miss depends on consensus and guidance, and none of us has consensus. The triggers work as reference points, but nobody should treat them as precise.

That's why the conservative's middle-zone rule is too harsh. It makes the most likely outcome a reason to cut further to 25 percent. In the middle zone, I'd skip the rebuild and let guidance, data-center royalty commentary and the price reaction decide. If the stock holds 263 after the print, keep the half, re-hedged if the verdict is still pending. If it closes below 263, the plan's existing cut to 25 percent already covers it. You don't need a new rule that sells on an ambiguous number.

Now sizing. The fight over 40 versus 50 percent collared is mostly noise. At the quoted collar, the worst case through the print is about 6.5 percent on the hedged shares. The extra 10 points of allocation adds about two-thirds of a point of worst-case loss, and about the same in upside up to 300.

What actually matters is how much you hold unhedged and whether the hedge covers the events. On unhedged size, I'd tie the cap to how many binary events are still ahead. With both the verdict and the print pending, the conservative is right at 25 percent. A gap to 198 is a 28 percent hit, and closing-price stops can't protect against a gap. Once one of those events passes without damage, the plan's original 35 percent is reasonable again. That isn't splitting the difference. It's sizing to the risk that's still live.

On execution, you're both partly wrong. The aggressive split leaves you at 75 percent of standard, with half the trim waiting for a 4 to 6.5 percent bounce, while a jury is out with no verdict date. Juries can come back faster than people expect, and the 264.79 weekly trigger is only 3.8 percent away.

The conservative's Friday time stop has the opposite problem. A bounce that size in one session is unlikely, so it effectively forces the full trim at the bottom of the range. The 50-day sits just under today's low, and with ADX at 12.45 the technical report favors selling the top of the range, not the bottom.

So I'd do this: - Sell down to about 60 percent at market now, which is already inside the plan's range. - Work the last 10 points with limit orders in 287 to 293. - Sell anything unfilled by the September CPI release, or immediately on a daily close below the 50-day around 269. - Put the collar on the core 50 percent today, not after the trim finishes.

The collar should expire after the confirmed earnings date, with some buffer. The midterms on November 3 also fall in that window, so it's really five events, not four.

On the call strike, the conservative wins: sell it at 300, where the CFO's plan sells and below the 307 lower high. But "add nothing before the print, whatever happens" goes too far in one case. If the Qualcomm verdict goes ARM's way before earnings, one of the two binary events is gone. That's exactly the rebound the aggressive analyst worries about missing.

The answer isn't to buy unhedged stock on top of a capped position. It's to pay to roll the short call up toward the 330s. That gives the collared half its upside back without adding share risk. It also fixes the plan's conflict at 307.49. Before the print, a close above that level should mean you stop trimming and roll the call, not add shares.

On the collar cost, I agree with the $8 cap, and the macro report is only half right here. It says options look cheap next to rate volatility, but that's based on VIX, which is the index. ARM's own options will price in the trial and the print.

If the quote comes in above the cap, don't go straight to 25 percent unhedged. Try a lower put first, around 255 to 258, about one ATR down. That puts the worst case somewhere around 7 to 9 percent, depending on the quote, instead of 28. Only if that doesn't price well either do you drop to the 25 percent cap.

On a flush to 233 to 244, I'm with the conservative. Roll the put down toward 235 and bank part of the gain. Don't close it right before the binary events.

On SoftBank, the conservative raises a real risk. But the report flags it as background, not this week's news, and prediction markets put only a 6 percent chance on the AI bubble bursting this year. A low-probability tail that no stop can manage is exactly what the put is for. It's a reason to keep the hedge on, not to cut the position further.

It does argue for something neither of you said: don't recycle the trim proceeds into other AI or chip names. This selloff is sector-wide, driven by long-term yields and OpenAI worries. Chip stocks even fell on Samsung's record guidance. Hold the money in cash earning near the Fed funds rate, which makes waiting cheap.

On insiders, you're both overplaying it. Most of the $72 million followed the May 15 vesting, and the CFO's sales look like a plan that sells at set prices. That tells us there's automatic selling at 300. It's a price level, not a judgment on the business. Neither "the CEO hasn't sold" nor "nobody bought" moves the needle much.

The rebuild is where both of you are furthest off. The aggressive "back to 100 percent on the first pullback" ignores the verdict. It also ignores that Q1 net income was three times operating income, and that the stock would still trade around 90 times forward earnings.

The conservative's condition that "the weekly trend turns up" has the opposite problem. The weekly SuperTrend only flips at 383.15, about 39 percent above today. That's not a rebuild rule; it's a rule never to rebuild.

I'd rebuild in two stages: - Go to 75 percent on operating income of $163 million or more, with a verdict that isn't adverse. - Go to full size on a daily close above 307.49 that holds, because that breaks the chain of lower highs.

I'd also turn the 10-year yield into a rule, since you both cite it but neither of you uses it. If it falls back below about 5 percent, the rebuild can move faster. If it pushes past the 5.31 percent peak after a hot CPI, take it slower.

So my adjustment keeps the Sell and the roughly half-size target: 1. Trim to 60 percent now, and sell the last 10 points into 287 to 293 with hard backstops. 2. Collar the core 50 percent today, with the call at 300 and expiry after the confirmed print. 3. Cap the collar cost at $8. If it's above that, try a lower put before cutting size. 4. Cap unhedged exposure at 25 percent while both the verdict and the print are ahead, and 35 percent once one has passed without damage. 5. On a favorable verdict, roll the call up rather than buying stock. 6. On a flush to 233 to 244, roll the put down rather than closing it. 7. If earnings land in the middle zone, hold and let the price reaction decide. 8. Rebuild in two stages, with conditions that can actually be met.

That protects against the gap the conservative fears and keeps a real path back for the aggressive, without paying for either side's overconfidence. Neutral Analyst: I'm still on the Sell. This debate has narrowed a lot. We agree on the trim, the 300 call, the $8 cost cap, the fallback put, the unhedged caps of 25 then 35 percent, cash for the proceeds, no stock added before the print, and rolling the put down on a flush. What's left are a few real disagreements and two gaps in the plan that neither of you has raised. Closing those gaps settles most of the remaining arguments.

Start with the rebound debate, because you're both right and it doesn't need a winner. September's move ran from 243.98 to 333.20 in four sessions, which is the aggressive's point. That gap was then fully filled in under three weeks, which is the conservative's. A stock that gaps on evidence and then gives most of it back is exactly the stock you hold a collared half through the events and rebuild in steps afterward. That's the structure we already have.

The first gap is in the stops. The cuts to 25 percent, on a weekly close below 264.79 or a daily close below 263, were written for an unhedged position. Once the core has a put at 265 to 270, those stops stop doing what you both assume. Below the put strike, stock plus put is already floored. Selling collared shares at 263 doesn't reduce risk, because the put already did that. It just locks in the floor and gives up the rebound.

So, conservative, when you say our rules will have cut us to 25 percent by the time ARM hits 240, that's the plan paying twice for the same protection. My fix is to split the rules by bucket. The price stops apply right away to the unhedged slice, meaning the last ten points still on limit orders. The collared core is governed by its put until expiry. At expiry or roll, the stops decide how much of the core you keep or re-hedge. The full-exit triggers still apply to everything: a weekly close below 219, or a royalty verdict that resets terms.

The second gap settles the call-spread argument. Picture ARM at 240 with the collar on. Stock plus a 265 put minus a 300 call has the same payoff as cash plus a long 265/300 call spread. Aggressive, the trade you want to fund with the put gain is a call spread capped at 300, and at that price the collared core already is one. Buying another doubles the exposure.

Now look at what the roll-down does. With ARM at 240, swap the 265 put for a 235 put. The position now participates fully from 240 up to 300, with about five points of downside to the new floor plus the new put's cost, and the banked gain pays for it. That's your "get paid for the flush" outcome, using shares we already own. So drop the call spread.

Conservative, the flip side is that rolling down isn't neutral either. By design, it adds back upside exposure. If that's more than you want after a flush, adjust the strike. Roll to 245 or 250 and bank less. The roll strike is where your two risk tolerances should meet, without a separate options trade.

On 40 versus 50 percent collared, I side with the conservative's rule of sizing to the floor. Aggressive, that's your own defined-risk logic applied consistently. "Trimming collared shares doesn't shrink the tail" is only true when the floor is close. With a 265 to 270 put inside the cap, the tail is about 3 to 6.6 percent a share. At 50 percent collared, that's roughly 3.3 percent of a full allocation at risk. If we're pushed to the 255 to 258 fallback, the tail is closer to 8 or 9 percent a share, and 50 percent would put around 4 to 4.5 percent at risk. So collar 50 with the near put and about 40 with the far one.

On the earnings middle zone, I owe the conservative a concession. My "up 47 percent from Q1" framing started from the weakest quarter in the table. Last year's seasonal step added 360 basis points of margin, and 260 is below that.

Here's the math that I think settles the guidance tiebreaker. Assume revenue of about $1.385 billion and a 97 percent gross margin. Then $163 million of operating income means opex grew about 25 percent year over year, and $130 million means about 29 percent. So the middle zone means opex growing 25 to 29 percent, right where Q1's 27.8 percent was. That's the same trajectory, neither the break the aggressive hopes for nor a deterioration.

Aggressive, your tiebreaker of guidance below 25 percent opex growth is essentially the $163 million trigger moved from a reported number to a forecast. If we rebuild on 25 percent reported, we shouldn't also rebuild on 25 percent promised. That's especially true if the guidance is on an adjusted basis that excludes stock compensation.

But conservative, your depreciation point is overstated. FY26's $545 million of capex went into service during FY26, so most of that depreciation is already in Q4's and Q1's opex. That's part of why Q1 jumped. The new depreciation for Q2 comes mainly from Q1's $197 million of capex. On your three-to-five-year life, that's roughly $10 to $16 million a quarter. It's real, and it says the higher opex level will stick, but it isn't another step-up the size of the whole trigger gap. The aggressive's $134 million base case already assumes the level sticks. It implies opex up only about 4 percent from Q1, almost exactly last year's seasonal step.

So in the middle zone, hold the half and don't step up on guidance alone. But give it an upward path based on reported evidence: let the market grade the guidance. Step to 75 percent if both of these happen after the print: - ARM posts a weekly close back above 293, which retakes the gap, the 50 percent retracement, the Bollinger middle band and the 10 EMA at once. - The royalty verdict is in and not adverse.

That's the technical report's recovery confirmation, and it's a price, not a promise. If ARM closes below 263 instead, the existing cut covers the downside.

On the full-size trigger, aggressive, the 75 percent waypoint you want to skip costs you almost nothing. The full-size trigger at 307.49 is only about 12 percent above today. A clean print plus a clean verdict that gaps ARM through 307 would fire both steps within days, so keep the waypoint. Conservative, a weekly close is stricter than it needs to be when the daily ATR is $17.8. I'd define "holds" as two consecutive daily closes above 307.49 after the print. Then apply your own yield rule: loosen to one close if the 10-year is back under 5 percent, and stop at 75 if it's above 5.31 after a hot CPI.

On the verdict, I'll take the conservative's three-part definition with one fix. "Royalty claims decided" has to mean the jury's verdict on those claims, not the end of post-trial motions or appeals. You're right that the fight dragged on last time. But if "decided" means fully resolved, the rule won't trigger before this print or the next one. That's the same trap as the 383 SuperTrend flip you just withdrew. The stock gaps on the verdict, so the verdict is what clears the event. The testing-tools trial alone doesn't count, and the requirement to hold 263 through the following week stays.

On rolling the call after a good verdict, I agree the cost counts against the hedge budget, but all-or-nothing is the wrong rule. If ARM gaps to 320, buying back the 300s and selling 330s could, by rough math, cost $15 a share or more, more than the whole collar. Roll whatever share of the calls the remaining budget covers and leave the rest capped at 300. You get some participation above 300 without breaking the cap.

On SoftBank, conservative, I'd push back on rolling the put indefinitely because OpenAI worries are "still moving the sector." That condition has no measurable end. The collar costs roughly 1 to 3 percent of price for about six weeks of cover. Rolled forever, even at lower volatility after the events, that's a heavy annual drag on a position whose whole case is upside.

Puts are for events with a date; position size is the tool for risks that have no date. So roll the core's put at expiry only if one of these is true: - the royalty verdict is still pending, - ARM is below the 50-day, - or the 10-year is above 5.31.

Otherwise, let it lapse and let the staged size carry the SoftBank risk. You're right that a margin call only sells, and that's exactly why the rebuild is staged.

One point on the wider book. The collar covers ARM's dated events, but the biggest driver right now is the 10-year, up 32 basis points while the 2-year stayed flat. If your book holds other long-duration AI or chip names, this collar does nothing for that shared exposure. Keep the proceeds in cash and check how much of your total book moves with long yields.

So my adjustment keeps the Sell at roughly half size: 1. Sell to 60 percent now and work the last ten points into 287 to 293. Sell anything unfilled at CPI, on a close below 269, or if tomorrow's weekly close is below 264.79. 2. Collar the core today with the 300 call and an expiry past the confirmed print. 3. Size the collar to the floor: 50 percent with the 265 to 270 put, about 40 with the 255 to 258 put, or 25 percent unhedged if neither prices under the cap. 4. Price stops govern the unhedged shares. The put governs the core until expiry. 5. On a flush, roll the put down, using the strike as the risk dial, and skip the call spread. 6. In the middle zone, hold. Step to 75 only on a post-print weekly close above 293 with a decided, non-adverse royalty verdict. 7. At $163 million or more with that verdict, go to 75. Go to full on two closes above 307.49, adjusted by the yield rule. 8. Roll calls only as far as the budget allows, and roll puts only on the observable triggers above.

That keeps the floor the conservative needs and the participation the aggressive wants, without paying twice for the same thing. Neutral Analyst: I'm still on the Sell, and we're now arguing details. The conservative's last round found two real holes, and I dug one of them myself. But a couple of his fixes go too far, two of his rules contradict each other, and our call-roll rules now conflict in a way none of us has flagged. Most of the aggressive's remaining asks don't survive the arithmetic, though one of his tail points does.

I'll start with the roll-down, because I owe a correction. I reran the conservative's numbers at the same rough 80 percent volatility, and they hold. With ARM at 240 and about a month left, the 265 put is worth around $37 and a 235 put costs around $19. The roll banks about $18, which doesn't pay for the new floor the way I claimed. My mistake was measuring the floor from 240. The risk budget is measured from entry, and from 275 the worst case on the core goes from about 5.6 percent a share to about 9.5.

For the aggressive, here's the part that settles it. Rolling from 265 to 235 at 240 banks at most the 25 points of intrinsic value while giving up 30 points of floor. You reopen the downside between the new strike and the spot. Waiting for volatility to drop after an event doesn't fix that, because the old put loses time value too. So the strike has to come from the budget, not from reading the price action.

Conservative, look at what your budget rule actually allows. At a $5 collar, rolling to about 255 banks only around $7 at 240, which isn't worth four legs of spread on an options chain loaded with event premium. At $8 there's no room at all. Only the cheap case, a 270 put at about $4, allows a roll to the mid-240s that banks roughly $16. So the rule is simpler than either of yours. In a flush before the events, hold the put, unless the collar went on cheap, and then roll only as far as the budget allows.

Aggressive, at 240 the core moves on a bounce like about a fifth of its share count. That's not a flaw. It's the insurance working between 240 and 265.

Second, the expiry gap. The conservative is right that there's a hole, but wrong about which cap fills it. The 25 and 35 percent caps were tied to how many binary events were still ahead. With both cleared, the plan doesn't say. Assuming 35 carries over is as arbitrary as assuming 50 does.

His fix is still close to right. A middle-zone print confirms opex growing 25 to 29 percent, on a stock at 300 times trailing earnings, and the SoftBank risk has no date. So at expiry, if no rebuild trigger has fired, re-hedge only the excess above 35, which is 15 of the 50 points. Once the event premium drains, that's cheap: on rough math, a one-month collar at post-event volatility runs two to three dollars a share.

That re-hedge needs an end. At the second expiry there's no third roll. Those 15 points either join a rebuild because a trigger fired, or they get sold. That holds his cap through the uncertain window and limits the hedging drag I objected to at one cheap roll.

I'd reject his other new condition, that stops should govern the core if we use the 255 to 258 fallback put. We already cut collared size from 50 to 40 because that floor is deeper. Putting the 263 stop on top pays twice for the same eight points, which is exactly the error the bucket split fixed. We can size to the floor or stop the core, not both. We chose size.

Third, the cheap-quote collar on all 60. Aggressive, sizing to the floor sets a ceiling, not a target. A cheap floor leaves slack under the budget, and the best use of that slack is the call roll your own upside case depends on.

I get the same unwind math as the conservative. At 290 you'd buy back a 300 call worth about $25 and sell a 270 put worth about $19, netting an exit around 279. That's four dollars better than today on ten points of allocation, about 0.15 percent, before bid-ask spreads on four legs eat most of it.

But conservative, your own list contradicts itself. At a cheap quote you sell the last ten at market, and at a mid-range quote you work them with backstops. The collar's price only affects the collared shares. It says nothing about how to sell the unhedged ten.

The aggressive is right that those ten carry a bigger gap tail than the whole collared half: about 2.8 percent of an allocation in a gap to 198. But that exposure lasts about four sessions, until CPI. On a stock moving about 5 percent a day, the odds of a bounce to 287 within four sessions are better than even. That's worth a few days of exposure. So whatever the quote, collar the core and work the last ten with the backstops.

Fourth, the call roll, where there's a conflict nobody has flagged. We now have two triggers. Mine rolls the call on a pre-print close above 307.49. The conservative's rolls only after a verdict and two closes above 300. Rolling before the verdict is a paid bet on the exact event the collar exists to hedge. So I'm withdrawing my version. Before the verdict, a close above 307.49 means stop trimming, and nothing more.

After the verdict, the numbers favor the conservative on timing. At 320, rolling the 300 calls to 330 costs about $15 a share. At 340 a week later, it's about $18. So waiting costs around $3 if the move keeps running. Rolling on day one and watching ARM fade back under 300 into expiry costs the whole $15. Waiting wins if the chance of a fade is better than about one in six. With the September gap fully filled and Samsung's record guidance sold this week, it clearly is. Aggressive, your "far more a week later" works out to about three dollars.

Conservative, your reserve-first rule would quietly kill the roll if you sized it at today's option prices. Size it at post-event prices, and only for the 15-point excess the expiry rule actually re-hedges. That comes to well under a dollar per core share and leaves most of the budget for the roll.

Fifth, the tranche exits. The principle is right: every unhedged tranche needs its own exit. I'll keep the conservative's levels, about one ATR below each trigger, but the confirmation should match the entry. On a stock with a 6.45 percent daily range, a single close one ATR lower happens on noise alone. Then the entry trigger fires again a few days later, and each round trip costs an ATR on that tranche.

So match each exit to its entry: - The middle-zone tranche, bought on a weekly close above 293, exits on a weekly close below 275. - The full-size tranche, bought on two daily closes above 307.49, exits on two daily closes below 290. - The earnings tranche keeps 263.

On the verdict definition, you're each half right. "Resets royalty terms" is too narrow, because a multi-billion-dollar award matters even if the terms don't change. "Any outcome that cuts expected royalty income" is too broad for a full exit. A modest award against $3.06 billion of cash shouldn't dump the whole position on a headline.

So tier it. Any adverse royalty outcome freezes every rebuild step and the call roll. A full exit, collared core included, comes only on a terms reset or a loss or award above roughly $1 billion, about two-thirds of a year's free cash flow. Anything smaller goes to the 263 stop.

Conservative, your depreciation point also matters beyond this print. As depreciation builds every quarter, a fixed operating-income dollar figure becomes a weaker test. After this print, switch the rebuild test to margin, using the 14 percent operating margin the fundamentals report flags.

Here's where I land: - Sell to 60 now and get a live quote today. - Collar the core at 50 with the 265 to 270 put, or about 40 with the fallback put. If neither prices under the $8 cap, hold 25 unhedged. - In every case, work the last ten on limits with the CPI, 269 and weekly 264.79 backstops. - In a flush, hold the put. Roll it down only in the cheap case, and only as far as the budget allows measured from entry. - At expiry, re-hedge the excess above 35 once, then sell it or fold it into a rebuild. - Roll calls only after a non-adverse royalty verdict and two closes above 300, after setting aside a small post-event reserve. - Give each rebuild tranche an exit that mirrors its entry. - Exit fully on a weekly close below 219, a terms reset or a material award. - Keep the proceeds in cash, and check how much of the rest of your book moves with the 10-year, because this collar does nothing for that.

It's still a Sell. Every rule now has a number and an end date, and none of them pays twice for the same protection. Neutral Analyst: Neutral Analyst: I'm still on the Sell. Three disagreements are left. On two of them the conservative has the better arithmetic, but in both cases his fix puts the protection in the wrong place. On the third, the aggressive's fix doesn't work the way he thinks.

The last ten points

You're each quoting fill odds that answer different questions. ARM moves about 5 percent a day. At that pace, the chance of touching 287 at some point in four sessions is about two in three. So the aggressive's number is right if nothing else is in play.

But our backstops are in play. The 50-day will be near 270 to 271 by early next week, so the close-based stop sits about 2 percent below Thursday's close, while the limit is about 4 percent above. With both live in the same window, the odds that the limit fills first fall to roughly 40 to 50 percent. And on a stock with no reliable drift, a limit above and a stop below average out to an exit near where you started.

That was my mistake last round. I said the range favored waiting for the top, and that edge doesn't survive our own stops.

The bigger problem is the cancel rule. Juries usually report during court hours, and those overlap the trading day. Suppose a good verdict is read at 2 p.m. The stock is through 293 before anyone can cancel, so the limits fill. Suppose a bad one is read. His rule sells at market. Either way the ten get sold, just at a better or worse price than today. They stay uncapped only if the verdict lands after the close.

So the proposal isn't really a trim that keeps the upside. Most of the time it's an unhedged bet on the verdict that ends in a sale either way. And the last jury in this dispute went largely Qualcomm's way. If it's a trim, finish it. If it's a verdict bet, call it one and size it as one. Nobody here has argued for that.

Conservative, I agree with your conclusion, not your strongest-sounding reason. You compared a 2.8 percent loss in a gap to 198 with the 3.3 percent budget for the collared half. But you signed a 25 percent unhedged cap before the events, and the same gap on that costs 7 percent. Tail size isn't what decides this. What decides it is no expected edge plus a cancel rule that only works after the close.

So sell the ten Friday. Spread the sale across the session rather than one print at the open after a 1.9-times-volume down day.

Aggressive, you don't lose the verdict upside. On a good verdict, the collared half still runs from 275 to 300, about 9 percent on half the position. After that, we've agreed to roll the calls once ARM has closed above 300 twice, within budget. That roll is where your upside above 300 lives now.

There's also a sequencing gap in "sell to 50, then collar." Which collar prices decides whether you end at 50, 40 or 25. If you sell to 50 first and neither put prices under the cap, you're 50 unhedged over the weekend. That's double the cap, right after Friday's weekly test. So get the quotes first. Then size the stock sale to whichever collar prices, and put the collar on as one package. Don't go home Friday with more than 25 points unhedged.

The margin test

The conservative's arithmetic is right. 14.4 percent of about $1.385 billion is roughly $199 million, not $163 million. At $163 million, margin is about 11.8 percent, down 2.6 points year over year. Aggressive, "identical" was wrong. My flat 14 percent bar was wrong too, for the seasonal reason you gave.

One detail helps. Q1's margin was down 3.7 points year over year, so $163 million would show the gap narrowing, not closing. That's the right label for the 75 percent step: the decline is slowing, not reversing. It earns three-quarters of the position, not all of it.

Where I disagree with the conservative is where he puts the gate. He makes margin expansion a condition for buying the last quarter. Realistically this print can't reach $199 million, so the last 25 points would wait for the December-quarter print in early February. I checked his bar for that quarter: it needs opex growth near 21 percent. That's reachable, but it isn't the base case.

Now compare what each mistake costs. Suppose ARM breaks out above 307 in November and runs 25 percent by February, which a 3.79-beta stock can do. Missing that on 25 points costs about 6 percent of a full allocation. Suppose instead you buy the breakout and it fades the way September did. The agreed exit, two closes below 290, costs about 1.6 percent of an allocation. The fade case is already bounded.

What isn't bounded is carrying that last quarter unhedged into the next earnings report while margins are still down year over year. That's a dated event, and we agreed dated events are what hedges and position size are for.

So the margin evidence should decide whether you carry the last quarter through the next print, not whether you buy it. Go to full size on two closes above 307.49, after a $163 million-plus print and a clean verdict, adjusted by the yield rule, as agreed. Then, before the December-quarter print, either collar the last 25 points through it or trim back to 75, whichever prices better. The exception is if this print already showed year-over-year margin expansion, around $199 million.

If the December quarter clears last year's 14.9 percent, full size stands unhedged afterward. If it doesn't, you're back at 75, having kept the run in between. The aggressive gets the move between prints. The conservative gets proof before full size goes into a print unhedged.

The verdict tiers

Conservative, the "circular" critique is half right. A one-time award comes off equity value roughly dollar for dollar. You don't value a one-time payment at 300 times earnings. So measuring the cash against the market cap isn't circular, and 0.3 percent is the right size for the payment itself.

Your second point is the one that matters. What's really at risk is what the outcome says about ARM's ability to enforce royalty terms, and a denied ARM claim says something even if no money changes hands. So the dollar threshold is a proxy for how bad the signal is. We all accept the narrow full-exit tier now, so the fight is over the middle tier.

There, the conservative is right that the unhedged cap stays at 25. Our rule says it rises only when an event passes without damage. The aggressive's "freeze rebuilds," which was my wording too, never said what ends the freeze. That's a hole, and I own it.

But the conservative's end point has two problems. First, margin expansion answers the operating-leverage worry, not the legal one. Second, it ignores the timing. If the verdict lands in October, the print arrives in early November, before a November 20 expiry. So the expiry decision gets made with the print in hand.

The evidence should match the damage, and a royalty loss is answered by royalty numbers. After an adverse but contained verdict, keep the core at 50 only if all three of these hold: - The print clears $163 million. - The reported royalty line grows at least as fast as total revenue. - ARM posts a weekly close above 293.

That counts as a rebuild trigger under the expiry rule, so the 25 cap doesn't force a cut. Otherwise, cut to 25 at expiry with no bridge re-hedge. Anything above 50 waits for year-over-year margin expansion. At that point the stock has two strikes against it, and the conservative's higher bar fits.

I agree on the single package order and on confirming the earnings date before choosing November 20 over December. One point at the book level: keep the proceeds in cash. If the rest of your book holds other long-duration AI or chip names, one sector-level hedge sized to that shared exposure is cheaper than a collar on each name. This ARM collar does nothing for that exposure.

The plan

All sizes are in percent of your standard allocation. On Friday, get the collar quotes before selling anything: - If the 265 to 270 put prices under $8, sell to 50 and collar all 50 as one package. - If only the 255 to 258 put works, sell to 40 and collar 40. - If neither prices, sell to 25.

In every case, sell the last ten Friday rather than working limits, and don't hold more than 25 unhedged over the weekend.

Through the events: - In a flush, hold the put. - Roll calls only after a non-adverse royalty verdict and two closes above 300, and only from budget left after the re-hedge reserve. - At expiry after a clean verdict, re-hedge the excess above 35 once, with a call near 310. - After an adverse but contained verdict, keep 50 only on the royalty-matched evidence. Otherwise cut to 25.

Rebuilding: - Go to 75 on $163 million or more with a clean verdict. - In the middle zone, go to 75 on a post-print weekly close above 293 with a decided, non-adverse royalty verdict. - Go to full size on two closes above 307.49. Carry that last quarter into the December-quarter print only if it's collared or margins have already turned.

Exit fully on a weekly close below 219, a terms reset, or an award above about $1 billion.

It's still a Sell. The last ten go now because neither side found an edge in holding them. The last quarter of the rebuild gets bought on price and held through the next print only on proof. That's where each kind of protection actually works. Neutral Analyst: Neutral Analyst: I'm still on the Sell, and I think we're close to done. The conservative's last round established two facts. A quote isn't a fill. And the quarter ARM reports in November closed before any verdict could land. But on three of his six points he fixed the right problem with a reference point that won't hold still. He used a dollar figure where he needed a margin, strikes anchored to today's prices for a trade we'd place in January, and a yield level three basis points from where we are now. The aggressive's three holes mostly get closed by the conservative's own numbers, though not the way the aggressive wanted. And one state of this plan still has a tail double the others: the one where nothing prices.

Start with today's execution, since it's the only live part. Conservative, you're right that the options package is the uncertain leg and the stock is the easy one. So collar first, then sell stock down to whatever filled, keep your afternoon deadlines, and finish before the closing auction. One correction on how to work it: don't post the package at the $8 cap. A market maker who sees a bid at the cap will fill you at the cap. Start near the model mid, around $4 to $5 on our rough numbers, and step toward $8 as your deadlines approach.

On expiry, I'd go further than you. I'd lean toward the December 18 monthly even if ARM confirms an early-November date. December covers the print with real buffer. It also covers the December Fed meeting, where a hike is 78 percent priced and the yield risk we all keep citing comes to a head. Four extra weeks cost roughly a quarter to a third more on the net debit by square-root-of-time, so a $5 November collar becomes about $6.50, still inside the cap. The trade-off is that any call roll also gets pricier with the longer tenor. In return, the plan gets simpler. The one-time re-hedge at expiry moves to mid-December and can run straight through the February print, so the bridge re-hedge and the pre-February collar become one trade instead of two. If a December package won't fit under $8, I agree: drop to the fallback tier rather than buy a November floor that might expire before the print.

On the middle zone, aggressive, the conservative answered your estimation-error point correctly. Once ARM reports, the margin is a fact, not a forecast. His line also isn't arbitrary the way a line between $160 and $165 million would be. It's Q1's rate of decline, with margin down 3.7 points year over year. Above it the decline is narrowing, and below it the decline is widening. Your own $134 million base case is a 9.7 percent margin, a worse decline than Q1. So I accept the gate.

But conservative, write it as a margin, not as $148 million. That dollar figure assumes $1.385 billion of revenue. If revenue lands at $1.34 billion, $148 million is an 11 percent margin. At $1.43 billion it's 10.3. The test should be reported operating margin of about 10.7 percent or better, which is last year's 14.4 minus Q1's 3.7. That measures what you actually care about, whatever revenue does.

On whipsaw, conservative, you're right that the bound holds per round trip, not per quarter. But a one-shot rule until the next print throws away the most common way a stock like this breaks out: a shakeout, then the real move. I'd allow one re-entry per quarter, on a stronger trigger rather than the same one. The second entry needs closes above the September peak zone, about 332 to 337, where the daily SuperTrend flips up. That breaks the top of the range instead of retesting the same line. Its exit is two closes below about 314, one ATR under. Two failed attempts then cost roughly 1.4 plus 1.35, about 2.8 percent of an allocation for the quarter. That's inside the 3.3 budget, and a third attempt never happens. Aggressive, you keep a second shot at the breakout. Conservative, your whipsaw cost is capped.

On the pre-February collar, conservative, you're right that without a put strike the 3 percent cap can be met by pushing the put down until the floor means nothing. But your 290 and 325 are anchored to today's range for a trade we'd place in January. If ARM is at 360 by then, a 325 call is in the money and a 290 put protects nothing worth protecting. So set both strikes relative to the stock price at that point: the put no more than about 1.5 ATR below, the call at least 1.5 ATR above, all within 3 percent. Be honest about what that is. It's a box allowing roughly a 10 percent move each way on a stock that moves 6.5 percent a day. If the market won't give that much room inside 3 percent, trim to 75. That's cleaner than paying spreads on four legs. The same logic applies to the tranche exits. They shouldn't sit at 275 and 290 if ARM has run. Once a tranche is two ATR above its entry, move its exit up to the entry price.

On the royalty test, the conservative wins on timing. The September quarter closed before the jury could rule, so its royalty line shows chips shipped under the old terms whatever the verdict says. Aggressive, your Q1 benchmark isn't in our data either. I accept his mirror rule: after an adverse but contained verdict, a $163 million print plus a weekly close above 293 keeps 50, with the excess above 25 re-hedged.

I'd add two clarifications. First, that weekly close has to come after the verdict, not just after the print. Otherwise a pre-verdict close is clearing a post-verdict risk, the same error he just caught. Second, the aggressive's test isn't dead; it's just placed in the wrong quarter. The February print covers October through December, the first quarter that can show any post-verdict effect. In the adverse branch, that's where it belongs: royalty growth no slower than in the quarters before the verdict. Pull those numbers from ARM's press releases now so we know the bar in advance. That test, together with the margin test, gates anything above 50 in that branch.

On the yield exit, mirroring entries is fair in principle, but the mirror isn't exact. The entry blocker had two conditions: the 10-year above 5.31 and a hot CPI. The exit as written has one, and 5.31 is three basis points above Wednesday's 5.28. That trigger could fire on noise in almost any week. A December hike priced at 78 percent isn't news on its own, so what matters is whether the long end breaks out and whether ARM feels it. Give the exit two conditions as well: a weekly 10-year close above 5.31 and ARM closing that same week below its 50-day. The macro report says a 10-year above 5.3 makes ARM lag. Trim when the lag shows up in ARM's price, not just when the bond moves.

Now the hole neither of you has fixed. In the 50- and 40-collared states, the worst case is about 3.3 to 3.5 percent of an allocation. In the 25-unhedged state, it's 7 percent on a gap to 198 and about 12 on a repeat of the summer. We land in that state exactly when the options market is telling us the move will be bigger than our model assumes. Conservative, your daily close below 219 as the full exit is right there. Aggressive, you're right not to cut below 25 on a 263 close. But there's a better third tier than going naked.

If the collar fails the cap, the likely reason is skew. Puts are rich relative to calls because of the trial, and the richest part is the far tail. So before going unhedged, price a put spread: buy around 260, sell around 220, financed with the same 300 call. That covers exactly the zone a verdict gap would jump, from our 263 stop to our 219 exit. It sells the part below 219, where our exit fires anyway. My rough Black-Scholes, even at 90 percent volatility, says the 300 call covers most or all of the spread, but that's precisely the number that needs a live quote. On 25 points, a gap to 198 then costs about 3.4 percent of an allocation instead of 7, the same budget as every other state. Yes, it caps those 25 at 300 like the core, and the same call-roll rules apply. If even that won't price near zero, then hold 25 naked with the daily 219 exit.

One last thing for both of you. We should stop adding rules after this round. Every round has added branches, and the plan now has more than a desk can execute under stress on a verdict afternoon. Write it down today as a single table of states and triggers, with alerts set while things are calm. And keep the proceeds in cash. Check how much of the rest of your book moves with the 10-year, because nothing in this ARM structure covers that.

So here's where I land, in percent of your standard allocation. Today, work a December package from mid toward the $8 cap, a 265 to 270 put against the 300 call, and sell to 50 once it fills. If that fails, use the 255 to 258 put at 40. Failing both, put a 260/220 put spread against the 300 call on 25. Failing that, hold 25 unhedged with a daily 219 exit. The last ten go today, finished before the closing auction.

Through the events, keep what we've agreed: hold the put in a flush, and roll calls only after a decided, non-adverse royalty verdict and two closes above 300. At the December expiry, re-hedge the excess above 35 after a clean verdict, or above 25 after an adverse but contained one, through the February print.

On the rebuild, go to 75 as agreed. Go to full on two closes above 307.49. From the middle zone, that requires a reported margin of about 10.7 percent or better. Allow one re-entry per quarter on closes above about 332, and move tranche exits to the entry price once a tranche is two ATR in profit. Before the February print, collar the last quarter with strikes about 1.5 ATR either side of the price at that time, within 3 percent, or trim to 75. Trim from full on a weekly 10-year close above 5.31 only if ARM also closes that week below its 50-day. After an adverse verdict, the February royalty and margin tests gate anything above 50.

Exit fully on a weekly close below 219 (daily if unhedged), a terms reset, or an award above about $1 billion.

It's still a Sell. Every state of the plan now carries roughly the same worst case, every rule measures what it claims to, and nothing is pinned to prices that will have moved by the time the rule fires.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Underweight ARM: cut to about 50% of a standard allocation today, Fri Oct 9. First fill a December collar as one package (buy a 265-270 put, sell the 300 call, net cost no more than $8, working from about $4-5 toward the cap), then sell the stock excess through the session and finish before the closing auction. If only a 255-258 put fits under the cap, hold 40% collared; failing that, hold 25% with a 260/220 put spread against the 300 call, or 25% unhedged with a daily-close-below-219 exit. Add no stock and open no shorts before the Q2 FY27 print (estimated early November) and the Qualcomm royalty verdict; exit everything on a weekly close below 219, a royalty-terms reset or an award above about $1B, and exit the remainder if Q2 operating income comes in below $130M; rebuild to 75% on at least $163M with a non-adverse verdict and to full size on two daily closes above 307.49, over a 2-3 month horizon with a $253 technical target.

Investment Thesis: RATING CHOICE: The Research Manager, the trader and all three risk analysts land on the same action: trim to roughly half and hedge, without exiting or shorting. The trader's and analysts' 'Sell' means trim-and-hedge. On the 5-tier scale that is Underweight (reduce exposure), not Sell (exit). The deciding argument came from the bull side's own put-call-parity point: hold only what you would open today. No analyst would open unhedged ARM at 275 into this event cluster, and even the aggressive analyst's final plan buys no unhedged stock before the print. WHY REDUCE: (1) The valuation leaves no cushion. ARM trades at about 57x TTM sales, about 300x trailing GAAP EPS, about 90x forward EPS and about 330x EV/operating income, with a free-cash-flow yield near 0.5% against a 5.28% 10-year. (2) Operating leverage is negative. Q1 FY27 opex rose 27.8% YoY and 13.9% QoQ while revenue grew 22.4%. Operating income was $91M (down 20% YoY, a 7.1% margin). Net income of $270M was about 3x operating income, so roughly $179M came from below the operating line. (3) The Q2 arithmetic was accepted by all three analysts. Last year's seasonal step puts revenue near $1.385B and gross profit near $1.34B. Reaching $163M of operating income needs opex growth of about 25% YoY; $130M implies about 29%, against Q1's 27.8%. The base case is about $134-140M. The conservative's correction stands: even $163M is an 11.8% margin, down about 2.6 points YoY. Real YoY margin expansion would need about $199M, which means opex falling sequentially, and that is unrealistic this quarter. (4) Technicals lean weak. Weekly and daily SuperTrend point down. MACD has crossed bearish (histogram -2.12). RSI is 46.66 with lower peaks (71.4, 61.2, 58.5). OBV at 414.17M is back below its pre-gap 417.24M. Down days carry heavier volume, and closing highs keep falling (333.20, 310.32, 307.49). The 09-21 gap is fully filled, and the 61.8% retracement (278.06) broke on 1.9x volume. (5) Macro and event risk are high. The 10-year is up 32bp since 09-21 while the 2-year stayed flat, December hike odds are 78% and oil is about $103. Ahead are CPI, the Oct 27-28 FOMC, the Nov 3 midterms, a Qualcomm royalty verdict with no date (the December 2024 Delaware jury went largely Qualcomm's way) and the estimated early-November print. This is a 3.79-beta stock with an ATR of 17.76 (6.45% a day) that fell 49% in six weeks this summer, and closing-price stops cannot protect against a verdict gap. (6) Insiders sold $72M with no purchases. The CFO's price-ladder plan sold at $300, which marks mechanical supply there, so that is where the short call belongs. WHY NOT EXIT: Revenue has grown more than 20% for four straight quarters at about a 97% gross margin. ARM holds $3.06B of cash, has 0.06x debt-to-equity and a 5.25 current ratio, and generated about $2.09B of TTM operating cash flow and $1.5B of free cash flow. The risk is valuation, not solvency. The long-term trend is intact: price is 25.5% above the 200-day (219.35), the rising 50-day (269.37) is above the 200-day, the monthly SuperTrend is up (stop 198.17), and lows have stepped up (219.39, 225.46, 238.03). Nothing is stretched (daily z-score -0.49, ADX 12.45 range). Liquidating mid-range would give up a stock that gapped from 243.98 to 333.20 in four sessions on news. A collar estimated at $3-8 limits the core's worst case to about 3-6.6% a share. No shorts, because the monthly trend is up, MACD is still above zero and the verdict is binary. HOW THE DEBATE WAS SETTLED: The conservative analyst won the late arithmetic on three points. Rolling the put down at 240 banks only about $18-19 while giving up 30 points of floor, so hold the put. The last ten points have no expected edge on limit orders, and a verdict read during court hours defeats any cancel rule, so sell them today. And the September-quarter royalty line predates any verdict, so it cannot clear post-verdict risk. The neutral analyst supplied the structure that keeps the plan from paying twice for protection: size to the floor; let price stops govern only unhedged shares while the put governs the core; recognize that the collar already behaves like a 265/300 call spread, so buy no extra call spreads; use a December expiry; and try a put-spread tier before going naked. The aggressive analyst won on keeping the rebuild reachable: re-hedge calls go above the 307.49 trigger, and margin evidence decides whether the last quarter rides unhedged through the February print, not whether it gets bought. RULES (sizes in % of standard allocation; apply them to your own holding): TODAY: Work the December package first from mid toward the $8 cap, then sell stock down to whatever filled. Fallbacks, set by afternoon deadlines: a 255-258 put at 40 with no stop on the core; else 25 with a 260/220 put spread; else 25 unhedged with the daily 219 exit. Never hold more than 25 unhedged over the weekend. Option costs are Black-Scholes estimates at about 80% volatility, so confirm them with live quotes. BEFORE THE PRINT: No new stock and no extra call spreads. A close above 307.49 means stop trimming, nothing more. In a flush, hold the put; roll it down only if the collar went on cheap, and only within the roughly 3.3%-of-allocation budget measured from entry. Roll calls only after a decided, non-adverse jury verdict on the royalty claims plus two closes above 300, using budget left after reserving for a post-event re-hedge. Any adverse royalty outcome freezes rebuilds and call rolls and keeps the unhedged cap at 25. AT EXPIRY: After a clean verdict, re-hedge the excess above 35 once, with a call near 310. After an adverse but contained verdict, keep 50 only on a print of at least $163M plus a post-verdict weekly close above 293, and re-hedge the excess above 25. Otherwise cut to 25. AFTER THE PRINT: If operating income is below $130M, revenue growth is under 20% or opex growth is above 30%, exit the remainder. Go to 75 on at least $163M with a clean verdict, or on a middle-zone print plus a weekly close above 293 with a non-adverse verdict. Those tranches exit at 263 and on a weekly close below 275, respectively. Go to full size on two daily closes above 307.49; one close is enough if the 10-year is back under 5%, and stop at 75 if it is above 5.31 after a hot CPI. From the middle zone, full size also needs a reported operating margin of at least about 10.7% (last year's 14.4% minus Q1's 3.7-point decline). The full-size tranche exits on two closes below 290. Allow one re-entry per quarter, only on closes above about 332-337, with an exit below about 314. Move each tranche's exit up to its entry price once it is 2 ATR in profit. Before the February print, collar the last quarter (strikes about 1.5 ATR either side, net cost no more than 3%) or trim to 75, unless margins have already expanded YoY. Trim from full to 75 if the 10-year posts a weekly close above 5.31 and ARM closes that same week below its 50-day. Keep the proceeds in cash, and check how much of your wider book moves with long yields, since this collar does not cover that. Write all of this into one state-and-trigger table and set alerts today. WHAT CHANGES THE CALL: Move toward Hold or Overweight on at least $163M of Q2 operating income with a non-adverse royalty verdict, two closes above 307.49, and the 10-year back below 5%. Above about 337 the daily SuperTrend flips up and the near-term bear case is invalidated. Downgrade to Sell on a Q2 miss below $130M, a weekly close below 219, or a royalty-terms reset or an award above $1B. PRICE TARGET $253: The reports cite no consensus or fair value. Forward EPS of $3.06 is likely non-GAAP, and any multiple applied to it would be arbitrary, so I use no valuation objective. For the technical objective, the report's breakdown path targets 263-265 first, then 252-254. An operating-income miss is the more likely Q2 outcome and the weekly and daily trends point down, so I use the second support cluster: the 09-04 close of 252.09 and the 09-10 close of 254.18, midpoint about 253.1, rounded to $253. That is 275.29 - 253 = 22.3 points, or -8.1%, about 1.25 ATR, sitting between 1 ATR down (257.53) and 2 ATR down (239.77). The horizon of 2-3 months covers the print and the December expiry. The alternative is a 270-293 range if the 50-day holds. CONFIDENCE is medium. Agreement across analysts and the quality of the fundamental and technical data are strong. Missing inputs: live option quotes, a confirmed earnings date, a verdict date (and clarity on whether one or two trials are running), the royalty/licensing revenue split, consensus estimates and a capex breakdown. The outcome also hinges on binary events.

Current Price: 275.29

Price Target: 253.0

Confidence: Medium

Time Horizon: 2-3 months